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Clinical mastitis (CM) is a production limiting disease affecting dairy cattle worldwide. Cows 
suffering from CM may experience a loss in milk production, reduction in rate of conception an 
increased risk of mortality and culling. Direct costs to the dairy farmer include costs due to 
compromised milk quality, treatment and discarded milk costs if antibiotics are used. Given 
these effects, dairy farmers are often faced with the decision of what to do with their diseased 
cows; whether to keep or replace with a younger heifer. The economic model developed to assist 
dairy farmers with these decisions is based on dynamic programming. It was necessary to 
develop a pathogen specific model for several reasons: (1) The previous framework did not 
separate CM into the different pathogens that are causative, hence, in the past, the effects of 
pathogen specific CM were pooled while decisions may be pathogen specific and (2) Discarded 
milk due to treatment after adjusting for the loss of milk from disease was not accounted. 
Further, the previous framework did not have the flexibility to include additional pathogens 
easily. In developing this model, we estimated the effects of pathogen specific CM for inclusion 
in the model (i.e., risk of pathogen specific CM and risk of mortality (and culling)). Further, 
prior to developing a pathogen specific model, we expanded an existing generic CM model (i.e., 
where all CM pathogens were combined) to study the cost of 3 different types of CM i.e., gram-
positive, gram-negative and other CM. Cows with more cases of CM in the previous lactation 
 
 
were at greater risk of bacteria specific CM in the current lactation, e.g., among multiparous 
cows in wim ≥ 3, cows were 2.2 times more at risk of a first case of E. coli if they had 2 cases of 
CM (of any type) in the previous lactation compared with no cases in the previous lactation. 
Among multiparous cows, cows were at greater risk of a recurrent case within the first month 
after the previous case of CM, unlike primipara, where these cows were at greater risk of a 
recurrent case within 2 months of the previous case. Among first lactation cows, the presence of 
a first CM case generally exposed cows to a greater risk of mortality in the current month 
(compared with the absence of a first case). This was especially acute with a first case of 
Klebsiella, where cows were 4.57 (exp(1.52)= 4.57 [95% CI (2.75, 7.61)]) times more at risk of 
mortality, and with a first case of E. coli with cows 3.32 times more at risk (i.e., relative risk = 
exp(1.20)= 3.32, [95% CI (2.46, 4.48)]. In general the presence of a first or second case resulted 
in cows in parity ≥2 with a greater risk of mortality (compared with cows with no first or second 
case of bacteria specific CM in the current month in milk). In first parity cows, the risk of culling 
generally increased with the presence of a case of bacteria specific CM. Among cows of parity 
≥2, when a cow contracted a case of Streptococcus spp., she was more likely to be culled one 
month after the case of CM (regardless of whether it was a first, second or third case of 
Streptococcus spp.). The average costs per case (USD) of gram-positive, gram-negative and 
other CM were 133.73, 211.03 and 95.31, respectively. This model provided a more informed 
decision making process in CM management for optimal economic profitability and determined 
that 93.1% of gram-positive CM cases, 93.1% of gram-negative CM cases and 94.6% of other 
CM cases should be treated. The main contributor to the total cost per case of gram-positive CM 
was treatment cost (51.5% of the total cost per case), milk loss for gram-negative CM (72.4%) 
and treatment cost for other CM (49.2%). From the pathogen specific economic model, we 
 
 
determined the net returns per cow and year, with an incidence of CM (cases per 100-cow years) 
of 35.5 was 500 US$, of which 90.6% of cases were recommended to be treated under an 
optimal replacement policy. The cost per case of CM was 233.41. The average cost per case was 
greatest for Klebsiella (416), followed by other not treated cases (e.g., Trueperella pyogenes) 
(316), other treated cases (e.g. pseudomonas) (310), Escherichia coli (309), Staphylococcus 
aureus (298), Staphylococcus spp. (275), Streptococcus spp. (257) and Negative culture cases 
(151). Optimal recommended time for replacement was as great as 5 months earlier for cows 
with CM compared with cows without CM. This model provides economically optimal decisions 
depending on the individual characteristics of the cow and the specific pathogen causing CM. 
The parameter estimates may be altered so that the results are specific to a given farm
iii 
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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
Clinical mastitis (CM) is a production limiting disease affecting dairy cattle worldwide. 
There are different pathogens that can cause CM (hereafter referred to as „pathogen specific 
CM‟). The risk of pathogen specific CM is dependent on factors such as the presence of disease 
(CM/other diseases), management and cow factors (Halasa et al., 2009; Petrovski et al., 2009; 
Sampimon et al., 2009). Cows suffering from CM may experience a loss in milk production 
(Gröhn et al., 2004; Bar et al., 2007; Schukken et al., 2009), reduction in rate of conception 
(Hertl et al., 2010), an increased risk of mortality and culling (Bar et al., 2008a; Hertl et al, 2011; 
Reksen et al., 2006;) and greater costs due to treatment (and discarded milk if antibiotics are 
used). By the process of milk culture, one can identify the pathogen involved. A rationale  for 
identifying the exact pathogen causing CM is that treatment can then be tailored to the pathogen, 
which may result in less antibiotic use (as the antibiotic used will be tailored to the specific 
pathogen, increasing the probability of successful treatment), less discarded milk due to 
treatment (if the initial antibiotic treatment is not indicated for the pathogen involved, cows may 
need to be treated repeatedly resulting in more discarded milk) and a reduction in the overall cost 
per case of CM. In study by Ma et al., 2000, it was demonstrated that for high SCC milk, 
between 14 to 21 d post processing, sensory defects i.e., rancidity and bitterness were detected 
hence, adversely affecting the quality of pasteurized fluid milk. An elevated SCC also has 
implications on revenue; depending on the market, the acceptable range for the bulk tank SCC 
level varies. For example, while the regulatory limit in the USA is 750,000 cells/ml, the global 
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standard (also the limit in the European Union) is 400,000 cells/ml (Adkinson et al., 2001; 
Hoards Dairyman, 2011). As a result, these costs may affect a farm‟s net returns (Halasa et al., 
2009).   
Given the effects of CM on farm, dairy farmers are often faced with the decision of what 
to do with their diseased cows; whether to keep (and treat) or replace with a younger heifer. 
These decisions are dependent on a number of factors, namely the effects of CM on the cow e.g., 
if a cow is kept and is suffering from CM and the reduction in milk yield which would occur. 
With CM occurring in a cow the farmer is faced with a number of questions. Is the detrimental 
impacts of CM in a cow offset by the overall high milk producing capacity of the dairy cow, in 
which case it is better not to replace the cow immediately? Would it be better to keep the cow in 
the herd for an additional month before replacement? Essentially these questions can be 
summarized into the question of at what time is the value of replacing the cow greater than 
keeping the cow?  
Previous studies have demonstrated that production limiting effects of CM (which 
contribute to decision making) are dependent on the pathogen involved. For example, the milk 
loss for CM attributed to Escherichia coli is not the same as that for Staphylococcus spp (Gröhn 
et al., 2004). A focus of this thesis is to identify whether the risk of these pathogens causing 
repeated CM cases, the risk of mortality and culling, reduction in conception and treatment cost 
are also dependent on the pathogen involved. 
The economic model we developed to assist dairy farmers with these decisions is based 
on dynamic programming. One of the basic elements of dynamic programming is the sequential 
approach to decision making, which aligns well with sequential decisions in animal production, 
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including replacement of animals where at regular time intervals management decisions are 
made i.e., whether the animal should be replaced, inseminated or kept for another time period 
(Kristensen et al., 2010).  The development of dynamic programming dates to the 1950s. The 
application of this technique to animal replacement models was illustrated by Jenkins and Halter 
(1963); where the trait of lactation number (12 levels) was all that was included, but served the 
purpose of showing dynamic programming could indeed be applied to such a problem. In 1966, 
Giaever illustrated with various solution techniques (value iteration, policy iteration and linear 
programming) the feed intake and production of a dairy cow, then Smith (1971) was able to 
achieve a state space of 15 000, as opposed to the 106 states which was the upper limit in the 
Giaever study. Kristensen and Østergaard (1982) and van Arendonk (1985, 1986) and van 
Arendonk and Dijkhuizen (1985) studied the effect of prices and conditions on the optimal 
replacement policy (Kristensen, 2010). 
A problem with working with such large models is that as the state-space expands, it may 
become prohibitive to solve large problems, frequently termed the “curse of dimensionality”. A 
contribution to the solution of dimensionality was made by Kristensen (1988; 1991), where the 
computational advantages of the value iteration method and the exactness and efficiency of the 
policy iteration method were combined. This makes it possible to give exact solutions to models 
with even extremely large state spaces (Kristensen, 2010). It is this solver and Multi level 
Hierarchic Markov Process (MLHMP) software that is used as the application program interface 
to develop the pathogen specific model in this study (Kristensen, 2003). 
Optimal replacement models can be used to provide dairy farmers with guidance on what 
action to take with their animals. The advantage of these models is that they can assimilate large 
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amounts of information on health status, age of the cow, milk production etc., and provide the 
optimal action to be taken.  
Dairy cattle replacement models have been developed (De Vries et al. 2006; Nielsen et 
al., 2010; Demeter et al., 2011), with inclusion of information relating to disease (Houben et al., 
1994; Bar et al., 2008a). The model developed by Bar et al. (2008a) incorporated information on 
generic CM (i.e., CM that is not differentiated by causative agent), extending and building upon 
the assumptions of the optimal replacement model developed by Houben et al. (1994) and earlier 
asset replacement principles (Perrin, 1972). Because the focus of this dissertation is CM, 
subclinical mastitis (SC) was not included. SC has been modeled before; in a study by Yalcin 
and Stott (2001), 11 somatic cell count states were incorporated into a model with a time horizon 
of 20 years, 12 lactations and 15 milk yield states. In this study, the expected net present value 
was £285.50 and the percentage of cows with a SCC ≤400, 000 cells/ml was 76.90. 
To the authors‟ knowledge, there are very few studies that examine the cost of pathogen-
specific CM (Østergaard et al., 2005; Sørensen et al., 2010). In the study by Sørensen et al. 
(2010), economic values for pathogen-specific CM were estimated using a stochastic simulation 
model (SimHerd IV). The simulations were conducted over time with weekly time increments, 
where other diseases were included as well as severity of CM.  
The basis of this Ph.D dissertation was the development of a larger model which 
encompasses pathogen specific CM. It was necessary to develop this model for several reasons:  
1. The previous framework did not separate CM into the different pathogens that are 
causative or differentiate between different cases of CM, the associated properties of each 
pathogen i.e., risk of CM, milk loss (Hertl et al., unpublished), conception rate, mortality 
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risk and treatment cost were not accounted for individually. Rather, in the past, these 
estimates were pooled either at the generic CM level, or gram-specific level (i.e., gram 
positive, gram negative or other CM). The importance of pathogen information arises in 
more specific situations, e.g., when the profile of a cow results in a borderline decision 
(Østerås et al., 1999). That is, additional knowledge of the exact pathogen involved may 
assist in decision making, especially In those cases where one only knows the cow is 
suffering from CM (but not the pathogen involved) and it is uncertain which decision is 
optimal. 
2. We would like to assess whether the risk of CM differs depending on whether the cow 
has had a case of CM in the preceding lactation i.e., carry over effect, and if that is the 
case, to include this information in the economic model.  
3. Discarded milk due to treatment after adjusting for the loss to milk due to disease was not 
previously accounted. This would have an impact on the estimated cost per case of CM.   
4. We have additional information relating to the risk of CM by case, carryover and 
pathogen, milk loss by case and pathogen, and conception rate, mortality risk and 
treatment cost by pathogen and at the cow level which were not available before. 
5. The previous framework did not have the flexibility to include additional pathogens or 
additional diseases easily; the new framework affords the versatility to expand the model 
for further research purposes. 
6. We also allow more than one event to occur as a cow transitions from one month to 
another; e.g., a transition in CM status, pregnancy and milk yield are now all concurrently 
possible, thus, providing a more realistic representation of what happens in the real life of 
dairy cows. 
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In order to develop a pathogen specific CM economic model, the first step was to decide on 
the classification of the pathogen specific CM for inclusion. A total of eight culture result classes 
were identified for the purpose of this thesis: (1) Staphylococcus spp., (2) Staphylococcus 
aureus, (3) Streptococcus spp., (4) Escherichia coli, (5) Klebsiella, (6) Other treated (these 
included Enterobacter, Enterococcus, Citrobacter, Serratia, Pasteurella, Corynebacterium 
species,  Pseudomonas, Proteus, Corynebacterium bovis, Gram+ bacillus, Gram- bacillus, 
fungus, Strep. group „C‟, mold and Nocardia), (7) Other not treated (these included Trueperella 
pyogenes, Mycoplasma, Prototheca and yeast), and (8) Negative culture, contamination (more 
than two bacterial species on the culture plate) and no significant organisms. The latter, no 
significant organisms, was defined as no bacterial growth of either Staphylococcus aureus or 
Streptococcus agalactiae while the culture plate contained more than two different species. 
These cases exhibited clinical signs of mastitis.  
Clinical mastitis pathogens can also be classified based on gram-staining i.e., gram-positive, 
gram-negative and other CM. This classification is not as specific or as comprehensive as above, 
however, is more valuable than not knowing anything about the CM causing pathogen. Gram-
staining classification can also form a component of on-farm treatment protocols. 
 
The overall objectives of this Ph.D research were:  
(1) to estimate the risk of pathogen specific CM  
(2) to estimate the effect of pathogen specific CM on mortality and culling 
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(3) to expand an existing generic CM (i.e., where all CM pathogens are combined) economic 
model to estimate the cost of three different types of CM i.e., gram-positive, gram-negative 
and other CM,  
(4) to develop an economic optimization model which would incorporate the previously 
defined classes of pathogens that cause CM, as well as account for whether the CM was a 
first, second or third case in the current lactation and whether the cow had a previous case of 
CM in the preceding lactation and  
(5) to develop a model that would be versatile enough to add more pathogens, diseases or 
other factors in the future without significant alterations to the basic structure of the model.  
 
By developing a pathogen specific CM model, the model would provide economically 
optimal decisions depending on the individual characteristics of the cow and the specific 
pathogen or group of pathogens causing CM. We also elucidate the cost of each pathogen 
causing CM, and undertake sensitivity analyses of how these costs are affected by changes in 
milk price, pregnancy rate and replacement cost.  
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ABSTRACT 
The objective of this study was to estimate the risk of a first case and recurrent cases of 
bacteria specific clinical mastitis (CM) in Holstein dairy cows. The pathogens studied were 
Streptococcus spp., Staphylococcus aureus, Staphylococcus spp., Escherichia coli, Klebsiella 
spp., and Trueperella pyogenes. A total of 40,864 lactations (9,873 cows) were analyzed of 
which 17,265 were primiparous and 23,599 were multiparous lactations, in 5 large, high milk 
producing dairy herds in New York State. There were 12,725 first cases, 4,535 second cases and 
1,798 third cases of CM. Generalized linear mixed models with a Poisson error distribution were 
used to study the effects of parity, calving diseases, milk yield from 2 wks before the current 
week in milk (previous milk yield), current season, number of cases of CM in the previous 
lactation and previous cases of bacteria specific CM within the lactation on the risk of a first case 
and the conditional risks for second and third cases of bacteria specific CM. The first 2 weeks in 
milk (wim) and wim ≥ 3 were analyzed separately as the former analysis focused on calving 
diseases as risk factors and previous milk yield was not included. Cows with more cases of CM 
in the previous lactation were at greater risk of bacteria specific CM in the current lactation, e.g., 
among multiparous cows in wim ≥ 3, cows were 2.2 times more at risk of a first case of E. coli if 
they had 2 cases of CM (of any type) in the previous lactation compared with no cases in the 
previous lactation. In this same group of cows, those with a first case of mastitis caused by 
Staphylococcus spp. were 3.8 times more likely to have a second case of mastitis caused by 
Staphylococcus spp. than if the first case was not caused by Staphylococcus spp.; in general, 
multiparous cows were at greater risk of a second case of CM if they had suffered from a first 
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case of CM that was caused by the same pathogen as the second case. For third cases, however, a 
second case of CM caused by both the same and a different pathogen as the third case generally 
put cows at greater risk of a third case, compared with if they had either the same or a different 
pathogen as the second case. Among multiparous cows, cows were at greater risk of a recurrent 
case within the first month after the previous case of CM, unlike primipara, where those cows 
were at greater risk of a recurrent case within 2 months of the previous case. With reference to 
recurrent CM cases, there was no evidence for protective immunological memory due to a 
previous exposure to the same pathogen; cows that had suffered from the same pathogen 
previously were found to be at greater risk of a recurrent case of CM from the same pathogen. 
The risks from this study will be used to parameterize an economic model which will provide 
dairy farmers with economically optimal decisions for their diseased cows.  
 
Key words: bacteria specific, risk, recurrent, repeated, mastitis 
 
INTRODUCTION 
 
Mastitis is a disease of importance in dairy cows due to its biological and economic 
effects. Cows with mastitis experience a drop in milk yield (Gröhn et al., 2004; Bar et al., 2007; 
Schukken et al., 2009), an increased risk of culling (Reksen et al., 2006; Bar et al., 2008a; Hertl 
et al, 2011), and reduced fertility (Hertl et al., 2010). It is also an expensive disease, as these 
biological effects, coupled with the fact that mastitic cows may be treated with antibiotics, incur 
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not only a treatment cost, but also an economic loss due to milk that is rendered unsalable. 
Further, cows with subclinical or clinical mastitis with their accompanying increased somatic 
cell count (SCC) will be contributing to the bulk tank. As a result, these costs will affect a farm‟s 
net returns (Halasa et al., 2009), profitability and management as well as optimal treatment, 
culling and replacement policies (Bar et al., 2008b; Bar et al., 2009c; Cha et al., 2011).  
The risk of mastitis has been studied as a function of other factors such as disease, 
management and cow factors by different classifications: (1) generic (Rajala, P.J. and Gröhn, 
Y.T., 1998; Steeneveld et al., 2008), (2) gram-positive, gram-negative or other (Hertl et al., 
unpublished) and (3) bacteria specific mastitis (Barkema et al., 1998; Sargeant et al., 1998; 
Riekerink et al., 2008). To analyze the effect of mastitis on herd profitability, it is necessary to 
distinguish the different pathogens causing mastitis. This is essential as the losses to mastitis 
(milk yield, decreased conception risks), prognosis, cost of culture and cost of treatment depend 
on the specific agent causing clinical mastitis (CM). Inclusion of information relating to previous 
case(s) may also be useful; this could help explain whether a previous infection from one 
pathogen provides protection from a subsequent case of CM of the same pathogen, or if cows 
with a subsequent CM infection are actually more likely to suffer from the same bacteria as 
experienced in the previous case, suggesting persistence of infection. The persistence of infection 
can be examined within the same lactation and across lactations. A study by Green et al. (2002) 
found that the probability of a quarter succumbing to CM in the next lactation increased when 
Streptococcus dysgalactiae, Streptococcus faecalis, Escherichia coli or Enterobacter spp. were 
cultured at drying off and the risk of mastitis for specific pathogens increased if the same species 
of bacteria that had caused mastitis was isolated at least twice in the late dry and post-calving 
samples. Within lactation, Döpfer et al. (1999) demonstrated that the occurrence of recurrent 
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episodes of CM caused by E. coli in any quarter of a cow is high (13.04% of all episodes of 
mastitis caused by E. coli in the study).  Intracellular survival and replication is an important 
attribute for the maintenance of intracellular infections (Dogan et al., 2006). Dogan et al. (2006) 
explored the possibility that persistent strains are better able to invade, survive and replicate 
within cultured mammary epithelial strains than transient strains. The authors discovered that all 
persistent E. coli strains but only one transient strain, were able to survive and replicate 
intracellularly in MAC-T cells over 48 h. Staphylococcus aureus is reported to be a mastitis 
pathogen often involved in chronic cases and persistence in udder tissues with an intermittent 
shedding pattern (low sensitivity to diagnostic tests) (Vaarst and Enevoldsen, 1997). Atalla et al. 
(2008), reported for the first time the isolation of S. aureus small colony variants (SCV) from the 
milk of cows with persistent bovine mastitis, suggesting that SCV strains may be important 
contributors to persistent bovine intramammary infections.  
To the authors‟ knowledge, there are no studies which have estimated the risk of bacteria 
specific mastitis as a function of cow factors, with inclusion of information on whether a 
previous case of CM was the same, or different to the current case, the time delay between cases 
and the number of cases of CM in the previous lactation. While the effects of cow characteristics 
on the risk of CM have been studied extensively, the strength of this study is the new information 
that contributes to our knowledge of bacterial interactions and persistence. 
The objective of this study was to estimate the effects of parity, milk yield from 2 wk 
before the current week in milk (“previous milk yield”), calving diseases, current season, 
previous bacteria specific CM in the current lactation, time since previous CM case and number 
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of cases of CM from the previous lactation (“carryover”) on the risk of a first and recurrent cases 
of bacteria specific CM.  
 
MATERIALS AND METHODS  
 
Herd Descriptions 
We collected and analyzed data from 40,864 lactations ( 17,265 of parity 1 and 23,599 of 
parity 2 and greater in 9,873 cows). The data in this study were collected from 2003/2004 until 
2011 (7-8 years) from 5 large dairy herds in New York State. The 305-d rolling herd average 
milk production ranged from 11,260 to 13,123 kg/cow per year, and the monthly mean SCC 
ranged from 137,000 to 262,000cells/ml. The monthly mean SCC is calculated summing all the 
SCC contributed to the bulk tank by each cow (which is calculated by (milk produced by the 
cow) x (SCC that particular cow contributes/ml)) on the monthly test day.  
All herds performed a full milking routine which included fore stripping, pre dipping, 
wiping teats clean and dry with single use towels and dipping all teats at the end of milking. The 
order of fore stripping and pre dip applications varied on some farms. 
Cows were stratified by lactation, production, and reproductive status into feeding groups 
which were fed a Total Mixed Ration. Cows were milked 3 times a day and the milking units 
automatically recorded milk production. Lactation, reproductive and medical information were 
entered into DairyComp305 herd management software (Valley Agricultural Software, Tulare, 
CA) by herd personnel. Information on parity, diseases, drying off, calving and exit from all 
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herds were available as this information was used by herd personnel for management of the dairy 
(Bar et al., 2008; Hertl et al., 2011).  
The variables relating to milk yield, mastitis culture results, diseases and reproduction 
that were necessary to conduct this study were outputed to ASCII files from DairyComp305 and 
imported into SAS v. 9.2 (2008). The quality of the data was assessed through preliminary 
descriptive analyses of the variables of interest. 
 
Eligibility criteria 
All lactating cows in the 5 herds were eligible for inclusion in the study.  
 
Case definition and unit of observation 
Cows were identified as having CM based on (1) milkers observing clinical signs of CM, 
i.e. a warm, swollen udder or changes in milk consistency; otherwise, the remaining cases which 
were missed by milkers were identified by (2) herdspersons who examined cows due to elevated 
milk electrical conductivity in addition to a sudden concurrent milk loss as indicated by the farm 
computer system.  
The unit of observation was week (for first case analysis) or month (for recurrent case 
analysis) within the lactation of a cow. Some cows had two types of bacteria specific CM (at the 
quarter level) that were isolated within the same lactation within a few days of each other. If the 
second pathogen was isolated in the same quarter 5 or fewer days after the first pathogen 
(regardless of the pathogen isolated) or occurred within 14 d with the same pathogens isolated, it 
15 
 
was considered to be the same case of mastitis. Any mastitis case after 14 d since the previous 
mastitis case was considered a new case (Barkema et al., 1998).  
If a cow had multiple quarter infections at the same time (e.g., E. coli in the left rear 
quarter and Staphylococcus spp. in the right front quarter, or both pathogens in the same quarter), 
she was considered to have both E. coli and Staphylococcus spp. isolated within the one case 
(Hertl et al., 2011). These „mixed‟ cases were excluded in our statistical analyses as this would 
render the outcome variable to be unclear i.e., it is unclear which pathogen came first, hence, 
which pathogen is the risk factor for the other pathogen. In Figure 2.1, however, these mixed 
cases are included. 
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Figure 2.1. Weekly risk of a first case of generic clinical mastitis by only one pathogen isolated 
or 2 different pathogens isolated in the same week, in the first 43 weeks of lactation (all 
lactations included), in 5 New York State Holstein herds 
 
 
Sampling 
Cows with CM were segregated from pen mates immediately after milking for sampling 
and further evaluation. Milk samples from clinical quarters were collected aseptically. Teats 
were cleaned, dried then sanitized with and alcohol swab. The first several squirts of milk were 
discarded prior to collection of the diagnostic sample. Samples were labeled and refrigerated 
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immediately after collection. Samples were collected daily during the week (weekend samples 
were collected the following Monday) by the Quality Milk Production Services at Cornell 
University and transported to the laboratory under refrigeration. The culture procedures are 
described in Gröhn et al. (2004). Briefly, milk samples were plated by streaking 0.01mL on 
trypticase soy agar II with 5% sheep blood and 0.1% esculin (BBL; Becton Dickinson 
Microbiology Systems, Cockeyville, MD). Plates were incubated at 37°C for 48 h. Following 
observation of colony morphology and hemolytic patterns on blood agar, isolates were examined 
by means of 3% KOH, gram-staining organisms, catalase and oxidase testing, and additional 
biochemical and metabolic evaluations as required. Colony morphology on Mac Conkey agar 
and the BBL Crystal ID System (Becton Dickinson) identified gram-negative organisms. 
Streptococci that had a negative CAMP reaction were classified as Streptococcus spp. 
Staphylococci with β or αβ hemolytic patterns that had a positive tube test for free coagulase 
were classified as Staph. aureus. Nonhemolytic staphylococci with a positive tube coagulase test 
were further identified with the API Staph System (bio-Merieux Vitek, Hazelwood, MO). 
Coagulase-negative staphylococci were classified as Staphylococcus spp. Single quarter samples 
were used. Contamination was defined as more than two organisms on a plate. 
 
Treatment protocol 
The treatment protocol for diseased cows was similar across the 5 dairy herds and 
throughout the study. Treatment protocols were determined by the herd veterinarians and applied 
to clinical cows based on the identified pathogen and/or severity of signs displayed by the 
affected cow. All intramammary treatments involved the use of FDA approved commercially 
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available medications. Animals displaying systemic signs of mastitis also received supportive 
treatment which included systemic antibiotics, IV and oral fluids and anti-inflammatory drugs 
(flunixin meglumine) according to the farm protocols. Duration of treatment varied with the drug 
selection and signs exhibited by the cow. 
Contagious mastitis pathogens are well controlled in all study herds. The vast majority of 
clinical cases was environmental in origin and was considered to be mild to moderate in severity. 
Mild clinical cases exhibited only signs of abnormal milk. Cows with moderate CM displayed 
abnormal milk and the affected quarter showed signs of inflammation (pain and/or swelling) but 
no systemic signs of illness. Individuals displaying fever (>103.5
o
F), dehydration, decreased 
rumen motility (<1 rumen contraction per minute) or loss of appetite and/or depression were 
considered to have severe acute CM and received additional supportive therapy. 
 
Bacteria specific CM  
The bacteria causing CM studied were Streptococcus spp., Staphylococcus aureus, 
Staphylococcus spp., Escherichia coli, Klebsiella and Trueperella pyogenes.  
 
Other Diseases 
Five other diseases (milk fever, retained placenta, metritis, ketosis and displaced 
abomasum (DA)) were included as potential risk factors. They were defined as follows: 1) milk 
fever occurred if a cow was unable to rise or had cool extremities and sluggish rumen motility 
near the time of calving, but was treated successfully with calcium, 2) retained placenta was 
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retention of fetal membranes for at least 24 h post calving, 3) metritis involved a febrile state 
accompanying a purulent or fetid vaginal discharge or diagnosis of an enlarged uterus by 
veterinary palpation, 4) ketosis was diagnosed by a drop in feed intake and milk production with 
detection of ketones in milk, urine or breath and no other concomitant diseases and with response 
to treatment, and 5) DA occurred when the abomasum was enlarged with fluid, gas or both and 
was mechanically trapped in either the left or right side of the abdominal cavity; nearly every DA 
case was confirmed by surgery, but cows removed from the herd without treatment were also 
recorded. Written disease definitions were disseminated to participating dairy producers and 
veterinarians to ensure that disease definition and diagnostic criteria were consistent across study 
farms (Hertl et al., 2011). 
Carryover 
The carryover variable represented the number of cases of CM a parity ≥2 cow had in her 
previous lactation (ranging from 0 to ≥3).  
 
Previous milk yield 
Primipara and multipara were analyzed separately and the previous milk yield (milk yield 
from 2 wk before the current week in milk) was stratified into five quintiles. The first 2 wim of 
lactation that were recorded for the cow were also analyzed separately, as this analysis focused 
on calving diseases as a risk factor; previous milk yield was not included.  
 
Cases of bacteria specific CM 
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The outcome variable was bacteria specific CM of case 1, case 2 or case 3. The risk for 
cases 2 and 3 were conditional on the previous case of CM. Due to a very small number of 
second and third cases in the wim=1 and wim=2 analysis, only the risk of a first case of bacteria 
specific CM was estimated in the models for CM in the first two weeks in milk. Every effort was 
made to study the effects of interest for each bacteria specific CM and case; however, if solution 
convergence could not be attained, generic CM was the outcome variable (i.e., for primiparous 
cows of wim ≥3).  All the models that reached convergence are included in our results.   
 
Previous CM exposure and months since the previous case 
For cases 2 and 3, the previous case (pathogen) was included in the model. In addition to 
the bacteria specific CM, other CM (i.e. pathogens other than Streptococcus spp., 
Staphylococcus aureus, Staphylococcus spp., Escherichia coli, Klebsiella and Trueperella 
pyogenes), and no important growth (no bacterial growth above the level which could be 
detected from our microbiological procedures observed in the culture sample) were included as a 
previous case (pathogen). This variable had 3 levels: (1) the previous case (pathogen) could be 
the same as the outcome of interest, (2) the previous case (pathogen) could be different to the 
outcome of interest or (3) the cow may have had both (1) and (2). 
 
Statistical Methods  
The GLIMMIX procedure of SAS (SAS Institute, 2008) was used to study the risk of the 
bacteria specific (or generic) CM of interest occurring due to various factors. Variables for 
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inclusion were selected based on univariate analysis where a P-value below ≤0.20 was 
considered significant; variables of biological importance were also kept. These variables were 
then all included in the model and stepwise backward elimination was performed until all the 
variables included were significant at a P-value ≤0.05 or were considered biologically significant 
(i.e., calving diseases for first 2 weeks in milk analyses, previous CM history for recurrent CM 
analyses). The form of the generalized linear mixed model used was  
 
 Ln (Y) = β0 + β1x1 +  β2x2 + β3x3 + … + βkxk + Zγ + ε,                            [1] 
 
where Ln is a link function, here the natural log of the probability of a cow contracting the 
bacteria specific CM in a week for first case analyses and in a month for second and third case 
analyses; Y is the vector of observations (either presence or absence of bacteria specific CM in a 
given week or month); β0 is the regression parameter for the intercept, and β1, β2, β3 . . ., βk are the 
regression coefficients for the fixed effects x1, x2, x3 . . ., xk (described below); γ is an unknown 
vector of random-effect parameters with known design matrix Z, and ε, a presumed independent 
random Poisson distributed residual term. Fixed effects in our models were parity with 3 levels 
(i.e., second, third and fourth and greater in lactation), stage of lactation (for first case analysis, 
ranging from wim 1 to wim 43, and for second and third case analyses, months 1, 2 and 3 and 
greater); current season with four levels (summer i.e., June->Aug, fall i.e., Sep->Nov, winter i.e., 
Dec->Feb and spring i.e., Mar->May), carryover effect (CM cases in the previous lactation) with 
four levels (for multiparous cows only, i.e., 0, 1, 2, 3 and greater), other diseases with 2 levels 
(only for first case analysis; if she contracted the disease in the first two weeks – 
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presence/absence), milk weight with five levels (only for wim≥3), and her previous CM 
exposure (in the current lactation) with 3 levels (only for second and third case analyses, i.e., she 
had the same bacteria, a different bacteria, or both in her most recent previous case of CM).  
Herd was a random effect unless otherwise specified (if model fit improved with herd as fixed 
effect this was the model used, which was noted). We assumed that all cases of CM occurred at 
the end of the risk period; therefore an equal weight of 1 was assigned to every observation. 
The unit of analysis was relatively short; therefore the distinction between risk and rate 
diminishes. Hence, from here on the risk per cow-week (first case analysis) or cow-month 
(second and third case analyses) was used as a measure of CM occurrence. The relationship 
between risk (cumulative incidence) and rate is given by: 
CI = 1 – exp(-I * Δt), where CI is cumulative incidence and I is incidence rate. Δt would be the 
time measured in cow-months. For small CI, a good approximation is I*Δt, and as Δt in our 
models equals 1, essentially CI and I can be used interchangeably (Rothman, 1986). 
 
Because we were not interested in specific herds, but rather herds in general with the 
common characteristics of being large, high milk producing dairy herds with a low incidence of 
contagious mastitis, we always attempted to include herd as a random (intercept) effect. Model 
fit was evaluated by comparing the Pearson chi-square (where herd was a fixed effect) or 
Generalized chi-square (where herd was a random effect) with the remaining degrees of freedom 
as well as assessing the -2 log pseudo-likelihood value to determine residual variability in the 
marginal distribution of the data (SAS Institute, 2006). A ratio of 1 (Pearson or Generalized chi-
square/df) indicates good model fit. There was one model where the negative binomial 
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distribution provided a better fit, in which case the deviance statistic was provided in addition to 
the Pearson-chi square/df to assess model fit. Cows were censored at 44 wim (to approximate a 
305 day lactation), or when they contracted a fourth case of CM, or the cow died or was culled 
(whichever one came first). A sample coding scheme for four cows with a second case of CM is 
illustrated in Table 2.2.1.  
This particular example is of a dataset used to study a second case of CM which happens 
to be E. coli. Therefore, cows in this dataset are either free of CM, or have had a first case of CM 
(of any type) and are censored from the wim they have a second CM case which is identified as 
E. coli only (no concurrent infections with another pathogen were included). Hence, each 
bacteria by case (1, 2 or 3) had its own separate dataset for analysis. 
For the dataset with only wim 1 and 2, 2 models were fitted: (1ai) effects of risk factors 
(other diseases, season) on the risk of bacteria specific CM in primipara; (1bi) effects of risk 
factors (parity, carryover, other diseases, season) on risk of bacteria specific CM in multipara. 
Week of lactation was not included as wim 1 and 2 were combined into 1 time step. 
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Table 2.2.1. Covariate coding scheme used in this study for 4 example cows with a second case of CM. This particular example is of a 
dataset used to study the risk of a second case of E. coli in dairy cows.
 1 
Co
w 
ID 
Wee
k in 
milk 
CM1
2
: 
Staph 
spp. 
CM1: 
Staph 
aureu
s 
CM1
: 
Stre
p 
spp. 
CM1
: 
E. 
coli 
CM1: 
Klebsiell
a 
CM1: 
T. 
pyogene
s 
CM1
: 
Othe
r 
 
CM1: 
No 
imp. 
growt
h 
Previous 
CM 
exposur
e
3
 
Month
s since 
CM1
4
  
CM2
: 
Stap
h 
spp. 
CM2: 
Staph 
aureu
s 
CM2
: 
Stre
p 
spp. 
CM2
: 
E. 
coli 
CM2: 
Klebsiell
a 
CM2: 
T. 
pyogene
s 
1 4 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 
1 8 0 0 0 1 0 0 0 0 1 2 0 0 0 0 0 0 
1 12 0 0 0 1 0 0 0 0 1 3 0 0 0 1 0 0 
2 5 0 0 1 0 1 0 0 0 2 1 0 0 0 0 0 0 
2 9 0 0 1 0 1 0 0 0 2 2 0 0 0 0 0 0 
2 13 0 0 1 0 1 0 0 0 2 3 0 0 0 0 0 0 
2 17 0 0 1 0 1 0 0 0 2 3 0 0 0 0 0 0 
2 21 0 0 1 0 1 0 0 0 2 3 0 0 0 0 0 0 
2 25 0 0 1 0 1 0 0 0 2 3 0 0 0 0 0 0 
2 29 0 0 1 0 1 0 0 0 2 3 0 0 0 0 0 0 
2 33 0 0 1 0 1 0 0 0 2 3 0 0 0 0 0 0 
2 37 0 0 1 0 1 0 0 0 2 3 0 0 0 0 0 0 
3 13 0 1 0 1 0 0 0 0 3 1 0 0 0 0 0 0 
3 17 0 1 0 1 0 0 0 0 3 2 0 0 0 0 0 0 
3 21 0 1 0 1 0 0 0 0 3 3 0 0 0 0 0 0 
3 25 0 1 0 1 0 0 0 0 3 3 0 0 0 0 0 0 
3 29 0 1 0 1 0 0 0 0 3 3 0 0 0 0 0 0 
3 33 0 1 0 1 0 0 0 0 3 3 0 0 0 0 0 0 
3 37 0 1 0 1 0 0 0 0 3 3 0 0 0 1 0 0 
4
5
 10 0 0 0 0 0 1 1 0 2 1 0 0 0 0 0 0 
4 14 0 0 0 0 0 1 1 0 2 2 0 0 0 0 0 0 
4 18 0 0 0 0 0 1 1 0 2 3 0 0 0 0 0 0 
4 22 0 0 0 0 0 1 1 0 2 3 0 0 0 0 0 0 
4 26 0 0 0 0 0 1 1 0 2 3 0 0 0 0 0 0 
4 30 0 0 0 0 0 1 1 0 2 3 0 0 0 0 0 0 
4 34 0 0 0 0 0 1 1 0 2 3 0 0 0 0 0 0 
1
 The dataset contained only cows (all of which experienced a 1
st
 case of CM of any type) that had E. coli as their second case of CM and cows that did not have 
a second case of CM (of any type)
 
2
CM1 = is the first case of CM. Because this is an example dataset for a second case of CM, the first record kept for this analysis would be the week the cow had 
her first case of CM. Note that the time step is months since the week the cow had her first CM. 
3
Previous CM exposure had 3 levels: 1 = CM1 is due to the same pathogen as CM2 (second case of CM); 2 = CM1 is due to a different pathogen than CM2; 3 = 
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CM1 was due to both the same and different pathogens as CM2. Cow 3 is an example of level 3 i.e., her second case of CM is due to E. coli, and her first case of 
CM were both Staph aureus and E. coli. Hence, her previous risk is coded as „3‟. 
4 
Months since CM1 had 3 levels: 1 = 1 month since her first case of CM, 2 = 2 months since her first case of CM, 3 = 3 and or greater than 3 months since her 
first case of CM. 
5While we did not model „other‟ and „no important growth‟ as outcome variables, these were included as risk factors. Cow 4 demonstrates how these cases were 
treated. 
 
For the dataset with wim≥3, for primipara, generic CM models were fitted: (1aii) effects of risk factors (week of lactation, 
other diseases, season, previous milk yield) on the risk of a first case of generic CM in primipara; (2a) effects of risk factors (current 
season, months since first CM) on risk of a second case of generic CM in primipara and (3a) effects of risk factors (current season, 
months since second CM) on risk of a third case of generic CM in primipara. For multipara: (1bii) effects of risk factors (lactation, 
week of lactation, carryover, other diseases, season, previous milk yield) on the risk of a first case of bacteria specific CM in 
multipara, (2b) effects of risk factors (lactation, carryover, previous CM exposure, months since first CM, current season) on risk of a 
second case of bacteria specific CM in multipara and (3b) effects of risk factors (lactation, carryover, previous CM exposure, months 
since second CM, current season) on risk of a third case of bacteria specific CM in multipara. Not all models retained the variables 
listed in brackets; a P-value below 0.05 was considered significant. 
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RESULTS 
 
Descriptive findings 
A total of 40,864 lactations (9,873 cows) were analyzed of which 17,265 were 
primiparous and 23,599 were multiparous lactations, in 5 large, high milk producing dairy herds 
in New York State. There were 12,725 first cases, 4,535 second cases and 1,798 third cases of 
CM. The lactational incidence risk and median week in milk (wim) was 45.1% (19) for generic 
CM, 3.0% (20) for Staphylococcus spp., 2.7% (23) for Staph. aureus, 10.5% (20) for Strep. spp., 
10.2% (17) for E. coli, 3.9% (19) for Klebsiella, 0.9% (11) for T. pyogenes, 7.1% (19) for other 
and 11.3% (19) for no important growth. The summation of the pathogen specific lactational 
incidence risks (49.6%) are slightly greater than the generic lactational incidence risk (45.1%), as 
the cases with multiple pathogens are included as one in the generic lactational incidence risk, 
but individually in the pathogen specific lactational incidence risks. The most common 
pathogens found across lactation and cases were Strep. spp., E. coli and no important growth 
(Table 2.2). 
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Table 2.2. Distribution of pathogens causing clinical mastitis (CM) in 5 New York State dairy herds, in first and second and higher 
lactations
1 
 
 First lactation (17,265 lactations) Second and higher lactation (23,599 lactations) 
Pathogen 1
st
 CM case 
(3576) (%)6 
2
nd
 CM case  
(941) (%) 
3
rd
CM case  
(299) (%) 
1
st
 CM case 
(9149) (%) 
2
nd
 CM case 
(3594) (%) 
3
rd
 CM case 
(1499) (%) 
Staph. spp.  281 (7.9) 73 (7.8) 25 (8.4) 602 (6.6) 256 (7.1) 108 (7.2) 
Strep. spp.   906 (25.3) 199 (21.1)
 
48 (16.1) 2374 (25.9)
 
916 (25.5) 383 (25.6) 
Staph. aureus  272 (7.6) 74 (7.9) 32 (10.7) 379 (4.1) 233 (6.5) 96 (6.4) 
Klebsiella  159 (4.4) 66 (7.0) 14 (4.7) 765 (8.4) 336 (9.3) 147 (9.8) 
E. coli  807 (22.6) 153 (16.3) 42 (14.0) 2320 (25.4) 634 (17.6) 219 (14.6) 
T. pyogenes 92 (2.6) 31 (3.3) 7 (2.3) 191 (2.1) 51 (1.4) 17 (1.1) 
Other
2
        
  Enterobacter  3 (0.08) 3 (0.3) 1 (0.3) 15 (0.2) 3 (0.08) 2 (0.1) 
  Citrobacter  8 (0.2) 2 (0.2) 1 (0.3) 11 (0.1) 7 (1.9) 1 (0.07) 
  C. bovis  18 (0.5) 9 (1.0) 5 (1.7) 13 (0.1) 7 (1.9) 3 (0.2) 
  Prototheca  0 (0) 0 (0) 0 (0) 3 (0.03) 0 (0) 0 (0) 
  Mycoplasma  60 (1.7) 9 (1.0) 2 (0.7) 12 (0.1) 4 (0.1) 2 (0.1) 
  Pseudomonas  9 (0.3) 2 (0.2) 0 (0) 8 (0.09) 5 (0.1) 4 (0.3) 
  Pasteurella  63 (1.7) 16 (1.7) 8 (2.7) 34 (0.4) 12 (0.3) 8 (0.5) 
  Yeast  57 (1.6) 14 (1.5) 4 (1.3) 95 (1.0) 34 (0.9) 15 (1.0) 
  G+ bacillus  8 (0.2) 5 (0.5) 1 (0.3) 34 (0.4) 13 (0.4) 8 (0.5) 
  Contamination  34 (1.0) 22 (2.3) 7 (2.3) 87 (1.0) 48 (1.3) 30 (2.0) 
  Other
3
 403 (11.3) 105 (11.1) 33 (11.0) 1041 (11.4) 422 (11.7) 174 (11.6) 
No imp. growth
4
  772 (21.6) 248 (26.4) 90 (30.1) 2210 (24.2) 1017 (28.3) 457 (30.5) 
Unknown
5
  253 (7.1) 99 (10.5) 32 (10.7) 544 (5.9) 273 (7.6) 115 (7.7) 
1 
Total number of CM cases by case number in which the pathogen was identified. Each cow may have more than one lactation and in each case there may be 
more than one organism involved 
2 
This classification used in our analyses comprised all the organisms other than the main 6 that were modeled as outcome variables (Staph spp., Strep spp., 
Staph. aureus, Klebsiella, E. coli and T. pyogenes) 
3 This classification could be one of several pathogens, hence it was grouped into „other‟ 
4 
No bacterial growth (above the level which can be detected from our microbiological procedures) observed in the culture sample
 
5 
The etiologic agent was not identified in the cultured sample 
6 
Percentage of cases 
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All models described below had a Generalized Chi-square or Pearson Chi-square/df fit 
ranging from 0.84 to 1.20 unless otherwise specified in the tables of results.  
 
Risk of generic CM (one pathogen isolated or two different pathogens isolated for first case) 
by week in milk (Figure 2.1) 
Because we did not model cases of CM where a cow could have two pathogens isolated 
as an outcome, we illustrated this as a first case of generic CM in Figure 2.1. This figure 
demonstrates the risk of a first case of CM by the presence of only one pathogen or the presence 
of two pathogens. In calculating the risk of only one pathogen identified (two pathogens 
identified), cows were censored when they reached wim 44, died or contracted two pathogens 
(only one pathogen identified); whichever one came first. The risk of a first case of generic CM 
was greater where one pathogen was isolated, compared with two different pathogens throughout 
lactation, but also particularly at the beginning of lactation (i.e., wim ≤ 3). 
 
Risk of a first case of bacteria specific CM by week in milk (Figures 2.2.1 and 2.2.2) 
The risk of a first case of bacteria specific CM was generally greater at the beginning of 
lactation (Strep. spp., Staph. aureus, Staph. spp., Klebsiella, T. pyogenes) or peak lactation (E. 
coli), then decreased and leveled out as wim increased (Figures 2.2.1 and 2.2.2). The same trend 
was seen for generic CM where only one bacteria was isolated in case 1 and where two different 
bacteria were isolated in case 1.  
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Figure 2.2.1. Weekly risk of a first case of bacteria specific clinical mastitis (E. coli, Strep. spp. 
and Staph. aureus) by week in milk, in the first 43 weeks of lactation, in 5 New York State 
Holstein herds. 
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Figure 2.2.2. Weekly risk of a first case of bacteria specific clinical mastitis (Klebsiella, Staph. 
spp. and T. pyogenes) by week in milk, in the first 43 weeks of lactation, in 5 New York State 
Holstein herds. 
Risk of a first case of bacteria specific CM in the first two weeks of lactation 
First lactation cows with retained placenta within the first two weeks were found to be 
exp(1.11)=3.03 [95% CI (2.05, 4.48)] times more at risk of a first case of E. coli than cows 
without retained placenta. In multipara, cows in a higher lactation were found to be more at risk 
of bacteria specific CM than cows in a lower lactation. Cows with more cases of CM in the 
previous lactation (carryover) were at greater risk of a first case of bacteria specific CM (Table 
2.3).   
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Table 2.3. Parameter estimates and standard errors for the generalized linear mixed models used to estimate the effects of parity, 
retained placenta and carryover on the risk of first occurrence of bacterial specific clinical mastitis (CM) in the first two weeks of 
lactation in multiparous cows (23,563 lactations) in 5 New York State dairy herds
1
 
 
Parameter Estimate (SE) for risk of bacteria specific CM 
 Streptococcus 
spp. 
Staphylococcus 
aureus 
Escherichia coli Klebsiella spp. Trueperella 
pyogenes 
Intercept -5.02 (0.36)*** -7.03 (0.43)*** -5.43 (0.26)*** -6.32 (0.47)*** -6.20 (0.43)*** 
 
Week in milk in the model (estimates not shown) 
 
Parity      
2 (baseline) -0.79
2
 (0.22)*** -0.46 (0.51) -0.50 (0.24)* -0.56 (0.36) -1.16 (0.44)*** 
3 -0.27 (0.21) 0.25 (0.47) -0.18 (0.24) -0.28 (0.36) -0.09 (0.34) 
≥4 0 0 0 0 0 
      
Retained 
placenta  
-- --  -- -- 
  No  (baseline)   0   
  Yes   0.72 (0.23)***   
      
Carryover from 
previous 
lactation
3
 
     
0 (baseline) 0 0 0 0 0 
1 0.52 (0.21)*** 1.13 (0.41)*** 0.29 (0.25) 0.96 (0.34)*** 0.53 (0.39) 
2 0.46 (0.33) -0.19 (1.04) 0.69 (0.33)** 0.47 (0.61) 0.74 (0.53) 
3 0.93 (0.33)*** 0.94 (0.77) 0.71 (0.39)** 1.78 (0.45)*** 1.51 (0.47)*** 
1
Herd was a random effect
 
2
The risk ratio is calculated as exp(-0.79) = 0.45 
3The carryover is the number of cases of CM from the previous lactation: 0= none, 1= 1 case of CM, 2= 2 cases of CM and 3= ≥3 cases of CM.  
*** p≤0.05 
** p≤0.10 
* p≤0.15
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Risk of a first case of bacteria specific CM in wim ≥3 of lactation 
A generic CM model for a first case in primipara (Table 2.4) and a bacteria specific CM 
model for a first case in multipara were estimated (Table 2.5). In primipara, cows were at a 
greater risk of contracting a first case of CM in summer [exp(0.14)=1.15; 95% CI (1.08, 1.22)] 
compared with winter (baseline). The same seasonal effect was observed among multipara for a 
first case of Staph. aureus [exp(0.34)=1.40; 95% CI (1.16, 1.70)], Staph. spp. [exp(0.40)=1.49; 
95% CI (1.26, 1.77)], E. coli [exp(0.20)=1.22; 95% CI (1.14, 1.31)] and Klebsiella 
[exp(0.64)=1.90; 95% CI (1.63, 2.20)]. The trends in parity and carryover among multipara were 
the same in wim ≥3 as for wim 1 and 2 described above. A significant effect of previous milk 
yield on a first case of E. coli demonstrated that cows with a larger previous milk yield were at 
greater risk of a first case of E. coli. 
 
Risk of a second case of bacteria specific CM in wim ≥3 of lactation 
The risk of a second case of bacteria specific CM was higher within 1 month after the 
first case, then decreased as more months passed (Figures 2.3.1 and 2.3.2). A generic CM model 
for a second case in primipara (Table 2.4) and a bacteria specific CM model for a second case in 
multipara were estimated (Table 2.6).  
33 
 
Table 2.4. Parameter estimates and standard errors for the generalized linear mixed models used to estimate the effects of current 
season and previous milk yield on the risk of first occurrence of clinical mastitis (CM) in primiparous cows (16,554 lactations) in 5 
New York State dairy herds
1 
and effects of current season and months since previous CM, on the risk of a second occurrence of CM in 
primiparous cows (3,197 lactations) and third occurrence of CM in primiparous cows (754 lactations) in wim ≥ 3 in 5 New York State 
dairy herds
1 
Parameter Estimate (SE) for risk of CM 
 CM1 CM2 CM3 
Intercept -5.39 (0.23)*** -3.12 (0.18)*** -2.41 (0.17)*** 
 
 
 
 
Week in milk 
In the model 
(estimates not shown) 
  
Current season    -- 
  Fall -0.11 (0.06)* -0.09 (0.13)  
  Spring -0.005 (0.06) 0.35 (0.12)***  
  Summer 0.14 (0.06)*** 0.22 (0.12)**  
  Winter (baseline) 0 0  
    
Previous milk yield
2
   NA NA 
  Level 1 0   
  Level 2 -0.17 (0.07)***   
  Level 3 -0.18 (0.07)***   
  Level 4 -0.20 (0.07)***   
  Level 5 -0.11
3
 (0.07)*   
    
Months since 
previous CM case 
NA   
1 (baseline)  0 0 
2  0.19 (0.12)* 0.07 (0.20) 
3  -0.10 (0.13) -0.60 (0.28)** 
4+  -0.59 (0.11)*** -0.95 (0.23)*** 
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1
Herd was a random effect
 
2
Milk yield from 2 weeks before current wim; levels are quintiles of milk yield (1=lowest, 5=highest).  
3
The risk ratio is calculated as exp (-0.11) = 0.90 
*** p<0.05 
** p<0.10 
* p<0.15 
Table 2.5. Parameter estimates and standard errors for the generalized linear mixed models used to estimate the effects of parity, 
carryover, current season and previous milk yield on the risk of first occurrence of bacterial specific clinical mastitis (CM) in 
multiparous cows (23,017 lactations) in wim ≥ 3 in 5 New York State dairy herds1 
Parameter Estimate (SE) for risk of bacteria specific CM 
 Streptococcus 
spp. 
Staphylococcus 
aureus 
Staphylococcus 
spp.
 
 
Escherichia coli Klebsiella spp.
 2
 
Intercept -6.27 (0.26)*** -8.68 (0.60)*** -8.16 (0.55)*** -6.37 (0.24)*** -7.82 (0.33)*** 
 
Week in milk in the model (estimates not shown) 
 
Parity      
2  -0.23 (0.07)*** 0.05 (0.17) -0.56 (0.15)*** -0.41 (0.07)*** -0.31 (0.15)*** 
3 -0.19 (0.08)*** -0.05 (0.19) -0.49 (0.16)*** -0.10 (0.07) 0.10 (0.15) 
≥4 (baseline) 0 0 0 0 0 
      
      
Carryover
3
      
0 (baseline) 0 0 0 0 0 
1 0.51 (0.07)*** 0.70 (0.16)*** 0.29 (0.16)** 0.34 (0.07)*** 0.48 (0.14)*** 
2 0.77 (0.10)*** 0.42 (0.30) 0.76 (0.23)*** 0.81 (0.10)*** 0.20 (0.27) 
3 0.89 (0.14)*** 1.25 (0.29)*** 1.19 (0.25)*** 0.79 (0.13)*** 1.23 (0.23)*** 
      
Current season       
  Fall -0.23 (0.08)*** 0.06 (0.20) 0.04 (0.19) 0.03 (0.08) 0.03 (0.17) 
  Spring 0.04 (0.07) 0.06 (0.19) 0.08 (0.18) -0.05 (0.08) -0.29 (0.18)* 
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  Summer -0.13
4
 (0.08)* 0.34 (0.19)** 0.40 (0.17)*** 0.20 (0.07)*** 0.64 (0.15)*** 
  Winter 
(baseline) 
0 0 0 0 0 
      
Previous milk 
yield
5
 
-- -- --  -- 
  Level 1 
(baseline) 
   0  
  Level 2    0.30 (0.13)***  
  Level 3    0.53 (0.12)***  
  Level 4    0.52 (0.12)***  
  Level 5    0.70 (0.12)***  
1 
Herd was a random effect unless otherwise specified. 
2
 Herd was a fixed effect.  
3
 The carryover is the number of cases of CM from the previous lactation: 0= none, 1= 1 case of CM, 2= 2 cases of CM and 3= ≥3 cases of CM.   
4
 The risk ratio is calculated as exp (-0.13)=0.88 
5 
Milk yield from 2 weeks before current wim; levels are quintiles of milk yield (1=lowest, 5=highest). 
*** p<0.05 
** p<0.10 
* p<0.15 
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Figure 2.3.1. Monthly risk of a second case of bacteria specific clinical mastitis (Klebsiella, 
Staph. spp. and T. pyogenes) by months since the first case of clinical mastitis, in 5 New York 
State Holstein herds. 
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Figure 2.3.2. Monthly risk of a second case of bacteria specific clinical mastitis (Strep. spp., E. 
coli and Staph. aureus) by months since the first case of clinical mastitis, in 5 New York State 
Holstein herds. 
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Table 2.6. Parameter estimates and standard errors for the generalized linear mixed models used to estimate the effects of parity, 
carryover, previous clinical mastitis (CM) exposure, months since first CM and current season, on the risk of a second occurrence of 
bacterial specific clinical mastitis (CM) in multiparous cows (8,417 lactations) in wim ≥ 3 in 5 New York State dairy herds1 
Parameter Estimate (SE) for risk of  2
nd
 case of bacteria specific CM 
 Streptococcus 
spp.
2
 
Staphylococcus 
aureus
3
 
Staphylococcus 
spp.
 4
 
Escherichia coli Klebsiella spp.
5
 Trueperella 
pyogenes
6
 
Intercept -3.71 (0.19)*** -4.89 (0.39)*** -4.79 
(0.44)*** 
-3.89 (0.18)*** -4.85 (0.32)*** -5.62 (0.40)*** 
       
Parity       
2  -0.09 (0.12) 0.31 (0.25) -0.04 (0.25) 0.06 (0.14) 0.23 (0.20) -0.09 (0.42) 
3 -0.11 (0.13) 0.08 (0.27) -0.18 (0.27) 0.22 (0.14)* 0.004 (0.21) -1.03 (0.59)** 
≥4 (baseline) 0 0 0 0 0 0 
       
Carryover
7
      -- 
0 (baseline) 0 0 0 0 0  
1 0.36
8
 (0.12)*** -0.02 (0.24) 0.17 (0.25) 0.41 (0.13)*** -0.02 (0.21)  
2 0.40 (0.17)*** 0.20 (0.34) 0.26 (0.35) 0.28 (0.19) 0.60 (0.25)***  
3 0.84 (0.17)*** 0.41 (0.37) 0.68 (0.35)** 0.80 (0.19)*** 0.76 (0.27)***  
       
Previous CM 
exposure 
(associated with 1
st
 
CM case) 
      
 Different pathogen 0 0 0 0 0 0 
 Same pathogen 0.80 (0.11)*** 1.78 (0.27)*** 1.33 (0.32)*** 0.52 (0.12)*** 1.48 (0.21)*** 2.73 (0.50)*** 
 Both 0.22 (0.18) 0.67 (0.53) 0.38 (0.49) 0.09 (0.22) 0.56 (0.37) 1.91 (1.00)** 
       
Months since first 
case of CM 
      
1 (baseline) 0 0 0 0 0 0 
2 -1.18 (0.14)*** -1.71 (0.32)*** -2.51 -1.66 (0.19)*** -1.80 (0.28)*** -1.64 (0.61)*** 
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(0.49)*** 
3 -1.45 (0.18)*** -2.09 (0.44)*** -2.73 
(0.62)*** 
-1.64 (0.21)*** -2.13 (0.38)*** -4.90 (3.30)*  
4+ -2.21 (0.16)*** -3.76 (0.58)*** -2.43 
(0.33)*** 
-2.06 (0.16)*** -2.94 (0.34)*** -3.72 (1.06)*** 
       
Current season -- -- -- --  -- 
Fall     0.43 (0.25)*  
Spring     0.12 (0.26)  
Summer     0.53 (0.23)***  
Winter (baseline)     0  
1 
Herd was a random effect 
2
 Fit statistics: -2 log pseudo-likelihood= 218408.5; Gener. Chi-Square/df= 0.74 
3
 Fit statistics: -2 log pseudo-likelihood= 278804.3; Gener. Chi-Square/df= 0.54 
4 
Fit statistics: -2 log pseudo-likelihood= 272734.1; Gener. Chi-Square/df= 0.61 
5 
Fit statistics: -2 log pseudo-likelihood= 257412.6; Gener. Chi-Square/df= 0.51 
6 
Fit statistics: -2 log pseudo-likelihood= 359.25; Pearson Chi-Square/df= 0.33. Herd was fixed effect. 
7
 The carryover is the number of cases of CM in the previous lactation: 0= none, 1= 1 case of CM, 2= 2 cases of CM and 3= ≥3 cases of CM.   
8
The risk ratio is calculated as exp (0.36)=1.43  
*** p<0.05 
** p<0.10 
* p<0.15 
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In the statistical models, the analyses are stratified by lactation (i.e., primipara and 
multipara). In Figures 2.3.1 and 2.3.2, the lactations are combined. For generic CM in primipara, 
cows were found to be at a greater risk of a second case of CM between 1-2 months after a first 
case of CM [exp(0.19)=1.21; 95% CI (1.07, 1.36); Table 2.4]. In multipara, however, we 
discovered cows were at greater risk within 1 month since the first case of CM. The effect of 
carryover was the same as for first case of bacteria specific CM where applicable. Cows were at 
greater risk of a second case of pathogen specific CM if they had the same pathogen in their first 
case as in the second case, compared with a different pathogen in their first case. There was a 
greater risk of cows contracting a second case of Klebsiella in the summer compared with other 
seasons. 
 
Risk of a third case of bacteria specific CM in wim ≥3 of lactation 
             As above, the risk of a third case of bacteria specific CM was greater within 1 month 
after the second case, then decreased as more months passed (Figures 2.4.1 and 2.4.2). A generic 
CM model for a third case in primipara (Table 2.4) and a bacteria specific CM model for a third 
case in multipara were estimated (Table 2.7).  
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Figure 2.4.1. Monthly risk of a third case of bacteria specific clinical mastitis (Klebsiella, Staph. 
spp. and T. pyogenes ) by months since the second case of clinical mastitis, in 5 New York State 
Holstein herds. 
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Figure 2.4.2. Monthly risk of a third case of bacteria specific clinical mastitis (E. coli, Strep. 
spp. and Staph. aureus) by months since the second case of clinical mastitis, in 5 New York State 
Holstein herds. 
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Table 2.7. Parameter estimates and standard errors for the generalized linear mixed models used to estimate the effects of parity, 
carryover, previous clinical mastitis (CM) exposure, months since second CM and current season, on the risk of a third occurrence of 
bacterial specific CM in multiparous cows (3,031 lactations) in wim ≥ 3 in 5 New York State dairy herds1 
Parameter Estimate (SE) for risk of 3
rd
 case of bacteria specific CM 
 Streptococcus 
spp.
 2
 
Staphylococcus 
aureus
3
 
Staphylococcus 
spp.
 4
 
Escherichia 
coli 
Klebsiella 
spp. 
Trueperella 
pyogenes
5
 
Intercept -3.59 
(0.25)*** 
-5.92 
(0.51)*** 
-6.08 (0.65)*** -3.69 
(0.26)*** 
-4.60 
(0.44)*** 
-5.85 (0.73)*** 
       
Parity       
2  0.24 (0.26) 0.64 (0.41)* -0.21 (0.40) -0.36 (0.26) -0.13 (0.33) -0.45 (0.95) 
3 0.03 (0.28) 0.06 (0.48) 0.01 (0.40) -0.07 (0.25) -0.15 (0.34) 0.21 (0.85) 
≥4 (baseline) 0 0 0 0 0 0 
       
Carryover
6
  --    -- 
0 (baseline) 0  0 0 0  
1 0.24
7
 (0.24)  0.21 (0.38) 0.05 (0.25) 0.70 (0.33)**  
2 -0.73 (0.47)*  -0.36 (0.56) -0.09 (0.36) 0.76 (0.41)**  
3 0.20 (0.34)  0.31 (0.46) 0.32 (0.32) 0.78 (0.43)**  
       
Previous CM exposure 
(associated with 2
nd
 CM 
case) 
    --  
 Different pathogen 0 0 0 0  0 
 Same pathogen -0.13 (0.28) 1.97 (0.34)*** 0.27 (0.54) 0.39 (0.27)  3.66 (0.86)*** 
 Both -1.50 (0.72)** 1.15 (0.54)*** 0.47 (0.53) 0.66 (0.34)**  3.87 (1.14)*** 
       
Months since second case 
of CM 
      
1 (baseline) 0 0 0 0 0 0 
2 -1.36 
(0.31)*** 
-0.38 (0.35) -1.39 (0.48)*** -0.96 
(0.28)*** 
-2.27 
(0.59)*** 
-0.43 (0.84) 
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3 -3.45 (1.0)*** -5.63 (5.09) -1.96 (0.73)*** -1.74 
(0.47)*** 
-2.99 
(1.00)*** 
-6.01 (14.22) 
4+ -3.10 
(0.59)*** 
-1.96 
(0.61)*** 
-3.59 (1.01)*** -2.99 
(0.59)*** 
-3.0 (0.72)*** -1.61 (1.10)* 
       
Current season -- -- -- --  -- 
Fall      0.46 (0.41)  
Spring     -0.64 (0.51)  
Summer     0.71 (0.38)**  
Winter (baseline)     0  
1 
Herd was a random effect
  
2 
Fit statistics: -2 log pseudo-likelihood= 64833.70; Gener. Chi-Square/df= 1.26 
3
 Fit statistics: -2 log pseudo-likelihood= 416.56; Pearson Chi-Square/df= 0.58 and herd as fixed effect 
4
 Fit statistics: Deviance=0.0363; Pearson Chi-Square/df= 1.5 and herd as fixed effect. Negative binomial distribution employed to attain reasonable fit. 
5
 Fit statistics: -2 log pseudo-likelihood= 95.34; Pearson Chi-Square/df= 0.36 and herd as fixed effect 
6
 The carryover is the number of cases of CM in the previous lactation: 0= none, 1= 1 case of CM, 2= 2 cases of CM and 3= ≥3 cases of CM.   
7
The risk ratio is calculated as exp (0.24)= 1.27 
*** p<0.05 
** p<0.10 
* p<0.15 
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                As for second case, the Figures 2.4.1 and 2.4.2 combined lactations, unlike the 
statistical models whereby we separated by primipara and multipara. In primipara, we found a 
cow‟s risk of a third case was greater 1-2 months since her second case. In multipara, however, 
the risk was greater within the first month since her second case. The effect of carryover was the 
same as for first case of bacteria specific CM where applicable. The bacteria specific CM of her 
second case was again found to be significant; however, this time, cows were at greater risk if 
they had both (the same pathogen and a different pathogen) as the second case, followed by the 
same pathogen in their third case as second case, followed by a different pathogen. As for second 
case, there was a greater risk of cows contracting a third case which happened to be Klebsiella in 
the summer compared with other seasons. 
 
DISCUSSION 
 
The relationship between cow characteristics i.e., parity, carryover, previous milk yield, 
previous CM exposure, history of diseases near calving and season on the risk of a first, second 
and third case of bacteria specific CM were estimated. The effects of cow characteristics on the 
risk of CM have been previously extensively studied; the value of this study is the new 
information that contributes to our knowledge of bacterial interactions and persistence. The 
reason for including diseases (other than CM) was because they are among the most common 
clinical conditions that are universally a problem in dairy cows (Gröhn et al., 2004). Clinical 
mastitis infections may be described as „recurrent‟ and this can be explained by two different 
processes (1) the cases are really recurrent cases otherwise (2) these cases are chronic cases that 
are persistent and appear to be recurrent cases. Throughout this paper we distinguish recurrent 
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cases from infection persistence where recurrent cases are multiple CM cases occurring in the 
same animal in the same lactation whereas infection persistence refers to the infection process 
that may be the underlying cause for recurrent clinical cases. 
Compared with our recent previous publications on gram positive, gram negative and 
other CM (Schukken et al., 2009; Hertl et al., 2010; Hertl et al., 2011), we had approximately 
30% more data which allowed us to examine relationships at the bacteria specific level.  A key 
contribution of this study is findings which elucidate the effects of carryover cases of CM from 
the previous lactation, and previous cases of CM within the lactation on the risk of recurrent 
cases of bacteria specific CM. 
Studies have shown that higher milk producing cows are at a greater risk of CM (Gröhn 
et al., 1990; Houben et al., 1993). We also know that cows with CM will begin losing milk 
weeks before CM is identified, and how far back the loss begins is dependent on the pathogen 
involved (Gröhn et al., 2004).  Therefore, we analyzed primipara and multipara separately and 
previous milk yield was defined as milk yield from 2 wk before the current week in milk. 
While the statistical models were developed by parity, the figures in this paper are based 
on pooled observations (not predictive values from the statistical models). This was done to 
observe general trends without stratification of the data and to also compare the results from the 
statistical models with the raw data.  
We found the most common pathogens isolated were Strep. spp., E. coli and no important 
growth. This mirrors the ranking of the most common pathogens identified from our previous 
studies (Schukken et al., 2009; Hertl et al., 2010; Hertl et al., 2011). And as shown in other 
studies, we found cows were at greater risk of CM in general as they grew older (Sargeant et al., 
1998; Steeneveld, 2008; Petrovski et al., 2009). 
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Our results indicate that cows with more cases of CM in the previous lactation were at 
greater risk of bacteria specific CM in the current lactation. Similarly, Houben et al. (1993) 
reported findings of an increased risk of mastitis infections due to infections in the previous 
lactation ranging from a factor of 2.0 (one mastitis case) to 2.9 (3 or more cases). In that study 
however, unlike our study, CM cases were defined differently and at the quarter level. The effect 
of carryover we see in our study may be due to infections from the dry period that are having an 
effect in the subsequent lactation (Green et al., 2002); however, because we did not stratify 
carryover cases by when they occurred in lactation, it is unclear if this is the sole reason for our 
findings.  
The pathogens involved in the persistence of CM infections and the effect these have on 
subsequent infections have been studied extensively (Vaarst and Enevoldsen, 1997; Döpfer et al., 
1999; Green et al., 2002). In our study, we examine repeat cases of CM based on the bacteria 
causing the previous case and the time delay in between. We found multiparous cows were at 
greater risk of a second case of CM if they had suffered from a first case of CM that was caused 
by the same organism as the second case. For third cases, however, a second case of CM caused 
by both the same and a different pathogen as the third case generally put cows at greater risk of a 
third case, compared with if they had either the same or a different pathogen as the third case. 
For multiparous cows, the general trend we found was that cows were at greater risk of a 
recurrent case within the first month after the previous case of CM, unlike primipara, which were 
at greater risk of a recurrent case within 2 months of the previous case. Our results clearly 
suggest that a previous case of CM does not protect against a subsequent case. This is supported 
by the findings of Schukken et al. (2009); a previous case of gram-negative or gram-positive 
mastitis did not protect against a subsequent case of CM with the same Gram-stain classification. 
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For both types of CM, the incidence approximately doubled when a previous case was 
experienced, indicating there is no evidence for a protective immunological memory due to a 
previous exposure to an organism in the same generic class. In the study by Steeneveld et al., 
(2008), the incidence risk of CM for a multiparous cow in month ≥2 increased with increases in 
the accumulated number of CM cases in (1) the previous month in lactation [0 vs ≥2 cases; 
OR=3.12; 95% CI (1.35-8.81)] and also (2) the month in lactation before the previous month in 
lactation [0 vs ≥2 cases; OR=1.82; 95% CI (1.63-5.07)]. The specific pathogen involved in the 
previous case was not delineated; however, the results show that previous cases within the same 
lactation were positive risk factors for the incidence of CM. 
Similar conclusions have also been drawn from infections involving S. uberis and S. 
aureus mastitis (Zadoks et al., 2001a; Zadoks et al., 2001b). Our results indicate that at the cow 
level, those cows with a previous case of the same pathogen or previous case with both the same 
and different pathogens put those cows at greater risk of a subsequent case. Zadoks et al. (2001a) 
found that quarters that had recovered from S. uberis (Zadoks et al., 2001b) or S. aureus mastitis 
had a higher rate of infection compared with quarters that had not experienced infection before, 
indicating that recovery from infection does not confer immunity to reinfection with the same 
pathogen, and in fact, was a risk factor for reinfection with the same and also different bacterial 
species. Although persistence of single cases of CM were not addressed directly in this study, it 
may be that the clinical signs observed were a part of an underlying subclinical process that was 
chronic in nature, which could be applicable to some of the Strep. spp. cases in our study. In a 
study by Zadoks et al., (2003), it was shown that infections starting as clinical cases are 
significantly shorter (median of 13 d) compared with those infections that start subclinically 
(median of 45 d), and infections with a subclinical onset and clinical flare-ups are even longer 
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(median=90 d). Under our case definition of CM, it is therefore possible that the separate cases 
we observed are indications of a disease process that is chronic in nature. This may also lead to a 
longer window of opportunity for spread of infection from cow-to-cow (Zadoks et al., 2003), and 
in part explain the large numbers of Strep. spp. cases seen in this study. Further, Milne et al., 
(2005) showed that 96% (24 out of 25) of the cases of S. uberis that failed to respond to 
conventional treatment were persistent infections with one strain rather than reinfections with 
different strains.  The persistent infections of Strep. spp. observed  in our study could be 
attributable to strains that are different to recurrent infections; however, because we did not 
examine the Streptococcus isolates at the species or strain level this is not conclusive. 
Much attention has been given to the reason for persistent infections, specifically the 
biological mechanisms that facilitate an infection from being persistent compared with being 
transient. Dogan et al. (2006) found that the number of all persistent E. coli strains and one 
transient strain almost doubled during 48 h whereas transient E. coli strains and the non-
pathogenic E. coli strain DH5α decreased over 48 h within cultured mammary epithelial cells. 
The results of this study support an intracellular niche in persistent E. coli mastitis; invasion of 
cultured mammary epithelial cells involved host cell cytoskeletal rearrangement and intracellular 
signaling cascades. White et al. (2009) modeled the dynamics of intramammary E.coli infections 
in dairy cows with the aim of understanding the mechanisms that distinguish transient from 
persistent infections, where the risk of movement of E. coli to and from milk to intra-cellular 
reservoirs were used to parameterize each type of infection. The authors found the predicted 
minimum level of bacteria present was sensitive to changes in the duration of survival in the 
intracellular reservoir; long durations of survival corresponded with higher bacterial counts 
following the acute phase, indicating a failure to spontaneously clear the infection which then led 
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to a persistent infection. The authors proposed that bacterial strains that result in persistent 
infections are more effective at surviving in an intra-cellular reservoir in mammary epithelial 
cells. A study by Vaarst and Enevoldsen (1997) found that Streptococcus dysgalactiae causing 
mastitis (comprising 9% of cases) was typically persistent, virulent and manifested in periods of 
lower cow resistance; quarter abnormalities before the incident were positively related to mastitis 
cases involving this organism, suggesting that it caused severe damage to the udder tissue.   
Atalla et al. (2008) argue that the difficulty in eliminating Staphylococcus aureus mastitis 
may be due partly to the ability of this organism to exist as small colony variants (SCVs). The 
persistence of the intramammary infection may be related to the ability of SCVs to survive 
within the host cells causing minimal perturbation in cell physiology and minimal stimulation of 
the host defense system. It is protected against the host defense system and antimicrobial 
treatment by internalization of SCV within host cells. Although the slow-growing bacteria may 
release small amounts of antigens, it is not enough to induce an appropriate immune response, 
aiding the SCV to establish persistent infection within its host. These underlying biological 
mechanisms may explain the results we see in recurrent cases of S. aureus CM which can be 
translated to persistent infections across time. 
               The findings in our study relating to the absence of immunological memory across 
cases of pathogen specific CM is not directly comparable with the premise behind vaccine 
development. The purpose of vaccines is to elicit an immune response which confers the cow to 
being protected against the pathogen of interest. The same losses to production and damage to 
the mammary gland are not elicited by a vaccination, the same way that it is in a real life 
infection. Due to the detrimental effects of Staphylococcus aureus mastitis, many attempts have 
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been made in developing a vaccine (Calzolari et al., 1997; Leitner et al., 2003; Wallemacq et al., 
2012). Cows suffering from S. aureus mastitis experience damage to the mammary gland and a 
reduction in the quantity and quality of milk. Intracellular invasion protects the pathogen from 
the humoral immune response. Vaccination strategies to increase herd resistance to S. aureus 
exist, however, for these vaccines to be of real use, they need to work at increasing immunity 
without generating the same production limiting effects of the pathogen (Leitner et al., 2003; 
Wallemacq et al., 2012). The Escherichia coli J5 vaccine which has received much attention has 
been known to reduce the incidence of intramammary infections in addition to the associated 
clinical signs in first lactation heifers (Hogan et al., 1999) and multiparous cows (González et al., 
1989; Hogan et al., 1992). In the study by Hogan et al., (1999), the severity and duration of 
clinical signs following intramammary challenge with a heterologous strain of E. coli were 
reduced in vaccinated heifers compared with placebo-injected heifers; this is just one example of 
the value of vaccines in generating an appropriate immune response, which cannot be directly 
compared with the lack of immunological immunity following a real infection. The effect of 
combinations of pathogens in a CM case, and their added risk to subsequent CM cases, as 
demonstrated in our study, suggests that the effects of pathogens are interactive and we may gain 
greater understanding of their effects by considering their synergy instead of viewing them as 
independent organisms in assessing their contribution to future CM cases. 
                A greater risk of recurrent cases of CM, may therefore be due to an immune-
compromised state that cows may experience post-real life CM infection, but not post-
vaccination. Depending on the pathogen involved, the effect on the cow will vary. Therefore, it 
makes sense that this risk was greater when cows had experienced either the same pathogen 
before, or the same pathogen in combination with a different pathogen; the previous exposure to 
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the same pathogen has damaged the udder in such a way that infection with that pathogen again 
is less likely to be overcome. Further, we did not examine individual strains; it is possible that at 
the strain level, the same pattern of absence of immunological memory does not hold. 
              The advantage of developing generalized linear mixed models with an assumed Poisson 
error distribution, as in this study, is that the risk of CM can be easily calculated from the 
parameter estimates in the tables by taking the exponential of the summation of the intercept + 
parameter estimates of interest. As an example, referring to Table 2.3, the risk of a first case of 
Strep spp. within the first 2 weeks of lactation 3 with 2 cases of CM in her previous lactation 
(carryover=2) is calculated by exp(-5.02 -0.27 + 0.46)= 0.008 or 0.8%.  
               A practical application of this study is that the risk of bacteria specific CM by case can 
be calculated depending on cow characteristics, while accounting for variability about the 
estimates. This can guide farmers in identifying which pathogens are more pervasive and require 
particular attention. To quantify the economic consequences of these bacteria causing CM, we 
are currently developing an economic model. The risk of bacteria specific CM from this study 
will be used to parameterize this economic model which will provide dairy farmers with 
economically optimal decisions for their diseased cows. 
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ABSTRACT 
 
The objective of this study was to estimate the effect of a first and repeated cases of 
bacteria specific clinical mastitis (CM) on the risk of mortality and culling in Holstein dairy 
cows. The pathogens studied were Streptococcus spp., Staphylococcus aureus, Staphylococcus 
spp., Escherichia coli, Klebsiella spp., Arcanobacterium pyogenes, others and no growth. A 
Total of 50,166 lactations were analyzed from 5 large, high milk producing dairy herds in New 
York State from 2003/2004 until 2011. Generalized linear mixed models with a Poisson error 
distribution were used to study the effects of parity, month of lactation, CM, calving diseases, 
pregnancy status, current season and economic values on the risk of mortality and culling. 
Among first lactation cows, the presence of a first CM case generally exposed cows to a greater 
risk of mortality in the current month (compared with the absence of a first case). This was 
especially acute with a first case of Klebsiella, where cows were 4.57 (exp(1.52)= 4.57 [95% CI 
(2.75, 7.61)]) times more at risk of mortality, and with a first case of E. coli with cows 3.32 times 
more at risk (i.e., relative risk = exp(1.20)= 3.32, [95% CI (2.46, 4.48)]. In general the presence 
of a first or second case resulted in cows in parity ≥2 with a greater risk of mortality (compared 
with cows with no first or second case of bacteria specific CM in the current month in milk). 
This was greatest for cows with a first case of Klebsiella,; (exp (1.39)= 4.01 [95% CI (3.53, 
4.57)]), followed by  a second case of Klebsiella, (exp(1.14)=3.13 [95% CI (2.39, 4.10)]), then a 
first case of E. coli (exp(1.11) = 3.03 [95% CI (2.75, 3.35)]). In first parity cows, the risk of 
culling generally increased with the presence of a case of bacteria specific CM. This was 
observed among cows with a first case of T. pyogenes, (exp (2.46)= 11.70 [95% CI (9.03, 
15.18)]), a first case of Klebsiella, (exp(2.30)= 9.97 [95% CI (7.92, 12.55)]) and a first case of 
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Staphylococcus aureus, (exp(1.74)= 5.70 [95% CI (4.57, 7.10)]). Among cows of parity ≥2, 
when a cow contracted a case of Streptococcus spp., she was more likely to be culled one month 
after the case of CM (regardless of whether it was a first, second or third case of Streptococcus 
spp.). The risk of culling depending on the cow‟s characteristics can be easily calculated from 
the parameter estimates in provided tables.  
 
Key words: mortality, culling, bacteria specific, mastitis 
 
INTRODUCTION 
 
Mastitis is one of the top three reasons for culling  dairy cows, alongside lameness and 
failure to conceive (Esslemont and Kossaibati, 1997). The effects of mastitis include reduced 
conception (Hertl et al., 2010), losses to milk yield (Schukken et al., 2009), a higher risk of 
mortality (Bar et al., 2008a; Hertl et al., 2011) and, depending on the pathogen involved, 
significant treatment costs. In addition to the presence of disease, when making a decision, the 
dairy farmer considers milk yield, conception status, stage of lactation and parity (Gröhn et al., 
1998; Rajala-Schultz and Gröhn, 1999). From this perspective, studies have been performed to 
identify the cost of mastitis and optimal economical management decisions (Halasa et al., 2009; 
Sørensen et al., 2010). Farmers may justify that it is economically optimal to replace their 
diseased cows with heifers, in anticipation of accrued losses to production over their projected 
lifespan (Houben et al., 1994; Bar et al., 2008b; Cha et al., 2011) and management of milk 
quality.  
57 
 
In order to estimate the cost of mastitis, it becomes necessary to separate those events that 
are beyond the control of the dairy farmer from those events that are within the dairy farmer‟s 
control. Mortality, i.e., death, is a forced event that occurs with a given probability, whereas 
culling, i.e., selling a cow, is a decision that may or may not be economically optimal for a dairy 
farmer to make depending on the specific cow involved (Houben et al., 1994; Bar et al., 2008a; 
Bar et al., 2008b). 
The risk of mortality and culling is dependent on the pathogen that is causing the clinical 
mastitis (CM), the repeatability of cases, seasonality and cow characteristics. For example, a 
study of mortality among Danish dairy cattle showed that the most frequent specific diagnosis 
among udder/teat disorders resulting in death was septic mastitis caused by Escherichia coli 
(Thomsen et al., 2004). Hazlett et al. (1984) similarly found that E. coli followed by Klebsiella 
were the most common causes of fatal mastitis. The severity of mastitis has been shown to be 
time dependent; Bradley and Green (2001) demonstrated that E. coli mastitis had a tendency of 
being more severe between October and March than between April and September and a trend 
towards more severe mastitis occurring in the first 90 days of lactation than in the latter periods 
of lactation. The authors reason that this may be due to alterations in pathogenicity of the 
organisms present among environmental pathogens at various times of the year. This parallels 
the findings of Lehtolainen et al. (2003) where cows‟ responses, defined by local and systemic 
signs to intramammary infused E. coli endotoxin were significantly more severe in early 
lactation than late lactation. We have studied the risk of repeated cases of bacteria specific CM 
and have found that a previous case with the same pathogen will put cows at greater risk of a 
subsequent case (E. Cha, unpublished data). Earlier, Bradley and Green (2001) reported similar 
results i.e., repeat cases of CM occurred in 46 (16.4%) of affected quarters, and in 24 (8.6%) the 
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repeat cases were due to the same species of pathogens as the initial case. Although previous 
studies have examined the effects of repeated episodes of non-bacteria specific CM (Bar et al., 
2008a), repeated episodes of gram-positive, gram-negative and other CM (Hertl et al., 2011) and 
a first case of pathogen specific CM on mortality and culling in dairy cows (Hazlett et al., 1984; 
Gröhn et al., 2005), no study has investigated the role of repeated cases of pathogen specific CM. 
Specifically, it is unclear if repeated cases of the same pathogen and if a shorter time interval 
between repeated cases put cows at a greater risk of being culled.  
 
 
The objective of this study was to estimate the effect of a first and repeated cases of 
bacteria specific CM on the risk of mortality and culling in Holstein dairy cows. 
 
MATERIALS AND METHODS 
 
Herd Descriptions 
Data from 50,166 lactations were assembled (18,420 of parity 1 and 31,746 of parity 2 
and greater) from 23,409 cows. The data in this study were collected from 2003/2004 until 2011 
(7-8 years) from 5 large dairy herds in New York State. The 305-d rolling herd average milk 
production ranged from 11,260 to 13,123 kg/cow per year, and the monthly mean SCC ranged 
from 137,000 to 262,000 cells/ml. 
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Cows were housed in freestalls. Feed was provided in the feed alleys with headlocks 
which facilitated the treatment and examination of cows. Cows were stratified by lactation, 
production, and reproductive status into feeding groups which were fed a total mixed ration. 
Cows were milked 3 times a day and the milking units automatically recorded milk production. 
Lactation, reproductive and medical information were entered into DairyComp305 herd 
management software (Valley Agricultural Software, Tulare, CA) by herd personnel. 
Information on parity, diseases, drying off, calving and exit from all herds was available as it 
was used by herd personnel for management of the dairy (Bar et al., 2008a; Hertl et al., 2011).  
The variables relating to milk yield, mastitis culture results, diseases and reproduction 
necessary to conduct this study were exported to ASCII files from DairyComp305 and imported 
into SAS v. 9.2 (2008). The quality of the data was assessed through preliminary descriptive 
analyses of the variables of interest. 
 
Case definition 
All lactating cows in the 5 herds were eligible for inclusion in the study. Cows were 
identified as having CM based on (1) milkers observing clinical signs of CM, i.e., a warm, 
swollen udder or changes in milk color or consistency; otherwise, the remaining cases which 
were missed by milkers were identified by (2) herdspersons who examined cows due to elevated 
milk electrical conductivity in addition to a sudden concurrent milk loss as alerted by the farm 
computer system. The treatment protocol for diseased cows was similar across the 5 dairy herds 
and throughout the study. Herd personnel collected milk samples from quarters with signs of CM 
for microbiological culturing at the Quality Milk Production Services laboratories located in NY 
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state. The culture procedures are described in more detail Gröhn et al. (2004). Briefly, milk 
samples were plated by streaking 0.01mL on trypticase soy agar II with 5% sheep blood and 
0.1% esculin (BBL; Becton Dickinson Microbiology Systems, Cockeyville, MD). Plates were 
incubated at 37°C for 48 h. Following observation of colony morphology and hemolytic patterns 
on blood agar, isolates were examined by means of 3% KOH, gram-staining organisms, catalase 
and oxidase testing, and additional biochemical and metabolic evaluations as required. Colony 
morphology on Mac Conkey agar and the BBL Crystal ID System (Becton Dickinson) identified 
gram-negative organisms. Streptococci that had a negative CAMP reaction were classified as 
Streptococcus spp. Staphylococci with β or αβ hemolytic patterns that had a positive tube test for 
free coagulase were classified as Staph. aureus. Nonhemolytic staphylococci with a positive tube 
coagulase test were further identified with the API Staph System (bio-Merieux Vitek, 
Hazelwood, MO). Coagulase-negative staphylococci were classified as Staphylococcus spp. 
The unit of observation was month within the lactation of a cow. Some cows experienced 
two types of bacteria specific CM that were isolated within the same lactation within a few days 
of each other. If the second pathogen was isolated in the same quarter 5 or fewer days after the 
first pathogen (regardless of the pathogen isolated) or occurred within 14 d with the same 
pathogens isolated, it was considered to be the same case of mastitis. Any mastitis case after 14 d 
since the previous mastitis case was considered a new case (Barkema et al., 1998). 
If a cow had multiple quarter infections at the same time (e.g., E. coli in the left rear 
quarter and Staphylococcus spp. in the right front quarter, or both pathogens in the same quarter), 
she was considered to have both E. coli and Staphylococcus spp. isolated within the one case 
(Hertl et al., 2011). 
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Bacteria specific CM  
The bacteria causing CM studied were Streptococcus spp., Staphylococcus aureus, 
Staphylococcus spp., Escherichia coli, Klebsiella, Trueperella pyogenes, other CM (i.e., 
pathogens other than those listed above), and no growth. No growth was defined as either no 
growth on the culture plate, contaminated sample (more than two bacterial organisms on same 
plate) or no significant organisms. The latter, no significant organisms, were defined as no 
bacterial growth of either Staphylococcus aureus or Streptococcus agalactiae while the culture 
plate contained more than two different species.  
 
Other Diseases 
Five other diseases were included as potential confounders. These diseases are among the 
most common clinical conditions  universally problematic in dairy cows (Gröhn et al., 2004). 
The 5 diseases included were milk fever, retained placenta, metritis, ketosis and displaced 
abomasum (DA). They were defined as follows: 1) milk fever occurred if a cow was unable to 
rise or had cool extremities and sluggish rumen motility near the time of calving, but was treated 
successfully with calcium, 2) retained placenta was retention of fetal membranes for at least 24 h 
post calving, 3) metritis involved a febrile state accompanying a purulent or fetid vaginal 
discharge or diagnosis of an enlarged uterus by veterinary palpation, 4) ketosis was diagnosed by 
a drop in feed intake and milk production with detection of ketones in milk, urine or breath and 
no other concomitant diseases and with response to treatment, and 5) DA occurred when the 
abomasum was enlarged with fluid, gas or both and was mechanically trapped in either the left or 
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right side of the abdominal cavity; nearly every DA case was confirmed by surgery, but cows 
removed from the herd without treatment were also recorded. Every effort was made to ensure 
that disease definition and diagnostic criteria were consistent across herds and written disease 
definitions were provided to dairy producers and veterinarians involved to assist with diagnosis. 
 
Statistical Methods  
The GLIMMIX procedure of SAS v. 9.2 (SAS Institute, 2008) was used to study the 
effect of bacteria specific CM on the risk of mortality and culling. Variables for inclusion were 
selected based on univariate analysis where a P-value ≤0.20 was considered significant using 
stepwise barkward elimination; variables of biological importance were also kept. The form of 
the generalized linear mixed model used was  
 
 Ln (Y) = β0 + β1x1 +  β2x2 + β3x3 + … + βkxk + Zγ + ε,                            [1] 
 
where Ln is a link function, here the natural log of the probability of a cow dying or being culled 
in a month; Y is the vector  of observations (either dying or being culled in a given month); β0 is 
the regression parameter for the intercept, and β1, β2, β3 . . ., βk are the regression coefficients for 
the fixed effects x1, x2, x3 . . ., xk (described below); γ is an unknown vector of random-effect 
parameters with known design matrix Z, and ε, a presumed independent random Poisson 
distributed residual term. Fixed effects in our models were parity with 3 levels (for multiparous 
cows, i.e., second, third and fourth and greater in lactation), stage of lactation (months 1 to 10); 
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current season with four levels (Summer (Jun to Aug), Fall (Sep to Nov), Winter (Dec to Feb) 
and Spring (Mar to May)), pregnancy status (yes, no), other diseases with 2 levels (presence or 
absence), and non-bacteria specific CM indices. The selection of these periods are informative 
but also based upon needs of a later economic model to be constructed using the estimates. For 
the culling analysis, fixed effects included monthly profitability and monthly net replacement 
cost. Monthly profitability was defined to be monthly milk price – monthly operating cost. Milk 
prices were obtained from the USDA (USDA-National Agricultural Statistics Service, 2012) for 
each month of observation in the dataset, and are wholesale prices ($/cwt.) received by New 
York farmers. Operating costs were obtained from the USDA (USDA-Economic Research 
Service, 2010; USDA-Economic Research Service, 2012) for each month of observation and are 
the monthly dairy costs of production per hundredweight of milk sold for New York farmers. 
Monthly net replacement cost was defined as monthly purchase price of replacement – monthly 
cull price of cow. Purchase prices of replacements were obtained from the USDA (USDA-
National Agricultural Statistics Service, 2012) for each month of observation. More details can 
be found in Hertl et al. (2011). 
For the mortality analyses, we were particularly interested in estimating the risk of 
mortality based on the presence or absence of pathogen specific CM by case (1, 2 and 3) in the 
current month in milk, whereas in the culling analysis, we were also interested in observing 
whether the risk of culling was not only greatest in month of bacteria specific CM occurrence by 
case, but also how the risk varied as months passed since the case of bacteria specific CM. 
Models with a binomial, poisson and negative binomial distribution, as well as covariate coding 
schemes in accordance with the above were developed. In instances where such a detailed 
covariate coding scheme did not allow model convergence in any of these 3 different 
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distributions, alternative covariate coding schemes were explored. The best models were 
selected, based on whether convergence could be attained and model fit (-2 Log likelihood and 
Pearson or Generalized Chi Square/df). The models with the best fit are presented in this paper 
(with fit statistics reported in the results section). 
For the mortality analysis of primiparous cows, each bacteria specific CM had two 
separate binary variables (a) 1 = presence of a 1
st
 case of bacteria specific CM in the current 
month of lactation and 0 = absence of that bacteria specific CM in the current month of lactation 
and (b) 1 = presence of a second or third case of bacteria specific CM in the current month of 
lactation and 0 = absence of a second or third case of bacteria specific CM in the current month 
of lactation. For the mortality analysis of multiparous cows, each bacteria specific CM by case 
had a binary variable i.e. 1 = presence of a 1
st
 case of bacteria specific CM in the current month 
of lactation and 0 = absence of that bacteria specific CM in the current month of lactation (Table 
3.3.1). 
For the culling analysis of primiparous cows, each case of bacteria specific CM had 2 
binary variables i.e., (a) 1 = presence of a 1
st
 case of bacteria specific CM in the current month of 
lactation and 0 = absence of that bacteria specific CM in the current month of lactation and (b) 1 
= one or more months have passed since the 1
st
 case of bacteria specific CM and 0 = the cow had 
a 1st CM case of that bacteria specific CM (or if it is before that CM) or the cow did not have that CM.  
Lastly, the bacteria specific CM indices for the culling analysis of multiparous cows had, 
for each CM index variable and each case (e.g., Streptococcus spp. case 1, Streptococcus spp. 
case 2, Streptococcus spp. case 3, Staphylococcus aureus case 1, Staphylococcus aureus case 2, 
Staphylococcus aureus case 3, Staphylococcus spp. case 1, Staphylococcus spp. case 2, 
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Staphylococcus spp. case 3 etc), 3 levels as for the non-bacteria specific CM levels for the 
mortality analysis described above (Table 3.3.2). 
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Table 3.3.1. Covariate coding scheme used in the (multiparous cows) mortality analysis: data for 3 example cows with bacteria 
specific clinical mastitis. ( Only Escherichia coli and Staphyloccoccus spp. index variables are shown due to space restrictions)
 
Co
w 
ID
1
 
Mont
h in 
milk 
Mont
h of 
first 
CM 
case 
1
st
 case 
pathoge
n1 
Mont
h of 
secon
d CM 
case 
2nd case 
pathoge
n1 
Mont
h of 
third 
CM 
case 
3rd case 
pathoge
n1 
Escherich
ia coli 
case 12 
Escherich
ia coli 
case 22 
Escherich
ia coli 
case 32 
Stap
h 
spp. 
case 
12 
Stap
h 
spp. 
case 
22 
Stap
h 
spp. 
case 
32 
Mont
h 
died 
Die
d 
1 1 2 EC 2 SP - NA 0 0 0 0 0 0 - 0 
1 2 2 EC 2 SP - NA 1 0 0 0 1 0 - 0 
1 2 2 EC 2 SP - NA 0 0 0 0 0 0 - 0 
1 3 2 EC 2 SP - NA 0 0 0 0 0 0 - 0 
1 4 2 EC 2 SP - NA 0 0 0 0 0 0 - 0 
2 1 1 SP - NA - NA 0 0 0 1 0 0 4 0 
2 2 1 SP - NA - NA 0 0 0 0 0 0 4 0 
2 3 1 SP - NA - NA 0 0 0 0 0 0 4 0 
2 4 1 SP - NA - NA 0 0 0 0 0 0 4 1 
3 1 - NA - NA - NA 0 0 0 0 0 0 - 0 
3 2 - NA - NA - NA 0 0 0 0 0 0 - 0 
3 3 - NA - NA - NA 0 0 0 0 0 0 - 0 
3 4 - NA - NA - NA 0 0 0 0 0 0 - 0 
3 5 - NA - NA - NA 0 0 0 0 0 0 - 0 
3 6 - NA - NA - NA 0 0 0 0 0 0 - 0 
3 7 - NA - NA - NA 0 0 0 0 0 0 - 0 
3 8 - NA - NA - NA 0 0 0 0 0 0 - 0 
3 9 - NA - NA - NA 0 0 0 0 0 0 - 0 
3 10 - NA - NA - NA 0 0 0 0 0 0 - 0 
1
Note that a max of 2 pathogens is listed because of space limitations. EC= Escherichia coli; SP= Staphylococcus spp. and NA= none  
2
The index variable for cases of CM had 2 levels: 0 = absence of that pathogen and case in the current month of lactation; 1 = presence of that pathogen and case 
in the current month of lactation 
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Table 3.3.2. Covariate coding scheme used in the (multiparous cows) culling analysis: data for 4 example cows with bacteria specific 
clinical mastitis (CM indices; only Streptococcus spp. case 2, Streptococcus spp. case 3, Staphylococcus spp. case 1, Escherichia coli 
case 2, Klebsiella case 1, no growth case 1, no growth case 2 and other case 1 are shown due to space restrictions)
 
Cow 
ID 
Month 
in 
milk 
Month 
of first 
CM 
case 
Month 
of 
second 
CM 
case 
Month 
of 
third 
CM 
case 
Month 
sold 
Index 
variable for 
Streptococcus 
spp. CM case 
2
1
 
Index variable 
for 
Streptococcus 
spp. CM case 
3  
Index variable 
for 
Staphylococcus 
spp. CM case 1 
Index 
variable for 
Escherichia 
coli CM 
case 2 
Index 
variable 
for 
Klebsiella 
CM case 
1 
Index 
variable for 
no growth 
CM case 1 
Index 
variable 
for no 
growth 
CM 
case 2 
Index 
variable 
for 
other 
CM 
case 1 
Sold 
1 1 1 2 - - 10 10 10 10 10 1 10 10 0 
1 2 1 2 - - 10 10 10 1 10 2 10 10 0 
1 3 1 2 - - 10 10 10 2 10 3 10 10 0 
1 4 1 2 - - 10 10 10 3 10 3 10 10 0 
1 5 1 2 - - 10 10 10 3 10 3 10 10 0 
1 6 1 2 - - 10 10 10 3 10 3 10 10 0 
1 7 1 2 - - 10 10 10 3 10 3 10 10 0 
1 8 1 2 - - 10 10 10 3 10 3 10 10 0 
1 9 1 2 - - 10 10 10 3 10 3 10 10 0 
1 10 1 2 - - 10 10 10 3 10 3 10 10 0 
2 1 2 2 3 4 10 10 10 10 10 10 10 10 0 
2 2 2 2 3 4 10 10 10 10 10 1 1 10 0 
2 3 2 2 3 4 10 1 10 10 10 2 2 10 0 
2 4 2 2 3 4 10 2 10 10 10 3 3 10 1 
3 1 - - - 3 10 10 10 10 10 10 10 10 0 
3 2 - - - 3 10 10 10 10 10 10 10 10 0 
3 3 - - - 3 10 10 10 10 10 10 10 10 1 
4 1 3 3 8 - 10 10 10 10 10 10 10 10 0 
4 2 3 3 8 - 10 10 10 10 10 10 10 10 0 
4 3 3 3 8 - 1 10 10 10 10 10 10 1 0 
4 4 3 3 8 - 2 10 10 10 10 10 10 2 0 
4 5 3 3 8 - 3 10 10 10 10 10 10 3 0 
4 6 3 3 8 - 3 10 10 10 10 10 10 3 0 
4 7 3 3 8 - 3 10 10 10 10 10 10 3 0 
4 8 3 3 8 - 3 1 10 10 10 10 10 3 0 
4 9 3 3 8 - 3 2 10 10 10 10 10 3 0 
4 10 3 3 8 - 3 3 10 10 10 10 10 3 0 
1 The index variable for cases of bacteria specific CM (Streptococcus spp., Staphylococcus aureus, Staphylococcus spp., Escherichia coli, Klebsiella, Trueperella pyogenes, no 
growth, other by case, although not all are shown here) had 3 levels: 1 = case of CM occurring in the current month of lactation; 2 =  case of CM occurring in the previous month 
(in the same lactation); 3 = case of CM occurring ≥ 2 months ago (in the same lactation) 
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We analyzed the occurrence of CM per cow-month at risk. Because we used such a short 
time-period as our unit of analysis, the distinction between risk and rate diminishes. The 
relationship between risk (cumulative incidence) and rate is given by: 
 
Cumulative Incidence = 1 – exp(-Incidence * delta t), where delta t would be the time unit of 
cow-months. For a small cumulative incidence, a good approximation is Incidence*delta t, and 
where delta t in our models equals 1, and where essentially the cumulative incidence and 
incidence can then be used interchangeably. For that reason we will use risk as a measure of 
disease occurrence throughout this paper (Rothman, 1986). 
Because we were not interested in specific herds, but rather herds in general with the 
common characteristics of being large, high-milk producing dairy herds with a low incidence of 
contagious mastitis, we always attempted to include herd as a random  effect. Observation 
periods were censored at a typical lactation of 10 months, or when cows died or were culled. A 
sample coding scheme for the mortality (culling) analysis is illustrated in Table 3.3.1 (Table 
3.3.2).  
For the mortality dataset, 2 models were fitted: (1a) effects of risk factors (current season, 
month of lactation, bacteria specific CM cases, pregnancy status, other diseases) on the risk of 
mortality in primipara; (1b) effects of risk factors (parity, current season, month of lactation, 
bacteria specific CM cases, pregnancy status, other diseases) on risk of mortality in multipara. 
For the culling dataset, 2 models were fitted: (2a) effects of risk factors (month of lactation, 
bacteria specific CM cases including time since previous case, pregnancy status, other diseases, 
economic values) on the risk of culling in primipara; (2b) effects of risk factors (parity, season, 
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month of lactation, bacteria specific CM cases, pregnancy status, other diseases, economic 
values) on the risk of culling in multipara. Not all models retained the variables listed in 
brackets; a P-value below 0.05 was considered significant. 
 
RESULTS 
 
Descriptive findings 
The number of observations were 416,016 months, from, 50,166 lactations (18,420 of 
parity 1 and 31,746 of parity 2 and greater in 23,409 cows) from 5 large dairy herds in New York 
State. In primipara (multipara) there were 3,712 (11,388) first cases, 959 (4,352) second cases 
and 300 (1,816) third cases of CM. The median day in milk for mastitis occurrence for each case 
was greater for primiparous cows compared with multiparous cows. This was also the trend for 
the median day in milk of mortality (culling); in  primipara, 100 (269) compared with 74 (207) in 
multipara (Table 3.3). The most common pathogens in both groups were Streptococcus spp., E. 
coli and no growth (Table 3.4). 
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Table 3.3. Number of lactations, and median day in milk of occurrence of a first, second, or third case of clinical mastitis (CM), 
mortality (dying) or being culled (sold) in the first 10 months of lactation, in 5 New York State Holstein herds 
 First lactations (n=18,420) Second and greater lactations (n=31,746) 
 Number Median day in milk Number Median day in milk 
First case of CM 3,712 128 11,388 103 
Second case of CM 959 200 4,352 159 
Third case of CM 300 226 1,816 190 
Mortality 727 100 2,855 74 
Culling 2,523 269 9,476 207 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 
 
Table 3.4. Distribution of pathogens causing clinical mastitis (CM) in 5 New York State dairy herds by lactation (1
st
 lactation and ≥2 
lactations)
 1
 
Lactation and pathogen Number (Lactation incidence risk %) 
First lactation (n= 18,420)
 2
  
  Streptococcus spp.  1,185 (6.4) 
  Staphylococcus aureus 393 (2.1) 
  Staphylococcus spp.  392 (2.1) 
  Escherichia coli  1,046 (5.7) 
  Klebsiella  278 (1.5) 
  Trueperella pyogenes  139 (0.8) 
  Citrobacter  0 (0) 
  Enterobacter  1 (0.005) 
  Pseudomonas  10 (0.05) 
  Mycoplasma  73 (0.4) 
  Corynebacterium bovis  30 (0.2) 
  Yeast  87 (0.5) 
  Miscellaneous 677 (3.7) 
  Contamination  61 (0.3) 
  Unknown
3 
 378 (2.1) 
  No growth
4 
 1,141 (6.2) 
Second and greater lactations (n= 31,746)
 5
  
  Streptococcus spp.  4,275 (13.5) 
  Staphylococcus aureus  974 (3.1) 
  Staphylococcus spp.  1,119 (3.5) 
  Escherichia coli  4,040 (12.7) 
  Klebsiella  1,844 (5.8) 
  Trueperella pyogenes  332 (1.0) 
  Citrobacter  35 (0.1) 
  Enterobacter  50 (0.2) 
  Pseudomonas  22 (0.07) 
  Mycoplasma  76 (0.2) 
  Corynebacterium bovis  36 (0.1) 
  Yeast  216 (0.7) 
  Miscellaneous 2,133 (6.7) 
  Contamination  218 (0.7) 
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  Unknown
2 
 1,073 (3.4) 
  No growth
3 
 4,363 (13.7) 
1
Total number of CM cases (first, second and third) in which the pathogen was identified. A cow may have more than one pathogen in one case. In 
the table 
above, both are accounted for. 
2
The number of cows that started their first lactation 
3
The etiologic agent was not identified in the cultured sample 
4
No bacterial growth above the level of detection of our microbiological procedures was observed in the cultured sample; however, these cases 
exhibited clinical signs of mastitis 
5
The number of cows that started their second or greater lactation 
 
Effect of bacteria specific CM on mortality in primiparous cows 
The fit statistics for the model estimated were as follows: -2 Log likelihood of 6744.03 and Pearson chi-square/df of 0.95. The 
presence of a first case in the current month in milk (compared with the absence of a first case) generally put cows at greater risk of 
mortality in that month; this was seen particularly with a first case of Klebsiella, where cows were exp(1.52)= 4.57 [95% CI (2.75, 
7.61)] times more at risk of mortality than cows without a first case of Klebsiella (Table 3.5). This was followed by a first case of E. 
coli (relative risk = exp(1.20)= 3.32 [95% CI (2.46, 4.48)] compared with the baseline of the absence of a first case of E. coli in the 
current month in milk). Cows with a second or third case of E. coli were exp (1.1)= 3.00 [95% CI (1.42, 6.36)] times more at risk of 
mortality compared with cows without a second or third case of E. coli in the current month in milk. Cows with retained placenta or 
displaced abomasum were also at greater risk of mortality i.e., exp(1)= 2.72 [95% CI (2.32, 3.19)] and exp(1.10)= 3.00 [95% CI (2.59, 
3.49)], respectively. Pregnancy had a protective effect i.e., exp(-1.34)= 0.26 [95% CI (0.23, 0.30)]. 
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Table 3.5. Effects of the first 3 pathogen specific clinical mastitis (CM) cases and other factors on mortality in primiparous cows 
(18,420 lactations) in 5 New York State dairy farms over the first 10 months of lactation
1
 
Parameter
 
Estimate (SE) 
 
Intercept
 
-4.61 (0.13)***
 
  
Fall2  -0.08 (0.12) 
Spring -0.43 (0.13)*** 
Summer -0.05 (0.11) 
Winter (baseline) 0 
  
Month 1 of lactation (baseline)
 
0
 
Month 2 of lactation
 
-1.16 (0.14)*** 
Month 3 of lactation
 
-1.57 (0.20) *** 
Month 4 of lactation
 
-1.09 (0.18) *** 
Month 5 of lactation
 
-1.69 (0.26) *** 
Month 6 of lactation
 
-0.83 (0.20) *** 
Month 7 of lactation
 
-1.04 (0.22) *** 
Month 8 of lactation
 
-0.78 (0.21) *** 
Month 9 of lactation
 
-0.77 (0.22) *** 
Month 10 of lactation 
 
-0.60 (0.22) *** 
  
First CM case (Streptococcus. spp.) occurring in the current month of 
lactation 
0.22 (0.42) 
No first CM case (Streptococcus. spp.) in the current month 
(baseline) 
0 
  
Second or third CM case (Streptococcus. spp.) occurring in the 
current month of lactation 
-3.17 (6.10) 
No second or third CM case (Streptococcus. spp.) in the current 
month (baseline) 
0 
  
First CM case (Escherichia coli) occurring in the current month of 
lactation 
1.20 (0.3)*** 
No first CM case (Escherichia coli) in the current month (baseline) 0 
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Second or third CM case (Escherichia coli) occurring in the current 
month of lactation 
1.10 (0.75)* 
No second or third CM case (Escherichia coli) in the current month 
(baseline) 
0 
  
First CM case (Klebsiella) occurring in the current month of lactation 1.52 (0.51)*** 
No first CM case (Klebsiella) in the current month (baseline) 0 
  
Second or third CM case (Klebsiella) occurring in the current month 
of lactation 
1.35 (1.04) 
No second or third CM case (Klebsiella) in the current month 
(baseline) 
0 
  
First CM case (no growth
3
) occurring in the current month of 
lactation 
-0.49 (0.71) 
No first CM case (no growth) in the current month (baseline) 0 
  
Second or third CM case (no growth) occurring in the current month 
of lactation 
0.84 (0.72) 
No second or third CM case (no growth) in the current month 
(baseline) 
0 
  
First CM case (other
4
) occurring in the current month of lactation 0.65 (0.35)** 
No first CM case (other) in the current month (baseline) 0 
  
Second or third CM case (other) occurring in the current month of 
lactation 
1.06 (0.64)** 
No second or third CM case (other) in the current month (baseline) 0 
  
Pregnant (yes vs. no) -1.34 (0.14) *** 
  
Retained placenta (yes vs. no) 1.0 (0.16) *** 
Displaced abomasum (yes vs. no) 1.10 (0.15) *** 
  
Farm 1 -0.10 (0.18) 
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Farm 2 0.46 (0.12) *** 
Farm 3 0.41 (0.13) *** 
Farm 4 0.18 (0.15) 
Farm 5 0 
1
Estimates were obtained from a generalized mixed model with a Poisson distribution  
2
The rate ratio is calculated as exp(-0.08)=0.92 
3
No bacteriological growth (i.e., no bacterial growth above the level of detection of our microbiological procedures) was observed in the cultured sample; 
however, these cases exhibited clinical signs of mastitis
 
4
These included Mycoplasma, Corynebacterium bovis, yeast, miscellaneous, contamination and unknown CM 
*** p<0.05 ** p<0.10 * p<0.15 
 
Effect of bacteria specific CM on mortality in multiparous cows 
The fit statistics for the model estimated were as follows: -2 Log likelihood of 24572.08 and Pearson chi-square/df of 0.98. A 
first or second case of Streptococcus spp. had a protective effective on the risk of mortality (evidenced by negative parameter 
estimates) (Table 3.6). In general, however, the presence of a first or second case put cows at greater risk of mortality (compared with 
the absence of a first or second case). This was greatest for cows with a first case of Klebsiella in the current month in milk (exp 
(1.39)= 4.01 [95% CI (3.53, 4.57)]), followed by  a second case of Klebsiella, (exp(1.14)=3.13 [95% CI (2.39, 4.10)]), a first case of 
E. coli (exp(1.11)= 3.03 [95% CI (2.75, 3.35)]), a first case of T. pyogenes (exp(1.08)= 2.94 [95% CI (2.27, 3.82)]) and a third case of 
other CM (exp(1.03)= 2.80 [95% CI (1.92, 4.10)]). As for the primiparous cow analysis, pregnancy had a protective effect and other 
diseases (retained placenta, displaced abomasum and milk fever) increased the risk of mortality. The risk was greatest in the summer 
(compared with winter); exp(0.16) = 1.17, [95% CI (1.12, 1.23)]. 
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Table 3.6. Effects of the first 3 pathogen specific clinical mastitis (CM) cases and other factors on mortality in multiparous cows 
(31,746 lactations) in 5 New York State dairy farms over the first 10 months of lactation
1 
Parameter
 
Estimate (SE) 
 
Intercept
 
-4.51 (0.07)***
 
  
Parity 2 (baseline)
 
0
 
Parity 3
 
0.42 (0.05)***
 
Parity 4
 
0.72 (0.05)***
 
  
Fall2  -0.15 (0.06)*** 
Spring -0.10 (0.06)* 
Summer 0.16 (0.05)*** 
Winter (baseline) 0 
  
Month 1 of lactation (baseline)
 
0
 
Month 2 of lactation
 
-0.86 (0.07)*** 
Month 3 of lactation
 
-0.86 (0.08) *** 
Month 4 of lactation
 
-0.89 (0.09) *** 
Month 5 of lactation
 
-0.86 (0.09) *** 
Month 6 of lactation
 
-0.92 (0.10) *** 
Month 7 of lactation
 
-0.72 (0.10) *** 
Month 8 of lactation
 
-0.68 (0.11) *** 
Month 9 of lactation
 
-0.74 (0.12) *** 
Month 10 of lactation 
 
-0.57 (0.11) *** 
  
First CM case (Streptococcus. spp.) occurring in the current month of 
lactation
2
 
-0.64 (0.22) *** 
No first CM case (Streptococcus. spp.) in the current month 
(baseline) 
0 
  
Second CM case (Streptococcus. spp.) occurring in the current month 
of lactation 
-0.74 (0.51)* 
No second CM case (Streptococcus. spp.) in the current month 
(baseline) 
0 
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Third CM case (Streptococcus. spp.) occurring in the current month 
of lactation 
-2.37 (1.94) 
No third CM case (Streptococcus. spp.) in the current month 
(baseline) 
0 
  
First CM case (Staphylococcus aureus) occurring in the current 
month of lactation 
0.64 (0.28) *** 
No first CM case (Staphylococcus aureus) in the current month 
(baseline) 
0 
  
Second CM case (Staphylococcus aureus) occurring in the current 
month of lactation 
0.29 (0.59) 
No second CM case (Staphylococcus aureus) in the current month 
(baseline) 
0 
  
Third CM case (Staphylococcus aureus) occurring in the current 
month of lactation 
-2.33 (3.59) 
No third CM case (Staphylococcus aureus)  in the current month 
(baseline) 
 
  
First CM case (Staphylococcus spp.) occurring in the current month 
of lactation 
0.29 (0.27) 
No first CM case (Staphylococcus spp.) in the current month 
(baseline) 
0 
  
Second CM case (Staphylococcus spp.) occurring in the current 
month of lactation 
1.02 (0.42)*** 
No second CM case (Staphylococcus spp.) in the current month 
(baseline) 
0 
  
Third CM case (Staphylococcus spp.) occurring in the current month 
of lactation 
1.00 (0.74) 
No third CM case (Staphylococcus spp.) in the current month 
(baseline) 
0 
  
First CM case (Escherichia coli) occurring in the current month of 1.11 (0.10) *** 
78 
 
lactation 
No first CM case (Escherichia coli) in the current month (baseline) 0 
  
Second CM case (Escherichia coli) occurring in the current month of 
lactation 
0.70 (0.24) *** 
No second CM case (Escherichia coli) in the current month 
(baseline) 
0 
  
Third CM case (Escherichia coli) occurring in the current month of 
lactation 
-0.21 (0.73) 
No third CM case (Escherichia coli) in the current month (baseline) 0 
  
First CM case (Klebsiella) occurring in the current month of 
lactation
2
 
1.39 (0.13) *** 
No first CM case (Klebsiella) in the current month (baseline) 0 
  
Second CM case (Klebsiella) occurring in the current month of 
lactation 
1.14 (0.27) *** 
No second CM case (Klebsiella) in the current month (baseline) 0 
  
Third CM case (Klebsiella) occurring in the current month of 
lactation 
0.77 (0.48)* 
No third CM case (Klebsiella) in the current month (baseline)  
  
First CM case (Trueperella pyogenes) occurring in the current month 
of lactation 
1.08 (0.26) *** 
No first CM case (Trueperella pyogenes)  in the current month 
(baseline) 
0 
  
Second CM case (Trueperella pyogenes) occurring in the current 
month of lactation 
1.17 (0.72)* 
No second CM case (Trueperella pyogenes)  in the current month 
(baseline) 
0 
  
Third CM case (Trueperella pyogenes) occurring in the current 
month of lactation 
-2.44 (8.51) 
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No third CM case (Trueperella pyogenes) in the current month 
(baseline) 
0 
  
First CM case (no growth
3
) occurring in the current month of 
lactation 
-0.14 (0.21) 
No first CM case (no growth) in the current month (baseline) 0 
  
Second CM case (no growth) occurring in the current month of 
lactation 
-0.18 (0.36) 
No second CM case (no growth) in the current month (baseline) 0 
  
Third CM case (no growth) occurring in the current month of 
lactation 
0.72 (0.41)** 
No third CM case (no growth) in the current month (baseline) 0 
  
First CM case (other
4
) occurring in the current month of lactation 0.54 (0.13) *** 
No first CM case (other) in the current month (baseline) 0 
  
Second CM case (other) occurring in the current month of lactation 0.09 (0.29) 
No second CM case (other) in the current month (baseline) 0 
  
Third CM case (other) occurring in the current month of lactation 1.03 (0.38)*** 
No third CM case (other) in the current month (baseline) 0 
  
Pregnant (yes vs. no) -1.17 (0.07) *** 
  
Retained placenta (yes vs. no) 0.68 (0.07) *** 
Displaced abomasum (yes vs. no) 0.48 (0.08) *** 
Milk fever (yes vs. no) 1.69 (0.10) *** 
  
Farm 1 -0.06 (0.09) 
Farm 2 0.65 (0.06)*** 
Farm 3 0.67 (0.06)*** 
Farm 4 0.28 (0.07)*** 
Farm 5 0 
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1
Estimates were obtained from a generalized mixed model with a Poisson distribution  
2
The rate ratio is calculated as exp(-0.15)=0.86 
3
No bacteriological growth (i.e., no bacterial growth above the level of detection of our microbiological procedures) was observed in the cultured sample; 
however, these cases exhibited clinical signs of mastitis
 
4
These included Mycoplasma, Corynebacterium bovis, yeast, miscellaneous, contamination and unknown CM 
*** p<0.05 ** p<0.10 * p<0.15 
 
Effect of bacteria specific CM on culling in primiparous cows 
The fit statistics for the model developed were as follows: -2 Log likelihood of 14790.97 and Pearson chi-square/df of 0.89. 
The risk of culling generally increased with the presence of a case of bacteria specific CM (compared with an absence of bacteria 
specific CM) (Table 3.7). This was observed among cows with a first case of T. pyogenes (exp (2.46)= 11.70 [95% CI (9.03, 15.18)]), 
a first case of Klebsiella (exp(2.30)= 9.97 [95% CI (7.92, 12.55)]), a first case of Staphylococcus aureus (exp(1.74)= 5.70 [95% CI 
(4.57, 7.10)]), a first case of E. coli (exp(1.21) =3.35 [95% CI (2.80, 4.01)]) and a third case of Klebsiella (exp (1.48)= 4.39 [95% CI 
(2.72, 7.10)]). We also observed a greater risk of culling 1 month after a case of CM (compared with (a) the cow not having 
experienced that CM, or (b) the cow was in the time period at or before that CM). For example, a month after a first case of T. 
pyogenes, the risk of culling was (exp(1.44)= 4.22 [95% CI (3.29, 5.42)]) times greater than the comparison group as described above. 
Pregnancy had a protective effect (exp(-1.87)= 0.15 [95% CI (0.14, 0.17)]) and cows with displaced abomasum were (exp(0.49)= 1.63 
[95% CI (1.45, 1.84)]) times more at risk of being culled compared with cows without displaced abomasum. Culling risk was greater 
as cows were further in their lactation. 
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Table 3.7. Effects of the first 3 pathogen specific clinical mastitis (CM) cases and other factors on culling in primiparous cows 
(18,420 lactations) in 5 New York State dairy farms over the first 10 months of lactation
1
 
Parameter
 
Estimate (SE) 
 
Intercept
 
-4.42 (0.13)***
 
  
Fall
2
  0.0015 (0.08) 
Spring -0.11 (0.08) 
Summer 0.07 (0.07) 
Winter (baseline) 0 
  
Month 1 of lactation (baseline)
 
0
 
Month 2 of lactation
 
0.07 (0.10) 
Month 3 of lactation
 
0.10 (0.11) 
Month 4 of lactation
 
-0.04 (0.12) 
Month 5 of lactation
 
0.39 (0.12)*** 
Month 6 of lactation
 
0.30 (0.13)*** 
Month 7 of lactation
 
0.71 (0.12)*** 
Month 8 of lactation
 
0.74 (0.12) *** 
Month 9 of lactation
 
0.87 (0.12) *** 
Month 10 of lactation 
 
1.06 (0.12) *** 
  
First CM case (Streptococcus spp.) occurring in the current month of 
lactation 
1.14 (0.18)*** 
No first CM case (Streptococcus spp.) in the current month (baseline) 0 
  
1 or more months since first CM case (Streptococcus spp.) 0.57 (0.12) *** 
It‟s not 1 or more months since first CM case (Streptococcus spp.) 
(baseline) 
0 
  
Second CM case (Streptococcus spp.) occurring in the current month 
of lactation 
0.006 (0.60) 
No second CM case (Streptococcus spp.) in the current month 
(baseline) 
0 
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1 or more months since second CM case (Streptococcus spp.) 0.23 (0.23) 
It‟s not 1 or more months since second CM case (Streptococcus spp.) 
(baseline) 
0 
  
Third CM case (Streptococcus spp.) occurring in the current month of 
lactation 
0.72 (0.76) 
No third CM case (Streptococcus spp.) in the current month 
(baseline) 
0 
  
1 or more months since third CM case (Streptococcus spp.) -1.17 (0.73)* 
It‟s not 1 or more months since third CM case (Streptococcus spp.) 
(baseline) 
0 
  
First CM case (Staphylococcus aureus) occurring in the current 
month of lactation 
1.74 (0.22) *** 
No first CM case (Staphylococcus aureus) in the current month 
(baseline) 
0 
  
1 or more months since first CM case (Staphylococcus aureus) 0.84 (0.18) *** 
It‟s not 1 or more months since first CM case (Staphylococcus 
aureus) (baseline) 
0 
  
Second CM case (Staphylococcus aureus) occurring in the current 
month of lactation 
-0.55 (1.03) 
No second CM case (Staphylococcus aureus) in the current month 
(baseline) 
0 
  
1 or more months since second CM case (Staphylococcus aureus) 0.29 (0.33) 
It‟s not 1 or more months since second CM case (Staphylococcus 
aureus) (baseline) 
0 
  
Third CM case (Staphylococcus aureus) occurring in the current 
month of lactation 
0.90 (0.81) 
No third CM case (Staphylococcus aureus)  in the current month 
(baseline) 
0 
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1 or more months since third CM case (Staphylococcus aureus) 0.55 (0.52) 
It‟s not 1 or more months since third CM case (Staphylococcus 
aureus) (baseline) 
0 
  
First CM case (Staphylococcus spp.) occurring in the current month 
of lactation 
0.28 (0.36) 
No first CM case (Staphylococcus spp.) in the current month 
(baseline) 
0 
  
1 or more months since first CM case (Staphylococcus spp.) 0.35 (0.20)** 
It‟s not 1 or more months since first CM case (Staphylococcus spp.) 
(baseline) 
0 
  
Second CM case (Staphylococcus spp.) occurring in the current 
month of lactation 
-0.49 (1.02) 
No second CM case (Staphylococcus spp.) in the current month 
(baseline) 
0 
  
1 or more months since second CM case (Staphylococcus spp.) 0.63 (0.31)*** 
It‟s not 1 or more months since second CM case (Staphylococcus 
spp.) (baseline) 
0 
  
Third CM case (Staphylococcus spp.) occurring in the current month 
of lactation 
-4.52 (12.5) 
No third CM case (Staphylococcus spp.) in the current month 
(baseline) 
0 
  
1 or more months since third CM case (Staphylococcus spp.) -1.25 (1.03) 
It‟s not 1 or more months since third CM case (Staphylococcus spp.) 
(baseline) 
0 
  
First CM case (Escherichia coli) occurring in the current month of 
lactation 
1.21 (0.18) *** 
No first CM case (Escherichia coli) in the current month (baseline) 0 
  
1 or more months since first CM case (Escherichia coli) 0.45 (0.13) *** 
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It‟s not 1 or more months since first CM case (Escherichia coli) 
(baseline) 
0 
  
Second CM case (Escherichia coli) occurring in the current month of 
lactation 
1.02 (0.37) *** 
No second CM case (Escherichia coli) in the current month 
(baseline) 
0 
  
1 or more months since second CM case (Escherichia coli) 0.61 (0.23) *** 
It‟s not 1 or more months since second CM case (Escherichia coli) 
(baseline) 
0 
  
Third CM case (Escherichia coli) occurring in the current month of 
lactation 
0.96 (0.55)** 
No third CM case (Escherichia coli) in the current month (baseline) 0 
  
1 or more months since third CM case (Escherichia coli) -0.66 (0.48) 
It‟s not 1 or more months since third CM case (Escherichia coli) 
(baseline) 
0 
  
First CM case (Klebsiella) occurring in the current month of 
lactation
2
 
2.30 (0.23) *** 
No first CM case (Klebsiella) in the current month (baseline) 0 
  
1 or more months since first CM case (Klebsiella) 0.30 (0.25) 
It‟s not 1 or more months since first CM case (Klebsiella) (baseline) 0 
  
Second CM case (Klebsiella) occurring in the current month of 
lactation 
0.27 (0.73) 
No second CM case (Klebsiella) in the current month (baseline) 0 
  
1 or more months since second CM case (Klebsiella) 0.38 (0.32) 
It‟s not 1 or more months since second CM case (Klebsiella) 
(baseline) 
0 
  
Third CM case (Klebsiella) occurring in the current month of 1.09 (0.77) 
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lactation 
No third CM case (Klebsiella) in the current month (baseline) 0 
  
1 or more months since third CM case (Klebsiella) 1.48 (0.48) *** 
It‟s not 1 or more months since third CM case (Klebsiella) (baseline) 0 
  
First CM case (Trueperella pyogenes) occurring in the current month 
of lactation 
2.46 (0.26) *** 
No first CM case (Trueperella pyogenes)  in the current month 
(baseline) 
0 
  
1 or more months since first CM case (Trueperella pyogenes) 1.44 (0.25) *** 
It‟s not 1 or more months since first CM case (Trueperella pyogenes) 
(baseline) 
0 
  
Second CM case (Trueperella pyogenes) occurring in the current 
month of lactation 
1.39 (0.72)** 
No second CM case (Trueperella pyogenes)  in the current month 
(baseline) 
0 
  
1 or more months since second CM case (Trueperella pyogenes) 0.60 (0.43) 
It‟s not 1 or more months since second CM case (Trueperella 
pyogenes) (baseline) 
0 
  
Third CM case (Trueperella pyogenes) occurring in the current 
month of lactation 
0.83 (1.12) 
No third CM case (Trueperella pyogenes) in the current month 
(baseline) 
0 
  
1 or more months since third CM case (Trueperella pyogenes) 0.16 (1.01) 
It‟s not 1 or more months since third CM case (Trueperella pyogenes) 
(baseline) 
0 
  
First CM case (no growth
3
) occurring in the current month of 
lactation 
1.07 (0.24) *** 
No first CM case (no growth) in the current month (baseline) 0 
86 
 
  
1 or more months since first CM case (no growth) 0.80 (0.13) *** 
It‟s not 1 or more months since first CM case (no growth) (baseline) 0 
  
Second CM case (no growth) occurring in the current month of 
lactation 
0.92 (0.31) *** 
No second CM case (no growth) in the current month (baseline) 0 
  
1 or more months since second CM case (no growth) 0.44 (0.20) *** 
It‟s not 1 or more months since second CM case (no growth) 
(baseline) 
0 
  
Third CM case (no growth) occurring in the current month of 
lactation 
1.11 (0.47) *** 
No third CM case (no growth) in the current month (baseline) 0 
  
1 or more months since third CM case (no growth) 0.06 (0.35) 
It‟s not 1 or more months since third CM case (no growth) (baseline) 0 
  
First CM case (other
4
) occurring in the current month of lactation 0.71 (0.20) *** 
No first CM case (other) in the current month (baseline) 0 
  
1 or more months since first CM case (other) 0.52 (0.12) *** 
It‟s not 1 or more months since first CM case (other) (baseline) 0 
  
Second CM case (other) occurring in the current month of lactation 0.41 (0.36) 
No second CM case (other) in the current month (baseline) 0 
  
1 or more months since second CM case (other) 0.04 (0.20) 
It‟s not 1 or more months since second CM case (other) (baseline) 0 
  
Third CM case (other) occurring in the current month of lactation 1.13 (0.41) *** 
No third CM case (other) in the current month (baseline) 0 
  
1 or more months since third CM case (other) 0.13 (0.34) 
It‟s not 1 or more months since third CM case (other) (baseline) 0 
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Pregnant (yes vs. no) -1.87 (0.07)*** 
  
Displaced abomasum (yes vs. no) 0.49 (0.12)*** 
  
Farm 1 -0.11 (0.10) 
Farm 2 -0.11 (0.08) 
Farm 3 0.42 (0.07)*** 
Farm 4 -0.002 (0.09) 
Farm 5 0 
1
Estimates were obtained from a generalized mixed model with a Poisson distribution; monthly net replacement cost  
was also included but estimates are not shown   
2
The rate ratio is calculated as exp(0.0015)=1.00  
3
No bacteriological growth (i.e., no bacterial growth above the level of detection of our microbiological procedures) was observed in the cultured sample; 
however, these cases exhibited clinical signs of mastitis
 
4
These included Mycoplasma, Corynebacterium bovis, yeast, miscellaneous, contamination and unknown CM 
*** p<0.05 ** p<0.10 * p<0.15 
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Effect of bacteria specific CM on culling in multiparous cows 
The fit statistics for the model developed were as follows: -2 Log likelihood of 1652172 
and Generalized chi-square/df of 0.79. The risk of culling was greater for cows as they 
progressed through lactations, i.e., cows in parity 4+ were exp (0.71) = 2.03 [95% CI (1.9,2.2)] 
times more likely to be culled compared with cows in lactation 2 (the baseline) (Table 3.8). As 
for primiparous cows, the culling risk was greater as cows were further in their lactation. When a 
cow contracted a case of Streptococcus spp., she was more likely to be culled one month after 
the case of CM (regardless of whether it was a first, second or third case of Streptococcus spp.). 
Similar trends were seen for Staphylococcus aureus and no growth, whereas a first or second 
case of E. coli or Klebsiella put cows at risk of being culled in the same month of CM 
occurrence. Pregnant cows were less likely to be culled compared with non-pregnant cows and 
ketosis and displaced abomasum were risk factors for culling. As monthly profitability increased, 
the likelihood of a cow being culled increased slightly. A $1 increase resulted in a rise in risk of 
culling from exp(-3.48)= 0.031 to exp (-3.48 + 0.008 * 1) = 0.0311. As net replacement cost 
increased, the probability of culling decreased slightly. A $100 increase in net replacement cost 
demonstrated a reduction in risk of culling from exp(-3.48)= 0.031 to exp (-3.48 -0.0005 * 100) 
= 0.029. 
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Table 3.8. Effects of the first 3 pathogen specific clinical mastitis (CM) cases and other factors on culling in multiparous cows 
(31,746 lactations) in 5 New York State dairy farms over the first 10 months of lactation
1 
Parameter
 
Estimate (SE)
 
Intercept
 
-3.48 (0.14)***
 
  
Parity 2 (baseline)
 
0
 
Parity 3
 
0.38 (0.03)***
 
Parity 4+ 
 
0.71 (0.03)***
 
  
Fall  -0.06 (0.03) 
Spring -0.12 (0.03)** 
Summer -0.09 (0.03)* 
Winter (baseline) 0 
  
Month 1 of lactation (baseline)
 
0
 
Month 2 of lactation
 
-0.25 (0.05) *** 
Month 3 of lactation
 
-0.06 (0.05)  
Month 4 of lactation
 
0.18 (0.05) ** 
Month 5 of lactation
 
0.53 (0.05) *** 
Month 6 of lactation
 
0.66 (0.05) *** 
Month 7 of lactation
 
0.88 (0.05)*** 
Month 8 of lactation
 
1.14 (0.05)*** 
Month 9 of lactation
 
1.24 (0.05)*** 
Month 10 of lactation 
 
1.24 (0.06)*** 
  
First CM case (Streptococcus. spp.) occurring in the current month of lactation
2
 0.33 (0.09)** 
First CM case (Streptococcus. spp.) occurring in previous month 0.62 (0.08)*** 
First CM case (Streptococcus. spp.) occurring ≥2 months ago 0.31 (0.05)*** 
No first CM case (Streptococcus. spp.) in the current month (baseline) 0 
  
Second CM case (Streptococcus. spp.) occurring in the current month of lactation -0.14 (0.14) 
Second CM case (Streptococcus. spp.) occurring in previous month 0.30 (0.13)* 
Second CM case (Streptococcus. spp.) occurring ≥2 months ago 0.18 (0. 09) 
No second CM case (Streptococcus. spp.) in the current month (baseline) 0 
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Third CM case (Streptococcus. spp.) occurring in the current month of lactation -0.02 (0.20) 
Third CM case (Streptococcus. spp.) occurring in previous month 0. 72 (0.17)** 
Third CM case (Streptococcus. spp.) occurring ≥2 months ago -0.38 (0.16)* 
No third CM case (Streptococcus. spp.) in the current month (baseline) 0 
  
First CM case (Staphylococcus aureus) occurring in the current month of lactation 0.81 (0.16)*** 
First CM case (Staphylococcus aureus) occurring in previous month 1.12 (0.14)*** 
First CM case (Staphylococcus aureus) occurring ≥2 months ago 0.11 (0.11) 
No first CM case (Staphylococcus aureus) in the current month (baseline) 0 
  
Second CM case (Staphylococcus aureus) occurring in the current month of lactation 0.62 (0.20)** 
Second CM case (Staphylococcus aureus) occurring in previous month 0.60 (0.22)* 
Second CM case (Staphylococcus aureus) occurring ≥2 months ago 0.22 (0.17) 
No second CM case (Staphylococcus aureus) in the current month (baseline) 0 
  
Third CM case (Staphylococcus aureus) occurring in the current month of lactation 0.14 (0.35) 
Third CM case (Staphylococcus aureus) occurring in previous month 0.37 (0.34) 
Third CM case (Staphylococcus aureus) occurring ≥2 months ago 0.08 (0.25) 
No third CM case (Staphylococcus aureus)  in the current month (baseline) 0 
  
First CM case (Staphylococcus spp.) occurring in the current month of lactation 0.64 (0.14)*** 
First CM case (Staphylococcus spp.) occurring in previous month 0.33 (0.17) 
First CM case (Staphylococcus spp.) occurring ≥2 months ago 0.13 (0.10) 
No first CM case (Staphylococcus spp.) in the current month (baseline) 0 
  
Second CM case (Staphylococcus spp.) occurring in the current month of lactation -0.31 (0.29) 
Second CM case (Staphylococcus spp.) occurring in previous month 0.23 (0.24) 
Second CM case (Staphylococcus spp.) occurring ≥2 months ago -0.15 (0.17) 
No second CM case (Staphylococcus spp.) in the current month (baseline) 0 
  
Third CM case (Staphylococcus spp.) occurring in the current month of lactation 0.44 (0.30) 
Third CM case (Staphylococcus spp.) occurring in previous month 0.05 (0.39) 
Third CM case (Staphylococcus spp.) occurring ≥2 months ago -0.71 (0.41) 
No third CM case (Staphylococcus spp.) in the current month (baseline) 0 
  
First CM case (Escherichia coli) occurring in the current month of lactation 1.02 (0.07)*** 
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First CM case (Escherichia coli) occurring in previous month 0.97 (0.07)*** 
First CM case (Escherichia coli) occurring ≥2 months ago 0.38 (0.05)*** 
No first CM case (Escherichia coli) in the current month (baseline)  
  
Second CM case (Escherichia coli) occurring in the current month of lactation 0.68 (0.11)*** 
Second CM case (Escherichia coli) occurring in previous month 0.61 (0.13)*** 
Second CM case (Escherichia coli) occurring ≥2 months ago -0.14 (0.11) 
No second CM case (Escherichia coli) in the current month (baseline) 0 
  
Third CM case (Escherichia coli) occurring in the current month of lactation 0.51 (0.18)* 
Third CM case (Escherichia coli) occurring in previous month 0.74 (0.20)** 
Third CM case (Escherichia coli) occurring ≥2 months ago 0.004 (0.15) 
No third CM case (Escherichia coli) in the current month (baseline) 0 
  
First CM case (Klebsiella) occurring in the current month of lactation
2
 1.75 (0.07)*** 
First CM case (Klebsiella) occurring in previous month 1.30 (0.10)*** 
First CM case (Klebsiella) occurring ≥2 months ago 0.44 (0.08)*** 
No first CM case (Klebsiella) in the current month (baseline) 0 
  
Second CM case (Klebsiella) occurring in the current month of lactation 0.95 (0.12)*** 
Second CM case (Klebsiella) occurring in previous month 0.56 (0.17)** 
Second CM case (Klebsiella) occurring ≥2 months ago 0.06 (0.12) 
No second CM case (Klebsiella) in the current month (baseline) 0 
  
Third CM case (Klebsiella) occurring in the current month of lactation 0.61 (0.18)** 
Third CM case (Klebsiella) occurring in previous month 0.67 (0.23)* 
Third CM case (Klebsiella) occurring ≥2 months ago 0.05 (0.19) 
No third CM case (Klebsiella) in the current month (baseline) 0 
  
First CM case (Trueperella pyogenes) occurring in the current month of lactation 1.80 (0.14)*** 
First CM case (Trueperella pyogenes) occurring in previous month 1.81 (0.16)*** 
First CM case (Trueperella pyogenes) occurring ≥2 months ago 0.97 (0.13)*** 
No first CM case (Trueperella pyogenes)  in the current month (baseline) 0 
  
Second CM case (Trueperella pyogenes) occurring in the current month of lactation 0.88 (0.28)** 
Second CM case (Trueperella pyogenes) occurring in previous month 1.58 (0.26)*** 
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Second CM case (Trueperella pyogenes) occurring ≥2 months ago -0.04 (0.31) 
No second CM case (Trueperella pyogenes)  in the current month (baseline) 0 
  
Third CM case (Trueperella pyogenes) occurring in the current month of lactation 1.08 (0.37)* 
Third CM case (Trueperella pyogenes) occurring in previous month 0.41 (0.90) 
Third CM case (Trueperella pyogenes) occurring ≥2 months ago -0.36 (0.54) 
No third CM case (Trueperella pyogenes) in the current month (baseline) 0 
  
First CM case (no growth
3
) occurring in the current month of lactation 0.65 (0.09)*** 
First CM case (no growth) occurring in previous month 0.72 (0.09)*** 
First CM case (no growth) occurring ≥2 months ago 0.24 (0.05)*** 
No first CM case (no growth) in the current month (baseline) 0 
  
Second CM case (no growth) occurring in the current month of lactation 0.15 (0.13) 
Second CM case (no growth) occurring in previous month 0.58 (0.12)*** 
Second CM case (no growth) occurring ≥2 months ago 0.07 (0.08) 
No second CM case (no growth) in the current month (baseline)  
  
Third CM case (no growth) occurring in the current month of lactation -0.12 (0.20) 
Third CM case (no growth) occurring in previous month 1.02 (0.14)*** 
Third CM case (no growth) occurring ≥2 months ago -0.12 (0.12) 
No third CM case (no growth) in the current month (baseline) 0 
  
First CM case (other
4
) occurring in the current month of lactation 0.59 (0.08)*** 
First CM case (other) occurring in previous month 0. 51 (0.09)*** 
First CM case (other) occurring ≥2 months ago 0.17 (0.06)** 
No first CM case (other) in the current month (baseline) 0 
  
Second CM case (other) occurring in the current month of lactation 0.38 (0.11)* 
Second CM case (other) occurring in previous month 0.66 (0.11)*** 
Second CM case (other) occurring ≥2 months ago 0.08 (0.09) 
No second CM case (other) in the current month (baseline)  
  
Third CM case (other) occurring in the current month of lactation 0.48 (0.15)** 
Third CM case (other) occurring in previous month 0.46 (0.19)* 
Third CM case (other) occurring ≥2 months ago -0.21 (0.15) 
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No third CM case (other) in the current month (baseline) 0 
  
Pregnant (yes vs. no) -1.66 (0.03)*** 
  
Retained placenta (yes vs. no) -0.37 (0.11)* 
Ketosis (yes vs. no) 0.14 (0.04)* 
Displaced abomasum (yes vs. no) 0.26 (0.05)** 
1
Estimates were obtained from a generalized mixed model with a Poisson distribution and random herd effect; monthly profitability, and monthly net 
replacement cost were also included but estimates are not shown 
2
The rate ratio is calculated as exp(0.33)=1.39 
3
No bacteriological growth (i.e., no bacterial growth above the level of detection of our microbiological procedures) was observed in the cultured sample; 
however, these cases exhibited clinical signs of mastitis
 
4
These included Mycoplasma, Corynebacterium bovis, yeast, miscellaneous, contamination and unknown CM 
*P <0.05 ; **P<0.01; *** P<0.001 
 
The risk of culling depending on the cow‟s characteristics can be easily calculated from the parameter estimates in our tables 
by taking the exponential of the summation of the intercept + parameter estimates of interest. As an example, referring to Table 3.8, 
the risk of culling a cow that is in parity 4, month in milk 5, in summer with a first case of E. coli which occurred 1 month ago and a 
second case of E. coli in the current month in milk that is pregnant and without any other disease is calculated by exp(-
3.48+0.71+0.53-0.09+0.97+0.68-1.66)= 0.096 or 9.6%.   
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DISCUSSION 
The effect of CM on mortality and culling has been studied previously (Neerhof et al. 
2000; Thomsen et al. 2004; Hertl et al., 2011); however, very few studies have examined the 
effect of bacteria specific CM on mortality and culling, and in particular, the effect of repeated 
cases of bacteria specific CM. While addressing these questions, we also took this one step 
further by demonstrating how culling risks are affected based on historical knowledge of the 
exact pathogens involved and cases a cow has experienced, e.g., the risk of culling for a cow that 
had a first case of E. coli that occurred 3 months ago and a second case of E. coli in the current 
month of lactation. This knowledge can help farmers identify which pathogens need particular 
attention and are responsible for the greatest  culling. We have been able to quantify for the first 
time the combined effect of different cases of pathogens on the risk of culling, while also 
accounting for time since case of bacteria specific CM. 
Based on the milk loss estimates for each pathogen by case which we have previously 
observed (J. Hertl, unpublished data), among multiparous cows, as a general rule, milk losses 
were greatest in the same week, or soon after the occurrence of any bacteria specific CM. The 
culling estimates of a cow that has a first or second case of E. coli or Klebsiella indicate greater 
risks of culling in the month in milk these occur, i.e., a farmer is less likely to wait to cull these 
cows, which reflect an action taken due to the immediate milk losses experienced or the 
anticipated losses. It is difficult to compare directly, as the milk loss models had a weekly time 
step, unlike the culling models which have a monthly time step. Hence it is possible that a case 
of CM could have occurred at the beginning or end of the month and the milk loss associated 
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with the CM case could be seen either within the same month, or soon after in the following 
month depending on when the CM occurred.  
In primipara and multipara, displaced abomasum was a risk factor for mortality, as well 
as milk fever (among multipara). Among all cows, displaced abomasum was a risk factor for 
culling. We also found that the risks of culling among multipara were greater for the coliforms 
compared with Staphylococcus and Streptococcus spp. These findings are similar to those of 
Thomsen et al. (2004); based on data from the Danish Cattle Database and a questionnaire study, 
the authors identified the most frequent diagnosis among udder/teat disorders resulting in 
unassisted death or euthanasia to be septicemic mastitis caused by E. coli. Milk fever constituted 
the majority of diagnoses among metabolic disorders and left and right displaced abomasum 
constituted the majority of diagnoses among digestive disorders. 
The increase in the risk of culling we observe from approximately month 6 (Tables 3.7 
and 3.8) could be explained by pregnancy status having an effect on culling; however, in our 
current study, we were unable to estimate an interaction between month in milk and pregnancy 
status due to lack of convergence of our statistical models. It is, therefore, unclear if the increase 
in risk of culling is definitively due to the additional effect of conception status. In a study by 
Rajala-Schultz and Gröhn (1999), the authors identified that the later a farmer knew a cow was 
pregnant, the higher her risk of being culled. Dechow and Goodling (2008) showed that as 
lactation progressed, reproduction became a more common reason for disposal (and the 
proportion of cows that died or were injured declined). In a study by Esslemont and Kossaibati 
(1997), poor fertility was the single most important reason for involuntary culling regardless of 
the cow‟s age, with 36.5% of disposals due to poor fertility.  
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The culling risks that are seen at the beginning of lactation are likely to be due to the 
incidence of disease at the beginning of lactation. This is in agreement with the increase in risk 
of CM often seen at the beginning of lactation, soon after the dry period (Green et al., 2002). 
Dechow and Goodling (2008) found most cows culled by 60 DIM had compromised health or 
were injured. The increase in mortality also seen at the beginning of lactation may also be 
explained by the composition of cases in that period of time. For example, Bradley and Green 
(2001) reported a trend towards more severe mastitis occurring in the first 90 days of lactation 
(14 of 167 cases) than in the rest of lactation (4 of 140) (P=0.09). 
We observed that the cows with CM in parity 1 had a drop in risk of culling between 
months 3 to 6. Similarly, Neerhof et al. (2000) report that the risk of culling due to mastitis 
increased with an increase in the stage of lactation, with the exception of diseased cows in parity 
1 which had the lowest risk of culling in the second stage (60 – 180d) of lactation. 
We did not include milk yield as it is an intervening variable between mastitis and 
culling, and in early lactation, cows have higher milk production so culling is less likely 
compared with late lactation when milk production tapers off (Gröhn et al., 2005). Although 
milk yield was not included in our models, by including the stage of lactation i.e., month in milk, 
this variable incorporated many factors including milk yield (Gröhn et al., 2005). From our 
parameter estimates, we observe that as month in milk increases, so does risk of culling. 
The reason for creating binary variables for the mortality analysis (both primipara and 
multipara) and culling analysis (primipara) was because when we created a bacteria specific CM 
variable encompassing all cases, we discovered that we were not able to attain model 
convergence. The advantage of the latter coding scheme, however, is that the baseline remains 
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the same within a bacteria specific CM. For this reason, throughout this paper we have specified 
what baseline the relative risks are in comparison to, because depending on the pathogen and 
case, the baseline is not always the same. 
 
CONCLUSIONS 
This study quantifies the effect of bacteria specific CM, by case, on mortality and culling 
among primiparous and multiparous cows. This provides farmers with information relating to 
which specific pathogens contribute to mortality and culling and where focus needs to be placed 
for improvements in management practices. Increases in the risk of mortality and culling were 
observed across all pathogens, but  particularly among cases of Klebsiella, E. coli and T. 
pyogenes,  buttressing our understanding of the severity of these pathogens and their effects on 
the bovine udder. The mortality risks of these models will be incorporated into a bacteria specific 
economic optimization model, aimed at calculating the cost of bacteria specific CM, and 
providing economically optimal decisions for dairy farmers with diseased cows. 
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ABSTRACT 
The objective of this study was to estimate the cost of 3 different types of clinical mastitis (CM) 
(due to gram-positive bacteria, gram-negative bacteria and other organisms) at the individual 
cow level and thereby identify the economically optimal management decision for each type of 
mastitis. We made modifications to an existing dynamic optimization and simulation model, 
studying the effects of various factors (incidence of CM, milk loss, pregnancy rate and treatment 
cost) on the cost of different types of CM. The average costs per case (USD) of gram-positive, 
gram-negative and other CM were 133.73, 211.03 and 95.31, respectively. This model provided 
a more informed decision making process in CM management for optimal economic profitability 
and determined that 93.1% of gram-positive CM cases, 93.1% of gram-negative CM cases and 
94.6% of other CM cases should be treated. The main contributor to the total cost per case of 
gram-positive CM was treatment cost (51.5% of the total cost per case), milk loss for gram-
negative CM (72.4%) and treatment cost for other CM (49.2%). The model affords versatility as 
it allows for parameters such as production costs, economic values and disease frequencies to be 
altered. Therefore, cost estimates are the direct outcome of the farm specific parameters entered 
into the model. Thus, this model can provide farmers economically optimal guidelines specific to 
their individual cows suffering from different types of CM.  
 
Key Words. mastitis, gram-positive, gram-negative, dynamic programming  
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INTRODUCTION 
Mastitis reduces dairy farm profitability with losses stemming from both milk production 
decreases and discarded milk, and treatment and culling costs (Gröhn et al., 2005). The specific 
inflammatory response from a mastitis incident is dependent on the bacterial species involved 
(Bannerman, 2008). Depending on the pathogen involved, the impact may vary, so studies 
determining which pathogens have the greatest impact on cow health, production and 
profitability are valuable (Gröhn et al., 2004). 
Treatment for mastitis is the most common cause of antibacterial use on dairy farms. 
There are public concerns, however, of the possible health hazards posed by the presence of 
antibiotic residues and other drugs in milk (Erksine et al., 2003). This is despite all bulk tanks 
being tested for antibiotics. Antibiotic use also raises questions of reduced animal welfare and 
biosecurity (Sørensen et al., 2010). 
A fundamental component of mastitis control programs is the identification of pathogens 
in mastitis samples. For example, the ability to determine whether a cow is suffering from gram-
positive or gram-negative CM would help determine the choice of antimicrobial therapy (Waage 
et al., 1994) and potentially reduce unnecessary use of antibiotics. 
Most pathogens which cause mastitis can be classified as gram-positive or gram-negative 
bacteria and determined by on-farm culturing, which is generally faster and more convenient 
than sending the milk sample to a commercial laboratory (Hertl et al., 2010). The on-farm culture 
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has an approximate 24 h turn-around time. The development of cow-side tests identifying 
whether a case of mastitis is gram-positive or gram-negative is ongoing (Waage et al., 1994; 
Yazdankhah, 2001). The objective of this study was to estimate the cost of different types of 
clinical mastitis (CM) (due to gram-positive bacteria, gram-negative bacteria and other 
organisms) and to determine the optimal management decision of whether it may or may not be 
economically optimal for a cow to be (1) replaced with a heifer, (2) kept in the herd (and treated 
if she has a CM case), but not inseminated or (3) kept (and treated if she has a CM case) and 
inseminated, for each type of CM. We did this by modifying an existing dynamic programming 
model previously used to study CM and other diseases in dairy cows (Bar et al., 2008a; Cha et 
al., 2010). 
MATERIALS AND METHODS 
Clinical mastitis categorization 
We classified CM into 3 categories: (1) CM due to gram-positive bacteria, (2) CM due to 
gram-negative bacteria and (3) CM due to other organisms (hereafter, referred to as gram-
positive CM, gram-negative CM and other CM). 
Gram-positive CM included Streptococcus spp., Staphylococcus aureus and 
Staphylococcus spp. Gram-negative CM included Escherichia coli, Klebsiella spp., Citrobacter 
spp. and Enterobacter spp. Other CM included Trueperella pyogenes, Mycoplasma spp., 
Corynebacterium bovis, Pseudomonas spp. and yeast. 
 
Replacements and inseminations optimization and simulation model         
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Software. The model was built using the Multi Level Hierarchic Markov Process 
(MLHMP) software as the application program interface (Kristensen, 2003). We modified an 
existing optimization and simulation model which was first developed to study the cost of 
generic CM in dairy cows, then 3 different types of lameness in dairy cows (Bar et al., 2008a; 
Cha et al., 2010). 
The model. The model was constructed as a 3-level hierarchic Markov process comprised 
of: the founder (parent) level containing state variables of permanent traits throughout the cow‟s 
life span, the child level divided into stages representing one whole lactation, and the grandchild 
level divided into stages of one month during lactation. The possible actions in a given month of 
lactation that could occur at the final level are: (1) replace the cow with a calving heifer, (2) keep 
the cow for another month without insemination and treat her if she has CM or (3) keep the cow 
for another month and inseminate her and treat her if she has CM (Bar et al., 2008a). Figure 4.1 
is a schematic representation of the model used in the current study on CM. At the founder level, 
5 milk yield categories (kg) were modeled as: -5, -2.5, 0, +2.5, and +5 from the mean level of 
milk production per day; these represented the cow‟s genetic potential. At the child level, 8 
possible whole lactation stages were modeled. At the grandchild level, 20 lactation stages (mo) 
were modeled. In each stage the cow was described by one level within each of the following 
states: 5 temporary (i.e., daily) milk yield levels, 9 pregnancy states (0 = open, 1-7 = 1-7 mo 
pregnant and milking and 8 = last 2 mo of pregnancy and dry (not milking)), 1 involuntarily 
culled state and 13 CM states. The CM states were defined as: 0 = no CM, 1 = first occurrence of 
gram-positive CM (observed at the end of the stage enabling immediate culling with no loss to 
treatment or production), 2, 3 and 4 corresponding to 1, 2, 3 and more mo after the first case of 
gram-positive CM (this does not mean reoccurrence, but rather time horizon since the first case 
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of gram-positive CM), respectively, 5 = first occurrence of gram-negative CM and 9 = other CM 
(with numbers from 6-8 and 10-12 corresponding to 1, 2, 3 and more mo after the first case of 
the CM type, respectively, and again, this does not mean reoccurrence, but rather time horizon 
since the first case of gram-negative or other CM, respectively).  
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b
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Figure 4.1. Schematic representation of the structure of the multi-level hierarchic Markov 
process optimization and simulation model, to determine the average cost of clinical mastitis in 
dairy cows  
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In the case of a reoccurrence, if a cow has reoccurrence of e.g. gram-positive CM, she 
will return to state 1, when she has a reoccurrence of gram-negative CM, she will return to state 
5, and in the case of other CM, she will return to state 9. 
The objective function maximized by the model was the discounting criterion 
(Kristensen, 2003), which maximizes the net present value of the cow using a yearly interest rate 
of 8% (De Vries, 2006; Bar et al., 2008a; Federal Reserve Bank of Kansas City, 2011).  
Optimization technique. By combining the advantages of the two types of iteration 
methods used to solve the Markov Process (namely value iteration and policy iteration), a new 
notion of a hierarchic Markov process was developed by Kristensen (1988; 1991), which forms 
the basis of our dynamic program. This solution approach allows us to obtain solutions to large 
state space problems as described below (Kristensen, 1996). 
Value iteration is performed to identify the decision that maximizes the total expected 
discounted rewards when the process starts from state i and continues for n stages before ending. 
Policy iteration involves choosing an arbitrary set of decision rules for each state at each stage 
and solving a set of simultaneous linear equations describing the expected future rewards of a 
process starting from state i and running over an infinite number of stages until the same optimal 
decision is reached (Kristensen, 1996; Cha et al., 2010). Our model is structured in such a way 
that a cow can be replaced until time infinity, hence at the founder (parent) level, we have an 
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infinite time horizon. At the subprocess (child and grandchild) levels, however, we have a finite 
time horizon (i.e., the lifespan of a specific cow). 
Kristensen (1988; 1991) combined the benefits of both policy and value iteration, by 
applying value iteration to the subprocesses and using these results in the final step of the policy 
iteration method of the main process. Hence, in our model, at the founder level, we used policy 
iteration, and at the child and grandchild levels, value iteration (Figure 4.1). More details of the 
mathematics pertaining to this technique can be found in Cha et al., 2010. 
 
Model parameters 
Description of data. Model parameters were obtained from analyses of data from 7 dairy 
herds in New York State. These 7 herds were followed for approximately 4 years, and contained 
a total of 23,902 lactations in 14,208 cows. 
Parameters. Model parameters specific to the 3 different types of CM are given in Table 
4.4.1. 
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Table 4.4.1. Model parameters specific to 3 different types of clinical mastitis. 
Parameter Time period Gram-positive Gram-negative Other Reference 
Milk loss 
(kg/d) 
1
st
 lactation, 1
st
 
month after CM 
3.1 5.4 3.38 Schukken et al., 
2009 
 1
st
 lactation, 2
nd
 
month after CM 
2.25 3.35 2.03 
 1
st
 lactation, 
following months 
1.0 2.6 1.7 
 2
nd
 &3
rd
 lactation, 
1
st
 month after CM 
3.43 7.58 2.88 
 2
nd
 &3
rd
 lactation, 
2
nd
 month after 
CM 
1.48 3.65 1.23 
 2
nd
 &3
rd
 lactation, 
following months 
0.9 2.4 0.6 
Pregnancy rate adjusted by odds 
ratios: 
0.76 0.65 0.84 Hertl et al., 
2010 
Treatment cost ($)  73.50 35.50 49.50 See materials 
and methods 
Risk (%) 1
st
 case 1
st
 lactation 0.019,0.005,0.006, 
0.006
1 
0.008, 0.006, 0.005, 
0.005
1
 
0.015, 0.008, 0.007, 
0.006
1
 
See materials 
and methods 
  2
nd
 lactation 0.017, 0.01, 0.013, 
0.01 
0.018, 0.02, 0.02, 0.013 0.022, 0.015, 0.016, 
0.013 
  3
rd
 lactation 0.02, 0.012, 0.016, 
0.013 
0.024, 0.026, 0.027, 
0.017 
0.027, 0.019, 0.02, 
0.016 
  4+ lactation 0.026, 0.013, 0.02, 
0.016 
0.027, 0.03, 0.03, 0.02 0.032, 0.023, 0.023, 
0.02 
 2
nd
 case 1
st
 lactation 0.035, 0.015, 0.013, 
0.01 
0.03, 0.02, 0.015, 0.01 0.04, 0.02, 0.01, 0.01 
  2
nd
 lactation 0.042, 0.03, 0.024, 
0.02 
0.046, 0.044, 0.026, 
0.017 
0.065, 0.048, 0.035, 
0.031 
  3
rd
 lactation 0.043, 0.03, 0.025, 0.054, 0.052, 0.044, 0.077, 0.074, 0.042, 
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0.02 0.021 0.037 
  4+ lactation 0.039, 0.03, 0.023, 
0.02 
0.051, 0.049, 0.029, 
0.019 
0.075, 0.056, 0.041, 
0.037 
Involuntary 
culling 
risk
2
 
 
 
  0.006, 0.01, 0.02, 
0.03, 0.04, 0.05, 
0.06, 0.07 
0.024, 0.4, 0.08, 0.12, 
0.15, 0.15, 0.15, 0.15 
 
0.006, 0.01, 0.02, 0.03, 
0.04, 0.05, 0.06, 0.07 
Bar et al., 2008a 
and unpublished 
data 
Mortality 
risk 
   0.02
3
 
0.04
4
 
 Gröhn et al., 
2005 
 
1
According to month 1, 2, 3 and 4+ 
2 
Monthly involuntary culling risks for lactations 1 through 8 
3 
primipara 
4 
multipara 
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A decision to treat a cow with gram-positive CM was associated with a cost (USD) of 
73.50. This cost was an estimated average from antibiotics (8), the decreased value of 5d worth 
of discarded milk from an average production cow (20), 50% of cows receiving anti-
inflammatory drugs and fluid IV or per os (15.50), labor (20) and culturing (10). A decision to 
treat a cow with gram-negative CM was associated with a cost of 35.50. This cost was an 
estimated average from 50% of cows receiving anti-inflammatory drugs and fluid IV or per os 
(15.50), labor (10) and culturing (10). The decision to treat a cow with other CM was associated 
with a cost of 49.50. This was an estimated average from antibiotics (4), 50% of cows receiving 
anti-inflammatory medication and fluid IV or per os (15.50), labor (20) and culturing (10); we 
assumed the discarded milk could be used in place of milk replacer for calves. Recognizing that 
the cost of treatment varies by farm (depending on drug administration, days of discarded milk 
due to drug use, etc.), a sensitivity analysis (described later below) of the cost of treatment was 
also performed.   
Pregnancy risk was set to 0.21 per month. Odds ratios which would reduce the rate of 
conception for each type of CM were applicable only for the first month after the cow got CM 
(i.e. CM states 1, 5 and 9) and also if she got another case of the same type of CM (where she 
would return to state 1, 5 or 9 for a recurrent case of gram-positive, gram-negative or other CM, 
respectively). If a cow contracted CM, her probability of going into the pregnancy state the 
following month was multiplied by this formula: (pregnancy rate*conception odds ratio for type 
of CM/(1-pregnancy rate+pregnancy rate*conception odds ratio for type of CM)). The voluntary 
waiting period was 60 d. The maximum calving interval was 20 mo and the involuntary culling 
risk at calving was 2%. 
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The monthly risk estimates (first case and recurrent cases), by lactation and CM type, 
were obtained from generalized linear mixed models with a random herd effect. The monthly 
risks for repeated cases were an average of the monthly risks for the second and third CM 
occurrence. The monthly risk estimates for the second CM occurrence in multiparous cows 
meant the cow could have had any type of CM within the lactation (and no CM in the previous 
lactation). The monthly risk estimates for the third CM occurrence in multiparous cows referred 
to cows that had already experienced 2 cases of CM (of any type) within the lactation and 
without CM in the previous lactation. 
The cost of a calving first lactation animal (all costs in USD) was 1,600, average monthly 
cow maintenance cost was 150 and insemination cost/month of insemination was 20. The 
average price for a calf born was 200. The milk price was $0.31/kg and the feed cost/kg of dry 
matter was $0.20. The cull price for voluntarily culled cows was $0.74/kg of body weight. 
Other parameters and prices and costs were taken from Bar, (2007), De Vries (2006) and 
Bar et al. (2008a). The milk yields, transition probabilities (the probabilities describing the 
different states a cow can transition to from one month to another), exit from the herd and effects 
of CM are described in Bar et al. (2008a).  
110 
 
Estimating CM cost 
The average net returns per cow per year for a herd without CM  were compared with the 
average net returns per cow per year for a herd with CM (by type), while keeping other 
parameters constant. The profit or loss was divided by the CM incidence to generate the herd 
average cost per case of CM. As the cost of CM was minimized under optimal treatment 
decisions, it is possible that these values differ from actual farm figures.   
The effects of milk loss, decreased fertility and treatment cost on the average cost of a 
CM case were also determined by obtaining the net present values of the model with and without 
the CM type and effect in question, then dividing by the incidence of CM. 
The net present value (NPV) is the current value of actions where the benefits and costs 
of the actions are calculated until the end of the time horizon. This is achieved by discounting the 
various benefits and costs by an annual interest rate over that time period. An interest rate of 8% 
was used (De Vries, 2006; Bar et al., 2008a; Federal Reserve Bank of Kansas City, 2011). The 
discounting factor (β) is equal to exp(-r) where r = 0.08, i.e. β = 0.92. The retention payoff 
(RPO) value is the NPV of retaining a cow compared with the NPV of her replacement (Bar et 
al., 2008b), i.e. NPVretaining - NPVreplacing. 
 
Exit from the herd 
Exit from the herd can be due to two reasons: (1) voluntary culling based on what the 
model recommends or (2) due to what is commonly referred to as involuntary culling. 
Involuntary culling can be due to euthanasia or cows sold for slaughter because of reasons other 
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than milk yield, pregnancy or CM (i.e. reasons not determined directly from the model). The 
values used for the probability of involuntary culling are discussed in Bar et al. (2008a). As the 
probability of involuntary culling of gram-negative mastitic cows was approximately 4 times that 
of healthy cows, this was reflected in the monthly involuntary culling values used in our model 
for gram-negative CM (unpublished data). The mortality of gram-negative CM was simplified to 
be 2% and 4% for primipara and multipara, respectively (Gröhn et al., 2005).  
 
Sensitivity analyses 
Given that economic values such as milk price, replacement cost and treatment cost can 
vary from time to time and farm to farm, a sensitivity analysis was performed to evaluate how an 
increase and decrease of 20% in each of these values individually affected the percentage of CM 
cases in the herd and the average cost per case. Further, we also measured the effect of halving 
the incidence of all 3 different types of CM, and also the effect of increasing the pregnancy rate 
by 20% (from 0.21 to 0.25) to determine which of these two management measures have the 
most beneficial effect on the average cost/case of CM.  
 
RESULTS 
 The cost of different types of CM 
The effects of each different type of CM on net return, incidence of CM, percent of CM 
cases treated, average cost of CM and average cost per case, are shown in Table 4.4.2.  
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Table 4.4.2. The effects of different types of clinical mastitis (CM) (gram-positive, gram-
negative, other) on net return, CM cases, % of CM cases treated, average cost of CM and 
average cost per case, following an optimal replacement policy (all costs in USD) 
 Net 
return
1
 
CM 
cases
2
 
% of CM 
cases 
treated
3
 
Average 
cost of 
CM 
Average 
cost per 
case
4 
No CM 
5
 426.05     
All
 6
 357.35 44.3 93.6 68.70 155.08 
Gram-negative and other
 7
 374.20     
   Only gram-positive
 8
  12.6 93.1 16.85 133.73 
Gram-positive and other 390.06     
   Only gram-negative  15.5 93.1 32.71 211.03 
Gram-positive and gram-
negative 
372.79     
   Only other  16.2 94.6 15.44 95.31 
1
 net returns in USD per cow and year 
2
 incidence of CM (cases per 100 cow years) 
3
 percent of treated CM cows per all CM cows 
4
 average cost per CM case  
5 
CM incidences set to 0
 
6 
all 3 different types of CM 
7 
incidences of gram-negative and other CM included only
 
8 
the added effects of gram-positive CM only 
 
The monetary values correspond to averaging over cow characteristics (parity, month of 
lactation, etc.). The average cost per case (USD) was greatest for gram-negative CM at 211.03 
(32.71/0.155) (where 32.71 is the average cost (=390.06-357.35) and 0.155 is the incidence of 
gram-negative CM), followed by gram-positive CM at 133.73 (16.85/0.126), and other CM at 
95.31 (15.44/0.162). The percentage of mastitic cows recommended to be treated, following an 
optimal replacement policy, was 93.1, 93.1 and 94.6 for gram-positive, gram-negative and other 
CM, respectively. For the remainder of cows, the recommended policy was to cull immediately. 
 
The effects of exogenous factors on the cost of different types of CM 
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We quantified how penalties associated with each type of CM, i.e., the milk loss, 
decreased fertility and treatment cost, contribute to the average cost per case of each type of CM. 
For gram-positive CM, the total cost (133.73) was comprised mostly of the treatment cost 
(68.89; 51.5% of the total cost), followed by milk loss (49.64; 37.1%) and decreased fertility 
(15.20; 11.4%). For gram-negative CM, the total cost (211.04) was primarily from the milk loss 
(152.76; 72.4%), followed by treatment cost (32.74; 15.5%) and decreased fertility (25.54; 
12.1%). For other CM, the same trend was seen as for gram-positive CM, i.e. the treatment cost 
(46.86; 49.2%) contributed most to the total cost (95.30), followed by milk loss (38.64; 40.5%) 
and decreased fertility (9.80; 10.3%). 
We increased and decreased the milk price by 20%, to observe how sensitive the average 
cost/case was to milk prices for each type of CM (Table 4.4.3). 
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Table 4.4.3. Effects of increasing and decreasing milk price replacement cost and treatment cost by 20%, halving the incidence of all 
3 different types of clinical mastitis (CM) and increasing pregnancy rate by 20% on CM cases and the average cost/case for all CM, 
and each different type of CM. 
Scenario All
1
 Gram-positive
2
 Gram-negative Other 
 CM cases
3
 Average 
cost/case
 4
 
CM 
cases
3
 
Average 
cost/case
4
 
CM 
cases
3
 
Average 
cost/case
4
 
CM 
cases
3
 
Average 
cost/case
4
 
Milk price +20% 
Milk price -20% 
43.5 
45.3 
173.23 
137.91 
12.4 
12.8 
145.36 
123.49 
15.1 
15.9 
240.63 
183.37 
15.9 
15.9 
105.08 
90.10 
Replacement cost +20% 
Replacement cost -20% 
45.1 
43 
163.23 
148.67 
12.8 
12.3 
138.70 
130.58 
15.8 
15 
225.15 
200.06 
16.5 
15.8 
99.05 
93.13 
Treatment cost +20% 
Treatment cost -20% 
Halving incidence of all 
3 different types of CM 
44.2 
44.3 
23 
164.97 
145.59 
158.17 
 
12.6 
12.6 
6.5 
 
147.60 
120.13 
141.42 
 
15.5 
15.5 
8 
 
218.57 
203.96 
218.93 
 
16.2 
16.2 
8.5 
 
104.10 
86.84 
100.41 
 
Increasing pregnancy rate 
by 20% 
45.7 150.35 12.9 131.55 16.1 205.90 16.7 92.70 
1
 all 3 different types of CM 
2
 gram-positive CM only 
3 
incidence of CM (cases per 100 cow years)                                                                           
4
 average cost per CM case 
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When we increased the milk price by 20%, the average cost/case of all CM increased by 
11.7% (from 155.08 to 173.23), and decreased by 11.1% (from 155.08 to 137.91) when we 
decreased milk price by 20%. Gram-negative CM was most sensitive to these changes; the 
average cost per case increased by 14% (from 211.03 to 240.63) and decreased 13.1% (from 
211.03 to 183.37) when milk price was increased and decreased by 20%, respectively.  
When we increased and decreased the replacement cost by 20%, the average cost/case of 
CM increased by 5.3% (from 155.08 to 163.23) and decreased by 4.1% (from 155.08 to 148.67), 
respectively (Table 4.4.3). Gram-negative CM was most sensitive to these changes; the average 
cost/case increased by 6.7% (from 211.03 to 225.15) and decreased by 5.2% (from 211.03 to 
200.06) when replacement cost was increased and decreased by 20%, respectively. 
When we increased and decreased the treatment cost by 20%, the greatest change in 
cost/case was seen for gram-positive CM (increase of 10.4%, from 133.73 to 147.60, and 
decrease of 10.2%, from 133.73 to 120.13, respectively), followed by other CM (increase of 
9.2%, from 95.31 to 104.10, and decrease of 8.9% from 95.31 to 86.84), and gram-negative CM 
(increase of 3.6%, from 211.03 to 218.57, and decrease of 3.4% from 211.03 to 203.96) (Table 
4.4.3). 
The average cost per case increased when the incidence of all different types of CM was 
halved. The greatest increase was in the other CM category (from 95.31 to 98.47, a 3.3% 
increase) (Table 4.4.3). 
When pregnancy rate was increased by 20%, the average cost per case decreased. Of the 
3 categories of CM, the largest decrease was seen in the other category (from 95.31 to 92.70, a 
2.7% decrease) (Table 4.4.3). 
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Retention payoff of open healthy and mastitic cows 
Our economic model calculates the retention payoff for cows, dependent on their 
individual characteristics. Figures 4.2 and 4.3 are hypothetical examples of retention payoffs 
under an optimal policy for cows free of CM and with different types of CM, specific to an open 
(non-pregnant), second lactation cow with average milk yield per 305 day lactation, and with 
permanent milk yield of 1,500 kg per 305 day lactation less than the average in the herd, 
respectively. The optimal policy recommended by the model (keep but not inseminate, keep and 
inseminate or replace) is also illustrated by the symbols on the graph.  
In Figure 4.2, the RPO (USD) of cows at calving was 1,227, 1,091, 1,053 and 933 for no 
CM, other CM, gram-positive CM and gram-negative CM, respectively. The average cost at 
calving was calculated by subtracting the RPO for the different types of CM from the RPO for 
no CM. The average cost at calving was 136 (1,227-1,091), 174 (1,227-1,053) and 294 (1,227-
933) for other CM, gram-positive CM and gram-negative CM, respectively. When the RPO is 
negative, it is more profitable to cull the cow than keep her. This was observed at month 12 for 
no CM, month 11 for other CM, and month 10 for gram-positive and gram-negative CM. Our 
figure illustrates the recommended policy until month 14; cows in month 14 and onwards were 
all recommended to be replaced. 
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Figure 4.2. Retention payoffs under an optimal policy for hypothetically open (non pregnant) 
cows free of clinical mastitis (CM) and with different types of CM, specific to a second lactation 
cow with average milk yield per 305 day lactation 
 
In Figure 4.3, it can be seen that the culling recommendation has shifted forward, i.e., 
culling was recommended at month 9 for a cow without CM, and at month 7 for cows with 
gram-positive, gram-negative and other CM. The RPO of these cows at calving was 626, 518, 
481 and 422, for no CM, other CM, gram-positive and gram-negative CM, respectively. 
Therefore, the average cost at calving was 108 (626-518), 145 (626-481) and 204 (626-422) for 
other CM, gram-positive and gram-negative CM, respectively. Our figure illustrates the 
recommended policy until month 12; cows in month 12 and onwards were all recommended to 
be replaced. 
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Figure 4.3. Retention payoffs under an optimal policy for hypothetically open (non pregnant), 
second lactation cows, with permanent milk yield of 1,500 kg per 305 day lactation less than the 
average in the herd, free of clinical mastitis (CM) and with different types of CM(note: gram-
positive and gram-negative CM graphs overlap from month 5) 
  
Endogenous factors affecting the cost of CM  
Tables 4.4 and 4.5 are a cross-sectional view of Figures 4.2 and 4.3 at 4 and 8 months 
after calving, respectively (but with more information than the figures, i.e., Tables 4.4 and 4.5 
also include cows of high permanent milk yield potential and pregnant cows). 
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Table 4.4. Average costs (in USD) of 3 types of clinical mastitis (CM) in cows with different levels (low, average, high) of permanent 
(genetically determined) milk yield potential 4 mo after calving, obtained by the insemination and replacement optimization model 
1
 Gram-positive CM 
2
 Gram-negative CM 
3
 Other CM 
 
Table 4.5. Average costs (in USD) of 3 types of clinical mastitis (CM) in cows with different levels (low, average, high) of permanent 
(genetically determined) milk yield potential 8 mo after calving, obtained by the insemination and replacement optimization model 
1
 Gram-positive CM 
2
 Gram-negative CM 
3
 Other CM 
 
The cost of CM is dependent on endogenous factors, i.e., permanent (genetic) milk yield potential, pregnancy status and 
lactation (Tables 4.4 and 4.5). The general trends are discussed below.  
 Permanent milk yield potential 
 Low Average High 
 Open Pregnant Open Pregnant Open Pregnant 
Lactation GP
1
 GN
2
 O
3
 GP
1
 GN
2
 O
3
 GP
1
 GN
2
 O
3
 GP
1
 GN
2
 O
3
 GP
1
 GN
2
 O
3
 GP
1
 GN
2
 O
3
 
1 136 150 126 125 140 115 167 216 154 125 154 115 152 245 160 125 171 115 
2 131 150 96 123 147 90 178 269 139 124 165 91 206 352 164 124 189 91 
3 116 136 86 121 151 92 156 240 127 122 180 93 176 323 148 124 219 95 
6 105 117 76 102 112 74 114 149 84 115 159 86 137 229 109 116 196 85 
 Permanent milk yield potential 
 Low Average High 
 Open Pregnant Open Pregnant Open Pregnant 
Lactation GP
1
 GN
2
 O
3
 GP
1
 GN
2
 O
3
 GP
1
 GN
2
 O
3
 GP
1
 GN
2
 O
3
 GP
1
 GN
2
 O
3
 GP
1
 GN
2
 O
3
 
1 15 15 15 125 137 115 151 193 142 125 150 115 170 248 164 125 167 115 
2 18 18 18 69 69 69 158 197 120 123 153 91 210 308 165 124 177 91 
3 21 21 21 30 30 30 133 153 103 122 157 93 177 264 146 123 196 94 
6 0 0 0 0 0 0 46 46 46 0 0 0 125 153 95 115 161 87 
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For a cow 4 months after calving (Table 4.4), we found that the average cost of CM was 
greater in open cows compared with pregnant cows. Also, the average cost of CM was greater in 
younger cows compared with older cows.  
The average cost was greatest for gram-negative CM, followed by gram-positive CM, 
and other CM, for each permanent milk yield potential and pregnancy status combination. Also, 
the cost was greatest for cows that were high milk producing, followed by average and low 
producing. 
At 8 months after calving (Table 4.5), the average cost was generally greater for cows 
suffering from gram-negative CM, and this was followed by gram-positive CM and other CM. 
Also, in the low permanent milk yield potential category, pregnant cows had a higher average 
cost of CM compared with open cows, but this was reversed in the average and high permanent 
milk yield potential categories. Similar to the trend at 4 months after calving, younger cows had 
a higher average cost of CM than older cows and the higher the permanent milk yield potential 
of the cow, the greater the average cost of CM (Table 4.5). 
 
Exit from the herd (voluntary culling and involuntary culling) 
When all the different types of CM were included in the model, the percentage exit from 
the herd  was 35.5 (comprised of 17% from voluntary culling and 18.5% from involuntary 
culling). This increased to 38.7 (20.8, 17.9) when milk price was increased by 20%, and 
decreased to 33.1 (13.8, 19.3) when milk price was reduced by 20%. When replacement cost was 
increased by 20%, herd exit decreased to 33.6 (14.4, 19.2) and increased to 39.3 (17.5, 21.8) 
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when replacement cost was reduced by 20%. When the incidences of CM were halved, herd exit 
decreased to 34.4 (15.7, 18.7), and when pregnancy rate was increased by 20%, it decreased to 
33.4 (13.8, 19.6). 
DISCUSSION 
When a cow contracts mastitis, the dairy farmer needs to decide whether treatment is 
warranted, and if so, what treatment is most appropriate. These decisions are ideally made based 
on the organism causing mastitis. In determining how to treat a cow, one common way of 
grouping these organisms is to separate them into gram-positive and gram-negative mastitis. 
These two groups of organisms cause mastitis of different symptoms and severity. This 
classification can form the basis of on-farm treatment protocols (Hertl et al., 2010). 
The importance and reliance on classifications of mastitis has become prevalent in the 
literature. For example, a study conducted by Neeser et al. (2006) found that there were 
significant reductions in the amount of antimicrobial use when on-farm culture systems were 
employed. Most producers treated gram-positive mastitis with antibiotics, whereas gram-
negative mastitis treatment varied. They concluded that the reduction in antimicrobial use could 
lead to several advantages, such as decreases in discarded milk and antimicrobial residues in 
milk, and improved treatment outcome due to targeted treatment. From our study, we found the 
average cost per case (USD) of gram-negative CM (211.03) was due mostly to milk loss, which 
is logical given that the milk loss was greatest for gram-negative CM out of the 3 types of CM 
(see also Schukken et al. (2009)). For gram-positive CM, this cost was primarily due to the 
treatment cost, which is also intuitive, given that the treatment cost was greatest for gram-
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positive CM, of all 3 types of CM. Similarly, treatment cost contributed most to the average cost 
per case of other CM. 
The average cost per case with all 3 different types of CM in the model was 155.08, 
which is lower than that found in the study by Bar et al. (2008a) for generic CM, where the 
average cost per case was 179. This difference is due to a number of reasons: our model was 
more detailed in that generic mastitis was differentiated into types and  data in our study were 
updated from Bar et al. (2008a), In Bar et al. (2008a) the parameter values used in the model 
(risk, treatment cost, involuntary culling, etc.) were for generic CM and not groups of CM, and 
we did not include a carryover state from the previous lactation. Unlike the generic CM case, if 
we were to include a carryover state, we would need to model all the different combinations of 
carryover effects possible (e.g. gram-positive CM in previous lactation, gram-negative CM in 
current lactation, or gram-positive CM in previous lactation, gram-positive CM in current 
lactation, etc.). This would cause the state-space of the model to grow considerably, increasing 
the time and computer capacity necessary to calculate an optimal solution. The inclusion of 
carryover effect is an area of future research. 
Although a few studies have examined the cost of CM in dairy cows, none have 
quantified this cost at the individual cow level for 3 different types of CM. The study that comes 
closest to examining such costs was conducted by Sørensen et al. (2010). In that study, the 
authors estimated the costs related to 5 different pathogen-specific mastitis traits and unspecific 
mastitis using a stochastic simulation model (SimHerd IV). Costs ranged from 189.42USD to 
724.64USD per case (converted on 20Aug2010 from €149 and €570, respectively), and were 
greater for contagious pathogens, compared with environmental pathogens. 
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In our study, not only did we estimate the cost of different types of CM, but also the 
sensitivity of these costs from parameter changes. When we increased the milk price, the average 
cost per case of CM increased, as the milk losses associated with each type of CM were higher 
valued. The reverse was seen when milk price was reduced. Again, as expected, the average cost 
of gram-negative CM was most sensitive to this change. The same pattern was observed when 
replacement cost was increased. 
We increased and decreased treatment cost by 20% to account for differences across 
farms in e.g. the use of antibiotics and associated discarded milk. What we found was, despite 
these changes, the order of the cost of CM from most costly to least costly did not change (i.e. 
gram negative was always most expensive, followed by gram positive then other CM).  
Between the two scenarios of increasing pregnancy rate or halving the incidence of CM, 
it was apparent that the former case led to a reduction in the average cost/case of CM, indicating 
the benefits to farmers of focusing on improving their breeding programs. In interpreting the 
results of the model, we emphasize that the cost of CM calculated by the model should be 
interpreted as the lowest cost possible following the optimal insemination and culling policy, 
under stable prices, and in a steady state. The best insemination and culling policy is assuming a 
constant number of cows on the farm and immediate availability of replacement heifers. As a 
result, if the incidence of CM is halved, fewer cows are culled because of CM. As the number of 
cows is constant, this means that when fewer cows are culled because of CM (hence, less need 
for young replacement heifers), the cows in the herd will be getting older on average, and these 
older cows will be more prone to other diseases. Decreased culling rate means there is also less 
intensive genetic improvement (as we assume each generation to be more genetically advanced 
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than the current genetic average). Therefore, our results show a slight decrease in the marginal 
net return per reduction of CM incidence. In reality, the decreased model related culling would 
be translated to inner expansion or better selection of replacement heifers. As such, the value 
calculated from our model slightly underestimates the cost of CM.  
Both Figures 4.2 and 4.3 illustrate that cows with CM should be replaced earlier than 
cows without CM, and that cows with lower milk yield should be replaced earlier than cows with 
higher milk yield. From Figure 4.3, it can be seen that cows with gram-negative CM are 
recommended to be inseminated only once compared with cows having gram-positive and other 
CM; this can be attributed to the greater milk loss from gram-negative CM (Schukken et al., 
2009), making it less economically optimal to spend the money on inseminating them from that 
one point onwards. The cross sectional views of the figures (Tables 4.4 and 4.5) quantified what 
one would expect in the average cost/case of CM, as permanent milk yield, age, type of CM and 
pregnancy status vary. For example, as permanent milk yield potential increased from low to 
high, the average cost/case of CM increased. As expected, the older the cow is, the lower the 
average cost/case of CM, as an older cow has less lifespan remaining, than a younger cow, for 
the cow to succumb to the detrimental effects of disease (and for these to be translated into 
monetary losses). Gram-negative CM generated the highest cost, as has been the case so far. 
Generally, CM cases were more costly in open cows, as they have the added effect of reduced 
fertility (unlike pregnant cows, as they are already with calf). Among cows 8 mo after calving 
(Table 4.5), in the low permanent milk yield potential category, however, pregnant cows had a 
higher average cost of CM compared with open cows, which is due to these cows being further 
into pregnancy, and a greater probability of going to term (unlike cows at 4 mo, where the 
opposite trend was seen in average cost/case of CM). 
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As anticipated, when milk price increased, culling (voluntary) increased as well, due to 
the increased cost from milk loss and the greater expected profit of a replacement heifer. When 
the incidence of CM was halved, and pregnancy rate increased, culling (voluntary) percentages 
decreased. When replacement cost increased, culling (voluntary) was reduced, as it was more 
expensive to replace than to keep a cow.  
In our model, we use a monthly time step, where we assume that e.g. all CM cases 
occurring 152 – 183 days after calving occur at day 183, enabling the decision to cull (and not 
treat) before incurring the costs of disease. The only exception to this is the first stage after 
calving which has a length of only 3 days, i.e. we assume that all cows that have mastitis shortly 
after calving have it by the third day after calving (Bar et al., 2008a). This is also because we 
estimate a greater risk for CM in these days.  
Our study focuses on decisions for individual animals, and as such is an individual based 
model. All modeling techniques have their advantages which need to be weighed with their 
disadvantages in selecting the technique most appropriate for the study. The limitations of our 
individual cow model are that we cannot include herd dynamics, e.g. infectivity of CM, and see 
the effects of this at the individual cow level. If the latter were the focus of our study, then 
another modeling technique would be appropriate.  
Our research was specific to cow characteristics which allow us to undertake a 
comprehensive analysis of the costs of CM by type. Further, the cost of disease depends on the 
fate of the cow. If the cow is to be culled, milk loss effects and fertility effects are not applicable. 
If the cow is pregnant, disease effects on fertility are not applicable. Pregnant cows were almost 
always recommended to be kept in the herd until the next lactation. Because the CM losses in 
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these cows are only the treatment cost and milk loss and these were assumed to be the same for 
both high yielding cows and low yielding cows, the cost of CM is the same for all these pregnant 
cows. Intuitively, one would assume that a high producing cow loses more milk to CM 
(compared with an average or low producer); however, we have assumed this to be the same. 
While we know that high milk production is a risk factor for mastitis (Gröhn et al., 1990; Gröhn 
et al., 1995), we have not investigated whether these losses are different for low or high milk 
producing cows, though this would not be unexpected. Because we do not included this risk 
factor in our model, and assume that milk loss is consistent across all milk production levels, it is 
possible that there may be more variability in the results than currently shown in our model.  
Further, we did not model seasonality and milk component variations, or the exact shape 
of the lactation curves beyond 10 mo, as these issues were beyond the scope of our study 
objectives. A further limitation includes the assumption that the farmer has complete knowledge 
of cow traits, and that a replacement heifer immediately enters the milking herd following a cow 
replacement, which is not always the case (Bar et al., 2008a).  
The „treat‟ decision which our economic model can recommend does not take into 
account how effective the treatment may be. And given that in our current model, CM is divided 
into 3 categories of gram-positive, gram-negative and other CM, the treatment policies for each 
type of bacteria in each category are assumed to be the same. Admittedly, the success and type of 
treatment for bacteria within each group, or even the same bacterial species between different 
strains, can differ; however, the focus of our economic model was not to assess the success of 
different types of treatment options. 
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This model, therefore, serves as a decision tool to aid farmers when deciding what to do 
with their diseased cows. The economic values, production costs and disease frequencies can be 
altered; hence, the results can be made applicable to individual farms, although our used values 
are representative.  
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ABSTRACT 
Intensive dairy farming is characterized by maximizing revenue through the sale of consumable 
milk, milk products and beef. In this industry, mastitis is a serious production limiting disease, 
having effects on milk yield, milk quality, conception rate and an increase in the risk of mortality 
and culling. Our objective was twofold: (1) to develop an economic optimization model which 
would incorporate all the different types of pathogens that cause CM categorized into 8 classes 
of culture results, as well as account for whether the CM was a first, second or third case in the 
current lactation and whether the cow had a previous case of CM in the preceding lactation and 
(2) to develop a model which would be versatile to add more pathogens, diseases or other factors 
in the future as more information becomes available without significant alterations to the basic 
structure of the model. The model provides economically optimal decisions depending on the 
individual characteristics of the cow and the specific pathogen causing CM. The net returns in 
US$ per cow and year for the basic scenario (with all CM included) was 500, where the 
incidence of CM (cases per 100-cow years) was 35.5, of which 90.6% of cases were 
recommended to be treated under an optimal replacement policy. The cost per case of CM was 
233.41. The CM cases were comprised of (all in %, totaling 35.5%) Staphylococcus spp. (1.6), 
Staphylococcus aureus (1.8), Streptococcus spp. (6.9), Escherichia coli (8.1), Klebsiella (2.2), 
Other treated cases (e.g., pseudomonas) (1.1), Other not treated cases (e.g., Trueperella 
pyogenes) (1.2) and Negative culture cases (12.7). The average cost per case even under optimal 
decisions was greatest for Klebsiella (416), followed by other not treated cases (bacteria like T. 
pyogenes) (316) which was similar to the other treated cases (bacteria like pseudomonas) (310) 
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and Escherichia coli (309). This was followed by the gram-positive pathogens, with the greatest 
cost per case being due to Staphylococcus aureus (298), then Staphylococcus spp. (275) and 
Streptococcus spp. (257). Negative culture cases had the lowest cost (151). Most CM cases (by 
pathogen), were recommended to be treated (i.e. all over 85%), and this was greatest for other 
treated cases (94.4%) and lowest for Staphylococcus aureus cases (86.4%). In general, the 
optimal recommended time for replacement was as great as 5 months earlier for cows with CM 
compared with cows without CM. Further, while the parameter estimates implemented in this 
model are specific to the dairy farms in this study, they may be altered so that the results are 
specific to any other farm. 
 
Keywords: mastitis, pathogen, cost, dynamic programming 
 
 
INTRODUCTION 
Intensive dairy farming is characterized by maximizing revenue through the sale of 
consumable milk, milk products and beef. In this industry, mastitis is a serious production 
limiting disease, having effects on milk yield (Gröhn et al., 2004; Bar et al., 2007; Schukken et 
al., 2009), milk quality,  conception rate (Hertl et al., 2010) and an increase in the risk of 
mortality and culling (Bar et al., 2008a; Hertl et al, 2011; Cha et al., 2012b). Further, treatment 
of cows may be necessary depending on the pathogen causing mastitis which creates a loss of 
saleable milk during and following treatment due to the required withholding period. 
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The economic model we developed is based on dynamic programming. One of the basic 
elements of dynamic programming is the sequential approach to decision making, which aligns 
well with sequential decisions in animal production, including replacement of animals where at 
regular time intervals management decisions are made such as whether the animal should be 
replaced, inseminated or kept for another period. Optimal replacement models can be used to 
provide dairy farmers with guidance on what action to take with their animals. The advantage of 
these models is that they can assimilate large amounts of information on health status, age of the 
cow, milk production etc., and provide the optimal action to be taken.  
An animal replacement model of value would need to include information that is 
considered to be necessary in identifying the optimal decision. Given that the goal of intensive 
dairy farming is typically to maximize revenue, one optimality criterion would logically be the 
maximization of net returns.  Dairy cattle replacement models have been developed (De Vries et 
al. 2006; Nielsen et al., 2010; Demeter et al., 2011), with inclusion of information relating to 
disease (Houben et al., 1994; Bar et al., 2008a; Cha et al., 2011). 
Bar et al. (2008a) developed an animal replacement model, incorporating information on 
generic clinical mastitis (CM), extending and building upon the assumptions of the optimal 
replacement model developed by Houben et al. (1994) and earlier asset replacement principles 
(Perrin, 1972). Cha et al. (2011) modified the original model by Bar et al. (2008a) to study 3 
groupings of CM (gram positive, gram negative and other).  
In the current study, we were motivated to develop a larger model for several reasons: 
1. The previous framework did not separate CM into the different pathogens that are 
causative or, in the case of Cha et al. (2011), differentiate between different cases of CM. 
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Specifically, CM is caused by a variety of different pathogens, and depending on the 
pathogen involved as well as whether it is the first, second or third case in the lactation, 
the risk of CM (Cha et al., 2012a), milk loss (Hertl et al., unpublished), conception rate, 
mortality risk (Cha et al, 2012b) and treatment cost will differ. The importance of 
pathogen information arises in more specific situations, e.g., when the profile of a cow 
results in a borderline decision (Østerås et al., 1999). 
2. We have additional information relating to the risk of CM by case, carryover and 
pathogen (Cha et al., 2012a), milk loss by case and pathogen (Hertl et al., unpublished), 
and conception rate, mortality risk (Cha et al., 2012b) and treatment cost by pathogen. 
3. The previous framework did not have the flexibility to include additional pathogens or 
additional diseases easily; the new framework affords the versatility to expand the model 
for further research purposes. 
4. By allowing more than one event to occur as a cow transitions from one month to 
another, a transition in CM status, pregnancy and milk yield will be concurrently 
possible. 
Our objective was twofold: (1) to develop an economic optimization model which would 
incorporate the different types of pathogens that cause CM categorized into 8 culture classes, as 
well as account for whether the CM was a first, second or third case in the current lactation and 
whether the cow had a previous case of CM in the preceding lactation and (2) to develop a model 
which would be versatile to add more pathogens, diseases or other factors without significant 
alterations to the basic structure of the model. Further, the model will need to provide 
economically optimal decisions depending on the individual characteristics of the cow and the 
specific pathogen causing CM. We will also elucidate the cost of each pathogen causing CM 
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under optimal decisions, and undertake sensitivity analyses of how these costs are affected by 
changes in milk price, pregnancy rate and replacement cost.  
 
 
MATERIALS AND METHODS 
Clinical mastitis categorization 
We classified CM into 8 categories: (1) Staphylococcus spp., (2) Staphylococcus aureus, 
(3) Streptococcus spp., (4) Escherichia coli, (5) Klebsiella, (6) Other treated (these included 
Enterobacter, Enterococcus, Citrobacter, Serratia, Pasteurella, Corynebacterium species,  
Pseudomonas, Proteus, Corynebacterium bovis, Gram+ bacillus, Gram- bacillus, fungus, Strep. 
group „C‟, mold and Nocardia), (7) Other not treated (these included Trueperella pyogenes, 
Mycoplasma, Prototheca and yeast), and (8) Negative culture, contamination (more than two 
bacterial species on the culture plate) and no significant organisms. The latter, no significant 
organisms, was defined as no bacterial growth of either Staphylococcus aureus or Streptococcus 
agalactiae while the culture plate contained more than two different species. These cases 
exhibited clinical signs of mastitis.  
 
Replacements and inseminations optimization and simulation model         
Software. The model was built using the Multi Level Hierarchic Markov Process 
(MLHMP) software as the application program (Kristensen, 2003). We made significant 
additions and changes to the structure of an existing optimization and simulation model which 
was first developed by Bar et al. (2008a) to study the cost of generic CM in dairy cows, then 
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modified to study 3 different types of lameness in dairy cows (Cha et al., 2010). In the current 
model, we included a pathogen class, where parameters specific to each pathogen can be 
changed in the user graphical interface, allowing for the study of the effect of different 
parameters and prices on the cost of CM and optimal replacement decisions.  
The model. The model was constructed as a 3-level hierarchic Markov process comprised 
of: the founder (parent) level containing state variables of permanent traits throughout the cow‟s 
life span, the child level divided into stages representing one whole lactation, and the grandchild 
level divided into stages of one month during lactation. The lactation number and stage of 
lactation are known properties from the hierarchical model structure, therefore, these are not 
included directly as state variables. The possible actions in a given month of lactation that could 
occur at the final level are: (1) replace the cow with a calving heifer, (2) keep the cow for another 
month without insemination and treat her if she has CM or (3) keep the cow for another month 
and inseminate her and treat her if she has CM (Bar et al., 2008a). Further, an alternative 
possible decision for CM cows is to keep without treatment; however, because we did not have 
access to detailed information on such cases, we did not have the parameter values necessary to 
model this. Figure 5.1 is a schematic representation of the model used in the current study on 
CM. At the founder level, 5 permanent milk yield categories were modeled as: -5, -2.5, 0, +2.5, 
and +5 (kg) from the mean level of milk production per day; these represented the cow‟s genetic 
potential. At the child level, 5 possible whole lactation stages were modeled. We also included a 
carryover state from lactation 2 onwards i.e., whether the cow had a case of CM in the preceding 
lactation (Y/N). At the grandchild level, 20 lactation stages (months) were modeled. In each 
stage the cow was described by one level within each of the following states: 5 temporary (i.e., 
daily) milk yield levels, 9 pregnancy states (0 = open, 1-7 = 1-7 mo pregnant and milking and 8 
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= last 2 mo of pregnancy and dry (not milking)), 1 involuntarily culled state and CM states. The 
CM states were defined as: 0 = no CM, 1 = Staphylococcus spp., 2 = Staphylococcus aureus, 3 = 
Streptococcus spp., 4 = Escherichia coli, 5 = Klebsiella, 6 = Other treated, 7 = Other not treated 
and 8 = Negative culture. We also introduced a history variable „H‟ which ranged from 0 to 3, 
where H indicates the case number if the cow has CM. H=3 means a case that is ≥3. For 
example, CM=2 and H=1 means the cow has a first case of Staphylococcus aureus. CM=0, H=0 
indicates that the cow has never had CM since calving. We also introduced a variable to indicate 
the number of months that have passed since the previous case of CM (if the cow had a previous 
CM case), termed „PM‟. This variable ranged from 0 to 3, where 3 indicates months ≥3. The 
resulting total state space is 2,095,425 combinations. The graphical user interface of the dynamic 
program is shown by Figure 5.2. 
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Figure 5.1. Schematic diagram of the DP structure. CM = clinical mastitis. 
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A)                                                                     B)                                                                     C) 
Figure 5.2. Graphical user interface of the dynamic program, with A) showing permanent milk yield 0, lactation 1, month 5 has been 
selected and the  first several clinical mastitis states are shown, with additional selected states shown by B) and C) 
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This model assumed that there were replacement heifers readily available, as well as a 
beef calf market, thus maintaining a constant herd size. We also assumed the decision was made 
at the end of the stage and the effects of the disease were accounted for in the following stage, 
depending on the decision taken. Also, when a cow made a transition from one state to another, 
we allowed for more than one change in her state at any one point in time. 
The objective function maximized by the model was the discounting criterion 
(Kristensen, 2003), which maximizes the net present value of the cow using a yearly interest rate 
of 8% (De Vries, 2006; Bar et al., 2008a).  
Optimization technique. By combining the advantages of the two types of iteration 
methods used to solve the Markov Process (namely value iteration and policy iteration), a new 
notion of a hierarchic Markov process was developed by Kristensen (1988; 1991) and later 
generalized by Kristensen and Jørgensen (2000). The notion forms the basis of solving this 
dynamic program. This solution approach allows us to obtain solutions to large state space 
problems as described below. 
Value iteration is performed to identify the decision that maximizes the total expected 
discounted rewards when the process starts from state i and continues for n stages before ending. 
Policy iteration involves choosing an arbitrary set of decision rules for each state at each stage 
and solving a set of simultaneous linear equations describing the expected future rewards of a 
process starting from state i and running over an infinite number of stages until the same optimal 
decision is reached (Kristensen et al., 2010). Our model is structured in such a way that a cow 
can be replaced until time infinity, hence at the founder (parent) level, we have an infinite time 
horizon. At the subprocess (child and grandchild) levels, however, we have a finite time horizon  
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(i.e., the lifespan of a specific cow). 
Kristensen (1988; 1991) combined the benefits of both policy and value iteration, by 
applying value iteration to the subprocesses and using these results in the final step of the policy 
iteration method of the main process. Hence, in our model, at the founder level, we used policy 
iteration, and at the child and grandchild levels, value iteration (Figure 5.1).  
Model parameters 
Description of data. Model parameters were obtained from analyses of data from 5 dairy 
herds in New York State. These 5 herds were followed for approximately 7-8 years (2003/2004-
2011), and contained a total of 50,166 lactations in 23,409 cows.  
Parameters. Model parameters specific to the 8 different pathogens causing CM are given in 
Tables 5.1 to 5.3.  
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1
The number of cases of CM the cow had in the immediate preceding lactation 
*The monthly risk estimates for the second (and third) CM occurrence applied to cows that had already experienced 1 (2) case(s) of CM (of any type) within the 
lactation.  
 
 
CM case Carry-
over 
Parity Month Staphylococcus 
spp. 
Staphylococcus 
aureus 
Streptococcus 
spp. 
Escherichia 
coli 
Klebsiella  Other 
treated 
Other not 
treated 
Negative 
culture 
1st case  1 0 0.0007   0.0006   0.0020   0.0009 0.00017   0.0004   0.0009   0.0012   
   1 0.0019   0.0019   0.0050   0.0030 0.0005   0.0062   0.0020 0.0060   
   2 0.0004 0.0006 0.0017 0.0047 0.0003 0.0016 0.0005 0.0066 
   3+ 0.0007 0.0010 0.0028 0.0034 0.0005 0.0005 0.0006 0.0041 
 0 2+ 0 0.0003   0.0003  0.0016  0.0005    0.0002   0.0001  0.0005  0.0015  
   1 0.0009 0.0008  0.0054 0.0073  0.0032 0.0008 0.0020 0.0093  
   2 0.0014 0.0011 0.0049 0.0112 0.0027 0.0006 0.0010 0.0133 
   3+ 0.0011 0.0012 0.0058 0.0077 0.0017 0.0008 0.0008 0.0093 
 >0 2+ 0 0.0007   0.0006   0.0033  0.0016   0.0006 0.0003   0.0015  0.0054   
   1 0.0030 0.0031  0.0127  0.0134 0.0064 0.0015 0.0032 0.0228 
   2 0.0021 0.0021 0.0094 0.0207 0.0047 0.0028 0.0015 0.0271 
   3+ 0.0030 0.0030 0.0124 0.0128 0.0035 0.0016 0.0012 0.0197 
2nd 
case* 
n/a 1 1 0.0050 0.0084 0.0208 0.0203 0.0072 0.0003 0.0028 0.0216 
   2 0.0020 0.0016 0.0044 0.0028 0.0000 0.0019 0.0031 0.0205 
   3+ 0.0003 0.0004 0.0013 0.0016 0.0004 0.0007 0.0013 0.0093 
  2+ 1 0.0118 0.0136 0.0344 0.0343 0.0166 0.0003 0.0020 0.0314 
   2 0.0012 0.0023 0.0104 0.0063 0.0027 0.0010 0.0029 0.0394 
   3+ 0.0008 0.0005 0.0042 0.0042 0.0008 0.0005 0.0011 0.0202 
3rd case* n/a 1 1 0.0041 0.0136 0.0245 0.0232 0.0054 0.0040 0.0027 0.0402 
   2 0.0058 0.0039 0.0080 0.0060 0.0000 0.0000 0.0000 0.0421 
   3+ 0.0006 0.0000 0.0006 0.0019 0.0006 0.0006 0.0013 0.0131 
  2+ 1 0.0110 0.0117 0.0416 0.0277 0.0219 0.0000 0.0018 0.0404 
   2 0.0028 0.0072 0.0182 0.0096 0.0033 0.0016 0.0022 0.0563 
   3+ 0.0006 0.0009 0.0049 0.0022 0.0013 0.0002 0.0021 0.0299 
Table 5.1. Monthly probability of pathogen specific clinical mastitis (CM) by case number, carryover1 (if applicable) and parity (Cha 
et al., 2012a). For cases 2 and 3, months are months since previous case of CM 
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Table 5.2. Average daily (kg) milk loss since onset of pathogen specific clinical mastitis, by case, parity and months passed (positive 
values are gains and losses are for the month(s) since CM as specified) (Hertl et al., 2012). 
CM 
case 
Parity Month Staphylococcus 
spp. 
Staphylococcus 
aureus 
Streptococcus 
spp. 
Escherichia 
coli 
Klebsiella  Other 
treated 
Other not 
treated 
Negative 
culture 
1st 
case 
1 1 0.07 -7.19 -6.35 -8.36 -5.87 -1.93 -12.35 -2.22 
  2 0.41 -2.81 -1.07 -0.90 -1.14 -0.79 -2.81 -0.98 
  3+ 0.38 -1.84 -0.73 -0.27 -0.65 -0.52 -1.72 -0.80 
 2 1 -0.34 -9.72 -5.84 -11.27 -10.11 -1.49 -12.16 -2.62 
  2 -0.35 -2.90 -0.75 -0.99 -3.14 -0.33 -1.81 0.29 
  3+ -0.16 -2.30 -0.39 -0.19 -1.97 -0.39 -0.73 0.66 
 3+ 1 0.95 -3.67 -6.30 -12.57 -12.22 -0.99 -13.60 -5.16 
  2 -0.37 -1.39 -0.49 -0.80 -2.93 -0.38 -3.48 -0.50 
  3+ -0.11 -0.78 0.01 0.48 -1.56 -0.97 -1.89 0.13 
2nd 
case 
1 1 0.73 0.26 -6.13 -11.21 -3.51 -1.03 -10.96 -4.87 
  2 0.06 -1.60 -1.67 -3.12 -1.61 0.85 -3.82 -1.38 
  3+ -1.45 -1.02 -1.05 -1.87 -2.0 1.24 -2.73 -1.29 
 2 1 -0.79 -6.44 -4.31 -12.40 -11.94 -2.11 -10.02 -5.54 
  2 -2.27 -4.60 0.06 -0.26 -1.22 -0.98 -3.76 -0.60 
  3+ -1.92 -4.52 -0.08 0.53 -0.53 -1.06 -2.43 0.02 
 3+ 1 -3.36 -4.64 -5.55 -10.11 -12.88 -1.72 -13.32 -6.71 
  2 0.07 -1.99 -0.33 0.24 -1.47 -1.27 -3.60 -1.16 
  3+ 1.65 -1.65 0.64 0.61 0.06 -1.27 -2.47 -0.54 
3rd 
case 
1 1 1.79 -2.65 -6.22 -9.64 -2.45 -5.44 -13.68 -4.63 
  2 -0.90 -1.38 -1. 60 -1.76 3.86 -0.48 -5.27 -0.27 
  3+ -0.34 -2.32 0.15 -1.14 7.50 -0.16 -2.87 0.69 
 2 1 -3.33 -3.68 -4.91 -9.01 -11.11 -0.38 -2.96 -7.47 
  2 -1.16 -1.69 1.52 -1.73 -1. 30 -1.32 0.40 -1.11 
  3+ -1.79 -1.27 1.84 -0.94 -0.41 -0.88 1.77 -0.03 
 3+ 1 -2. 50 -2.22 -5.18 -12.15 -6.96 -1.90 -6.06 -7.04 
  2 -0.03 -1.13 -1.86 -2.02 -1.38 -0.59 -2.43 -0.90 
  3+ -0.82 -1.0 -0.51 0.72 -1.90 0.52 -2.59 -0.26 
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Table 5.3. Treatment costs (USD), discarded milk days, odds ratios (for pregnancy rate adjustments) and probability of involuntary 
culling by pathogens causing clinical mastitis 
 
Item Staphylococcus 
spp. 
Staphylococcus 
aureus 
Streptococcus 
spp. 
Escherichia 
coli 
Klebsiella  Other 
treated 
Other 
not 
treated 
Negative 
culture 
References 
Treatment 
cost  
65.50 70.5 70.5 35.5 35.5 51.5 35.5 35.5 See 
footnote 3 
below. 
Discarded 
milk days 
10 8.5 8.5 0 0 3.5 0 0 As above 
Odds ratio
1
 
(for 
pregnancy 
rate 
adjustment) 
0.76 0.76 0.76 0.65 0.65 0.84 0.84 0.84 Hertl et 
al., 2010 
Risk of 
involuntary 
culling
2
 
0.006,  
0.01,  
0.02,  
0.03,  
0.04 
0.004,  
0.01,  
0.008,  
0.009,  
0.01 
0.004, 
0.00096, 
0.00645, 
0.011, 
0.00313 
0.02,  
0.03,  
0.04,  
0.04,  
0.03 
0.04,  
0.05,  
0.10,  
0.10,  
0.11 
0.005, 
0.02,  
0.02,  
0.13,  
0.13 
0.002, 
0.02,  
0.05,  
0.03,  
0.04 
0.003, 
0.007,  
0.01,  
0.01,  
0.003 
Cha et al., 
2012b 
1
 In calculating the pregnancy rate for CM cows by pathogen, this is the odds ratio by which pregnancy rate (for a cow without CM) was adjusted 
2 
Monthly involuntary culling risks for lactations 1 through 5 
3 
By determining the cost of drugs for a specific protocol times the number of recommended treatments  (on manufacturers label) or the protocol defined by the 
farm plus the value of the discarded milk at the current milk price. The cost of drugs was identified by researching three on-line drug sales companies (where 
prices would be similar for most products). Websites included Animart <http://www.animart.com/store/mastitis-tubes-lactatingtreatments/>  
Animal Livestock Supply Inc. <http://www.americanlivestock.com/cattle.html> and Dairy Health USA 
<http://www.pbsanimalhealth.com/category/Dairy/Mastitis-Treatments/D80200.html#cat_top> 
 
 
 
143 
 
The monthly involuntary culling risks for lactations 1 through 5 for healthy cows were 
0.003, 0.005, 0.008, 0.01 and 0.01 (pathogen specific involuntary culling risks are in Table 5.3). 
The treatment costs are displayed in Table 5.3. These treatment costs included costs that are for 
palliative care i.e., not necessarily only antibiotic treatments, but also the cost of sending samples 
for culturing. The cost of Streptococcus spp. and Staphylococcus aureus treatment (all in USD) 
was comprised of antibiotics (25), 50% of cows receiving anti-inflammatory drugs and fluids 
intravenously per os (15.50), labor (20) and cost of culturing (10) for a total of 70.50. 
The cost of Staphylococcus spp. treatment was comprised of antibiotics (20), 50% of 
cows receiving anti-inflammatory drugs and fluids intravenously per os (15.50), labor (20) and 
cost of culturing (10), for a total of 65.50. The treatment cost of Escherichia coli, Klebsiella, 
negative culture and other not treated was comprised of 50% of cows receiving anti-
inflammatory drugs and fluids intravenously per os (15.50), labor (10) and culturing (10), for a 
total of 35.50. Lastly, the treatment cost of the other treated category was comprised of 
antibiotics (6), 50% of cows receiving anti-inflammatory drugs and fluid intravenously per os 
(15.50), labor (20) and culturing (10), for a total of 51.50. 
The probability of pregnancy was set to 0.21 if the decision was to inseminate (Bar et al., 
2008a). Odds ratios which would reduce the rate of conception for each type of CM were 
applicable only for the first month after the cow got CM. If a cow contracted CM, her probability 
of transitioning into the pregnancy state the following month was multiplied by this formula: 
(pregnancy rate*conception odds ratio for type of CM/(1-pregnancy rate+pregnancy 
rate*conception odds ratio for type of CM)). The voluntary waiting period was 60 d. The 
maximum calving interval was 20 months and the involuntary culling risk at calving was 2%. 
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The cost of a calving first lactation animal (all costs in USD) was 1,600, average monthly 
cow maintenance cost was 150 and insemination cost/month of insemination was 20. The 
average price for a calf born was 200. The milk price was $0.31/kg and the feed cost/kg of dry 
matter was $0.20. The cull price for voluntarily culled cows was $0.74/kg of body weight.  
The milk yield estimation procedure used here is described in Bar et al. (2008a). Other 
parameters and prices and costs were taken from Bar (2007), De Vries (2006) and Bar et al. 
(2008a).  
Estimating CM cost 
The average net returns under optimization per cow per year for a herd without CM were 
compared with the average net returns per cow per year for a herd with CM (by pathogen), while 
keeping other parameters constant. The profit or loss was divided by the CM incidence to 
generate the herd average cost per case of CM. As the cost of CM was reduced under optimal 
treatment decisions, it is possible that these values differ from actual farm figures.   
The net present value (NPV) is the current value of actions where the benefits and costs 
of the actions are calculated until the end of the time horizon. This is achieved by discounting the 
various benefits and costs by an annual interest rate over that time period. The discounting factor 
(β) is equal to exp(-r) where r = 0.08 (interest rate), i.e. β = 0.92. The retention payoff (RPO) 
value is the NPV of retaining a cow compared with the NPV of her replacement (Bar et al., 
2008b), i.e. NPVretaining - NPVreplacing. 
Estimating components of CM cost 
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The components contributing to the average cost per case i.e., reduced milk production 
due to CM, reduced conception, treatment cost, milk discarded due to antibiotic treatment and 
risk of mortality are estimated by sequentially adding the effects of these components and 
comparing the difference in the average cost/case. 
Exit from the herd 
Exit from the herd can be due to two reasons: (1) voluntary culling based on what the 
model recommends or (2) due to involuntary culling. Involuntary culling can be due to 
euthanasia or cows sold for slaughter because of reasons other than milk yield, pregnancy or CM 
(i.e. reasons not determined directly from the model).  
Sensitivity analyses 
Given that economic values such as milk price, pregnancy rate and replacement cost can 
vary from time to time and farm to farm, a sensitivity analysis was performed to evaluate how an 
increase and decrease of 20% in each of these values individually affected the percentage of CM 
cases in the herd and the average cost per case.  
 
RESULTS 
The Cost of Pathogen Specific CM 
The net returns in US$ per cow and year for the basic scenario (with all CM included) 
was 500, where the incidence of CM (cases per 100-cow years) was 35.5, of which 90.6% of 
cases were recommended to be treated under an optimal replacement policy (Table 5.4).  
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Table 5.4. The effects of different pathogens causing clinical mastitis (CM) on CM cases, % of 
CM cases treated, average cost of CM and average cost per case, following an optimal 
replacement policy (all costs in US$) 
 
Item 
CM cases
1
 Percent of 
CM cases 
treated
2
 
Average 
costs of CM 
per cow in 
the herd 
Average cost per case
3
  
Basic scenario (incl. all 
CM) 
35.5 90.6 83 233 
Staphylococcus spp.
 
 1.6 91.4 4 275 
Staphylococcus aureus 1.8 86.4 5 298 
Streptococcus spp. 6.9 87.3 18 257 
Escherichia coli 8.1 90.7 25 309 
Klebsiella 2.2 90.2 9 416 
Other treated cases 1.1 94.4 3 310 
Other not treated cases 1.2 89.5 4 316 
Negative culture cases 12.7 92.6 19 151 
1
Incidence of CM (cases per 100-cow years). 
2
Percentage of treated CM cows per all CM cows 
3
Average cost per CM case 
 
The cost per case of CM was 233.41 (82.86/0.355). The CM cases (total of 35.5 per 100 
cows) were comprised of Staphylococcus spp. (1.6), Staphylococcus aureus (1.8), Streptococcus 
spp. (6.9), Escherichia coli (8.1), Klebsiella (2.2), Other treated cases (1.1), Other not treated 
cases (1.2) and Negative culture cases (12.7). The average cost per case was greatest for 
Klebsiella (416), followed by other not treated cases (316) which was similar to the other treated 
cases (310) and Escherichia coli (309). This was followed by the gram-positive pathogens, with 
the greatest cost per case being due to Staphylococcus aureus (298), then Staphylococcus spp. 
(275) and Streptococcus spp. (257). Negative culture cases had the lowest cost (151).  
Most CM cases (by pathogen), were recommended to be treated (i.e. all over 85%), and 
this was greatest for other treated cases (94.4%) and lowest for Staphylococcus aureus cases 
(86.4%). 
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The components contributing to the average cost per case i.e., reduced milk production 
due to CM, reduced conception, treatment cost, milk discarded due to antibiotic treatment and 
risk of mortality are presented in Table 5.5. 
Table 5.5. Breakdown of components (milk loss, reduction in conception, treatment cost, milk 
discarded due to antibiotic treatment and risk of mortality) contributing to the average cost per 
case by pathogen specific clinical mastitis (CM) 
 Components contributing to average cost per case of CM in 
USD (% of average cost/case) 
 
Pathogen Milk 
loss 
Reduced 
conception 
Treatment 
cost 
Discarded 
milk 
Risk of 
mortality 
Average 
cost/case 
(USD) 
Staphylococcus 
spp. 
2 (1) 35 (13) 110 (40) 64 (23) 64 (23) 275 
Staphylococcus 
aureus 
62 (21) 33 (11) 113 (38) 55 (18) 35 (12) 298 
Streptococcus 
spp. 
26 (10) 43 (17) 113 (44) 55 (21) 20 (8) 257 
Escherichia coli 58 (19) 61 (20) 57 (19) 0 132 (43) 309 
Klebsiella 25 (6) 25 (6) 56 (14) 0 257 (62) 416 
Other treated 22 (7) 80 (26) 85 (27) 22 (7) 101 (33) 310 
Other not treated 107 
(34) 
56 (18) 57 (18) 0 97 (31) 316 
Negative culture 25 (17) 35 (23) 59 (39) 0 31 (21) 151 
 
The Effects of Changes in Exogenous Factors on the Cost of Pathogen Specific CM 
In general, a 20% increase in milk price resulted in an increase in the average cost/case of 
CM. This same trend was observed as replacement cost and pregnancy rate increased by 20% 
(Table 5.6). The incidence of CM increased overall when replacement cost and pregnancy rate 
increased by 20%.
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Table 5.6.  Effects of increasing and decreasing milk price, replacement cost and pregnancy rate by 20% on clinical mastitis (CM) cases and the average cost/case for all CM and 
for each pathogen causing CM  
 
1Incidence of CM (cases per 100 cow-years) 
2Average cost/case (USD) 
 
Item Staphylococc
us spp. 
Staphylococcus 
aureus 
Streptococcus 
spp. 
Escherichia coli Klebsiella Other treated Other not treated Negative 
culture 
 CM 
cases
1 
cost/ 
case2 
CM 
cases1 
cost/ 
case2 
CM 
cases1 
cost/ 
case2 
CM 
cases1 
cost/ 
case2 
CM 
cases1 
cost/ 
case2 
CM 
cases1 
cost/ 
case2 
CM 
cases1 
cost/ 
case2 
CM 
cases1 
cost/ 
case2 
Milk price  
+20% 
1.6 303 1.8 333 6.8 291 8.0 344 2.2 456 1.1 345 1.2 360 12.5 170 
Milk price  
-20% 
1.6 247 1.8 259 7.0 222 8.2 270 2.3 361 1.1 277 1.2 272 12.9 131 
Replacement 
cost +20% 
1.6 288 1.8 307 7.0 258 8.1 332 2.2 465 1.1 331 1.2 337 12.8 154 
Replacement 
cost  -20% 
1.6 260 1.8 286 6.8 252 7.9 288 2.2 367 1.1 292 1.2 296 12.4 148 
Pregnancy 
rate +20% 
1.6 284 1.8 301 7.0 260 8.2 310 2.3 413 1.1 320 1.2 326 12.9 153 
Pregnancy 
rate  
-20% 
1.6 266 1.8 297 6.7 256 7.8 308 2.1 415 1.1 306 1.2 310 12.3 149 
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Retention Pay Off Value of Open Healthy and Mastitic Cows 
Our economic model calculates the RPO for cows, dependent on the cow‟s individual 
characteristics. Figures 5.3.1 and 5.3.2 are an example of a hypothetical cow‟s RPO under an 
optimal policy for cows free of CM and with CM by pathogen, specific to an open (non-
pregnant), second-lactation cow with >= 1 case of CM in the previous lactation and average 
permanent and temporary milk yields per 305-d lactation. The optimal policy recommended by 
the model [(1) keep (and treat if CM) and not inseminate, (2) keep (and treat if CM) and 
inseminate, or (3)  
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                        A)                                                                                                 B) 
Figure 5.3.1 and 5.3.2. Retention payoff values for a hypothetical cow in lactation 2 with >= 1 case of clinical mastitis in the previous 
lactation, with average permanent and temporary milk yields, by no mastitis or pathogen (first case only. 2A: Staphylococcus spp., 
Streptococcus spp., Escherichia coli and Staphylococcus aureus; 2B: Negative culture, Other treated, Other not treated and 
Klebsiella).
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replace] is also illustrated by the symbols in the figures. 
In Figures 5.3.1 and 5.3.2, the RPO (US$) of cows at calving was $1,121, $849, $833, 
$787, $713, $1,020, $843, $815 and $631 for no CM, Staphylococcus spp., Streptococcus spp., 
Escherichia coli, Staphylococcus aureus, Negative culture, Other treated, Other not treated and 
Klebsiella, respectively. The average cost at calving was calculated by subtracting the RPO for 
the pathogen specific CM from the RPO for no CM. The average cost at calving was $272 
($1,121 – $849), $288 ($1,121 – $833), $334 ($1,121 – $787), $408 ($1,121 – $713), $101 
($1,121 – $1,020), $278 ($1,121 – $843), $306 ($1,121 – $815) and $490 ($1,121 – $631) for 
Staphylococcus spp., Streptococcus spp., Escherichia coli, Staphylococcus aureus, Negative 
culture, Other treated, Other not treated and Klebsiella, respectively. When the RPO is negative, 
it is profitable to cull the cow than to keep her. This was observed in mo 12 for no CM, mo 10 
for Negative culture,  mo 9 for Staphylococcus spp. and Other treated, mo 8 for Streptococcus 
spp., Escherichia coli, Klebsiella and Other not treated and mo 7 for Staphylococcus aureus. 
Figures 5.3.1 and 5.3.2 illustrate the recommended policy until mo 15; the model recommended 
that cows in mo 15 and onward be replaced. 
 
Endogenous Factors Affecting the Cost of CM 
The cost of CM is dependent on endogenous factors, such as the permanent (genetic) 
milk yield potential of the cow, pregnancy status and lactation as shown in Table 5.7. 
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Table 5.7. Average cost (in US$) of a first case of pathogen specific clinical mastitis (CM) in cows with no CM in the previous lactation and 
different levels (low, average, high) of permanent (genetically determined) milk yield potential 4 mo after calving and open (i.e., not pregnant) or 
pregnant, obtained by the insemination and replacement optimization model
1 
 Permanent milk yield potential 
 Low 
 Open  Pregnant 
Lactation Sta S.aur Str E.coli Kleb Otht Othn Negc  Sta S.aur Str E.coli Kleb Otht Othn Negc 
1 123 123 123 123 123 123 123 123  257 260 260 235 241 235 260 233 
2 208 249 249 174 201 166 186 95  295 382 337 260 309 246 267 163 
4 184 229 220 157 195 163 198 145  265 317 291 231 281 250 276 209 
 Average 
 Open  Pregnant 
Lactation Sta S.aur Str E.coli Kleb Otht Othn Negc  Sta S.aur Str E.coli Kleb Otht Othn Negc 
1 328 450 394 365 457 299 388 287  349 434 398 361 440 308 379 293 
2 358 469 363 372 478 330 351 193  371 458 384 383 483 345 363 221 
4 327 361 311 280 397 391 327 215  350 370 328 308 452 470 341 236 
 High 
 Open  Pregnant 
Lactation Sta S.aur Str E.coli Kleb Otht Othn Negc  Sta S.aur Str E.coli Kleb Otht Othn Negc 
1 378 488 431 505 714 336 403 307  394 466 430 471 647 341 392 311 
2 416 530 371 519 709 431 450 225  424 509 397 505 675 432 446 252 
4 416 393 346 383 629 667 415 238  420 397 359 387 625 684 401 256 
1
Sta = Staphylococcus spp.; S. aur = Staphylococcus aureus; Str = Streptococcus spp.; E. coli = Escherichia coli; Kleb= Klebsiella; Otht = Other treated; Othn = 
Other not treated; Negc = Negative culture 
 
These average costs are for a cow 4 months after calving with no CM in the previous lactation. The average cost was greater in 
pregnant cows compared with open cows. Younger cows also had a greater average cost compared with older cows. The average cost
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increased as permanent milk yield potential increased. While the pathogen with the greatest 
average cost varied by pregnancy status and genetic milk yield potential, Klebsiella appeared to 
have the largest average cost overall. This reflects the average cost/case trend seen in Table 5.5.  
Exit from the Herd (Voluntary and Involuntary Culling) 
The percentage of involuntary cullings over a year was 10.4%, and the percentage of 
voluntary cullings, 20.2%, for a total exit of 30.6% when all CM was included in the model. The 
total exit increased to 33.0% (10.3% involuntary and 22.7% voluntary cullings) when milk price 
increased by 20%, and reduced to 28.6% (10.5% and 18.1%) when milk price was decreased by 
20%. The total exit reduced to 29.1% (10.5% and 18.6%) when replacement cost was increased 
by 20%, and increased to 33.3% (10.2% and 23.1%) when replacement cost was decreased by 
20%. When pregnancy rate was increased by 20%, the total exit reduced to 28.8% (10.7% and 
18.1%) and increased to 33.4% (9.9% and 23.5%) when pregnancy rate was reduced by 20%. 
 
DISCUSSION 
The objective of this study was to develop and solve an economic optimization model 
which provides dairy farmers optimal decisions for management of their cows suffering from 
CM. The economic value of one decision compared with another is quantified by the calculation 
of retention pay off values. We analyzed the effect of different scenarios by making changes to 
input parameter values and comparing the net returns. A limitation of including other diseases 
aside from CM is that the economic model becomes prohibitively large as the state space 
expands, and also, not all the parameters required to run such a model are available. Because it 
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may be possible to include other diseases in the near future as data are available, we  developed 
this model from the beginning to have a relatively versatile structure, allowing for relatively easy 
expansion.  
By stratifying by pathogen, we were able to identify that mortality and treatment cost 
contribute largely to the cost of pathogen specific CM, and the effect of reduced milk production 
due to CM was actually smaller than what we observed when CM was combined into one group 
(Bar et al., 2008), or stratified by gram-groups (Cha et al., 2011). This is largely attributed to the 
data being different across the time periods (we have collected more data with each progressive 
study). Also, in this study, we identified that other CM (i.e. those that are not gram-positive or 
gram-negative CM) actually have a high cost/case comparable with gram-positive CM cases. 
The total percent of cows recommended to be culled in our study was lower than that in Cha et 
al. (2011) i.e., 30.6%, mainly due to a lower involuntary culling percentage. The percentage of 
cows recommended to be culled by the economic model i.e., voluntary cullings, however, was 
similar.  
As expected, the average cost of CM generally increased as cows were in greater milk 
yield potentials and decreased as they progressed across lactations. The latter is explained by 
cows getting older, hence, having less time remaining for losses to production from CM to take 
effect. While we observed similar trends in average costs across different permanent milk yield 
levels and across lactations as reported by Cha et al. (2011), we found the average costs were 
lower for open cows compared with pregnant cows. This is because in the previous study, the 
effects of reduced conception were allowed to span for 3 months since the case of CM; however, 
in this study, we have accounted for reduced conception for 1 month after a case of CM, which 
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we have found is when the reduced conception effects following CM occurrence have the most 
effect (Hertl et al., unpublished). 
It is difficult to validate animal replacement economic models as other existing models 
often differ in their structure and parameter values. Interestingly, the net return/year from our 
study (500 USD) is comparable with the expected net present value of £285.50 (approx. 457 
USD) from a study by Yalcin and Stott (2001); however, the latter model had a time horizon of 
20 years, 12 lactations, 15 milk yield states and 11 somatic cell count states. The net return in our 
current study is greater than that from the generic CM study by Bar et al., (2008) i.e., 355 USD 
and the gram-positive, gram-negative and other CM study by Cha et al., (2011) i.e., 357.35. 
Differences in these values are attributed to the varying structure and parameter estimates 
adopted. In the model by Bar et al. (2008), CM was included as one group, not separated by 
culture classes. This meant that the effects of CM i.e., repeated risks, milk loss, mortality risks 
and reduced conception were all for generic CM and not culture classes as in the case of our 
model. Also, the withholding period due to antibiotic treatment was not incorporated as an 
adjustment to the already lower milk production among CM cows. 
To the authors‟ knowledge, there are very few studies that examine the cost of pathogen-
specific CM (Østergaard et al., 2005; Sørensen et al., 2010). In the study by Sørensen et al. 
(2010), economic values for pathogen-specific CM were estimated using a stochastic simulation 
model (SimHerd IV). The simulations were conducted over time with weekly time increments, 
other diseases were included as well as severity of CM, and an annual interest rate of 4% was 
used (unlike 8% in our study). While we found the average cost/case was in general greater for 
Escherichia coli and Klebsiella, the study by Sørensen et al. (2010) found the opposite trend, 
where the cost per case in €(USD) was greater i.e., 570 (725) for Staphylococcus aureus and 380 
156 
 
(483) for CNS, and less i.e., 206 (262) for Escherichia coli and 149 (189) for Streptococcus 
dysgalactiae and Streptococcus uberis. The model by Sørensen et al. (2010) did not model  
contagious spread between herd mates, hence, this assumption is the same as our dynamic 
program. The difference in the costs/case may be due to the mortality risks we adopted (Cha et 
al., 2012b), and based on this, it did not come as a surprise that risk of mortality contributed 
largely to the cost per case in our study, especially for Escherichia coli and Klebsiella. 
The cost of CM (Table 5.4) calculated by the economic model following optimization 
and simulation reflect what has been observed on average across our study farms (Cha et al., 
2012a). The average cost per case for each pathogen is an economic consequence of the 
assimilation of the pathogen specific CM effects (i.e., milk loss, reduced conception, treatment 
cost, discarded milk days and mortality risk) with which we parameterized our model. By 
including discarded milk due to treatment after adjusting for the loss to milk due to CM, our 
results were more accurate than if the discarded milk was accounted for without considering the 
initial drop in milk due to CM. Through scenarios analyses, we were able to break down the 
contribution of each effect to the average cost per case by pathogen (Table 5.5). It may seem 
counterintuitive that some pathogens may be treated with antibiotics given that the milk loss due 
to days of discarded milk post antibiotic therapy is greater than the effects of reduced conception 
and reduced milk production combined. For example, for CM attributed to Staphylococcus spp., 
there is less cost to a reduction in milk production due to CM (0.8% of the total average 
cost/case) and reduced conception (12.8%) combined, compared with the cost of discarded milk 
(23.1%). A reason for treating these cows suffering from CM attributed to Staphylococcus spp. 
Regardless of our empirical results, may be because the overall quality of the milk is 
compromised, resulting in milk price penalties. However, we did not model poor milk quality 
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directly. In study by Ma et al., 2000, it was demonstrated that for high SCC milk, between 14 to 
21 d post processing, sensory defects i.e., rancidity and bitterness were detected which resulted 
in lower quality ratings. These defects were found to be consistent with higher levels of lipolysis 
and proteolysis, adversely affecting the quality of pasteurized fluid milk. A study by Wilson et 
al. (1997) showed that cows suffering from CM due to Staphylococcus spp. infection had a linear 
score of SCC of 3.7, corresponding to 162,000 cells/ml (Western Canadian Dairy Herd 
Improvement Services, accessed Nov. 9, 2012). While the regulatory limit in the USA is 750,000 
cells/ml, the global standard (and also the European Union limit) is 400,000 cells/ml, 
highlighting the economic ramifications of CM and why treatment is often warranted (Adkinson 
et al., 2001; Hoards Dairyman, 2011). Milk loss for Escherichia coli cases in this study is 
representative of farms that use a J5 vaccine which has been demonstrated to reduce milk loss 
due to Escherichia coli (Wilson et al., 2007). 
The sensitivity analyses of milk price, replacement cost and pregnancy rate were 
performed to identify the effect of these factors on the direction and magnitude of the average 
cost/case and incidence of CM. When milk price was increased by 20%, the average cost per 
case increased because the production limiting effects of CM have a greater impact at higher 
milk prices. The incidence of CM was reduced when replacement cost was decreased by 20%, as 
an increase in replacement would lead to an overall younger herd of animals with an overall 
lower incidence of CM compared with an older herd of animals. The increased level of CM 
when pregnancy rate was increased by 20% is explained by there being more cows being kept in 
the herd, as pregnancy adds value to the cow, thereby lending to more older cows in the herd, 
and a greater incidence of CM compared with a younger group of animals. These trends are in 
agreement with those from our previous studies (Bar et al., 2008a; Cha et al., 2011). 
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From month 3, the first month cows can be inseminated, we observed that until the 
optimal policy is replacement (the latest being at month 12), the cows are recommended to be 
inseminated regardless of CM status (Figures 5.3.1 and 5.3.2). Because the length of each 
lactation was a maximum of 20 months, and any cows that became pregnant from month 13 
would be automatically replaced at the end of the lactation, all cows from month 12 onwards 
were recommended to be replaced. The point at which cows were recommended to be replaced 
could be different if the maximum number of months were changed to another value; however, it 
was necessary to have a maximum stopping point for the lactation. We also used a constant 
pregnancy rate of 21% throughout lactation for primiparous and multiparous cows; if we had 
modeled pregnancy rate to decrease throughout lactation, it is possible that the optimal decision 
would not have been to inseminate each month until cows are replaced. This would depend on 
the value of the decision to keep the cow compared with the decision to inseminate her, which is 
a function of the probability of pregnancy, the expected gain from pregnancy and the cost of 
insemination. 
Given that the quantity of milk produced is by far one of the key determinants of net 
returns in a dairy operation, it would be ideal for an economic optimization model to contain 
very detailed information on the lactation curve of the dairy cows, while accounting for 
seasonality. While the replacement heifers in this study do follow a skewed distribution toward 
genetic improvement which is a reflection of what is taking place on farms, we do not account 
for each successive replacement to be an improvement since the previous replacement. These 
considerations were beyond the scope of this study, and we are working toward expanding this 
model further, and to include more diseases of importance as well as other significant production 
effects.  
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Key assumptions of the model include (1) that a constant herd size is maintained, (2) if an 
animal is replaced a replacement heifer is readily available and (3) there is a market for beef 
calves. In reality, these assumptions may not always be true. These assumptions are the same as 
those applicable to the generic CM model (Bar et al., 2008a). Unlike the generic CM model, we 
included 5 lactations (as opposed to 8 lactations), as 5 lactations includes over 98% of cows in 
the herd (Cha et al., 2012b). Another motivation was that by reducing the number of lactations, 
we could also reduce the prohibitive effects of a large state space, otherwise known as the curse 
of dimensionality (Kristensen et al., 2010). Even though inclusion of a carryover state 
significantly increased the state space of the model, it became necessary to include this 
information as we have identified that the risk of CM differs depending on whether a cow 
suffered from cases of CM in the previous lactation (Cha et al., 2012a). This prohibitive effect 
would also be in effect if more stratifications of CM or additional diseases (if such information 
were available) were included.  
In our study, the stage length adopted was 1 month, hence, milk production parameters 
were specific across 1 month, although we did have access to daily milk yields. A daily time step 
would have expanded the state space enormously and it is not clear whether the benefits would 
have been sufficient given the benefits of modeling more detail elsewhere as we did. Nielsen et 
al. (2010) developed a model with a daily time step with Bayesian updating to predict the 
performance of cows in the herd; however, their focus was milk yield and not dairy cattle 
diseases.  
In addition to calculating the cost of disease and optimal replacement decisions, this 
model can be used to investigate the value of different control strategies as has been explored by 
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the generic CM model (Bar et al., 2008b). A next step would be to assess different control 
strategies specific to each pathogen specific CM using the current model.  
 
CONCLUSION 
The dynamic programming model developed and solved generates optimal economic 
decisions to make with the diseased cows experiencing CM. The recommendations are specific 
to an individual cow, and hence, are dependent on the permanent milk yield potential, lactation, 
month of lactation, pathogen causing CM, temporary milk yield and pregnancy status. In general, 
the average cost per case was greatest for Escherichia coli and Klebsiella CM. Optimal 
recommended time for replacement was as great as 5 months earlier for cows with CM compared 
with cows without CM. Further, while the parameter estimates implemented in this model are 
specific to the dairy farms in this study, results should prove useful to farmers with cows of the 
modeled traits. In addition, the cows characteristics and model parameters may be altered so that 
the results are specific to any farm. Inclusion of additional information pertaining to other 
diseases of importance in dairy cattle, detail to the milk yield distribution and genetic 
improvements would also add value to the existing model and forms the basis for future research 
efforts. Further, we are currently studying the value of information i.e., monetary losses or gains 
to having information on CM at the pathogen-specific or gram-specific level, compared with 
knowing the cow is suffering from non pathogen-specific CM. This information would provide 
the value of pathogen specific tests. 
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CHAPTER 6 
 
GENERAL DISCUSSION AND CONCLUSIONS 
 
The advantage of animal replacement models is that they can include a vast amount of 
information that is available to dairy farmers that one would otherwise not be able to completely 
assimilate when making informed decisions. Often times, dairy farmers employ rules of thumb 
when deciding what to do with their diseased cows. The economic model developed in this study 
is not designed to override the decisions dairy farmers make, but rather, provide an adjunct to 
this decision process. Our model provides economically optimal decisions based on the 
probability of events that are projected into the future and expected future losses due to CM. The 
recommended decision is specific to a cow dependent on the cow‟s characteristics and stage of 
lactation while maximizing net returns in general.  
In developing this model, we needed to parameterize the model with the risks of bacteria 
specific CM and their production limiting effects. For the risk and mortality and culling analyses, 
generalized linear mixed models (GLMM) with an assumed random Poisson distributed error 
were developed. We decided to adopt this method of analysis because a key reason for 
estimating the risk and mortality estimates was for the purpose of parameterizing the economic 
model. For the economic model, probabilities were needed, and from the parameter estimates of 
these GLMM, the risks can be easily calculated. This made the GLMM approach favorable to 
other methods of analyzing the data in this study e.g., survival analysis or logistic regression. 
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Interestingly, we found that cows with a second or third case of CM that had been 
exposed to the same pathogen previously were at greater risk of that same pathogen (compared 
with cows that had been exposed to a previous case of CM that was different to the second or 
third case in question). The findings in our study relating to the absence of immunological 
memory across cases of pathogen specific CM is not directly comparable with the premise 
behind vaccine development. The purpose of vaccines is to elicit an immune response which 
confers the cow to being protected against the pathogen of interest. The same losses to 
production and damage to the mammary gland are not elicited by a vaccination, the same way 
that it is in a real life infection. In the study by Hogan et al., (1999), the severity and duration of 
clinical signs following intramammary challenge with a heterologous strain of E. coli were 
reduced in vaccinated heifers compared with placebo-injected heifers; this is just one example of 
the value of vaccines in generating an appropriate immune response, which cannot be directly 
compared with the lack of immunological immunity following a real infection. A greater risk of 
recurrent cases of CM, may therefore be due to an immune-compromised state that cows may 
experience post-real life CM infection, but not post-vaccination. 
In the mortality and culling analyses, the time step was 1 month, meaning it is assumed 
that the cow survives, dies or is culled at the end of each month. One could argue that this is a 
large time step and that weekly time steps would be more accurate, as there is a chance that we 
are underestimating the risk of mortality and culling. A reason for using a 1 month time step, 
however, was because the economic model had this time step to control dimensionality to 
produce a solvable model and the parameter estimates were required to be consistent to the 
economic model as detailed above.  
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In the mortality analysis, the CM indices were specific to the month in lactation as we 
were interested in immediate death due to CM. This is unlike the culling analysis, where it is 
possible that dairy farmers will wait 1 or even 2 months after the CM episode before deciding to 
replace a cow. The CM indices were, therefore, reflected to be able to ascertain whether the risk 
of culling was greatest in the month of CM occurrence or since „x‟ number of months after, and 
while this differed by pathogen, it was not uncommon for farmers to wait 1 month since the 
occurrence of CM before culling the cow. This may be due to the observed effects of CM not 
being seen immediately, but accumulated over a time delay of 1 month. 
Our results apply to large, well managed herds in New York State. The size of these 
herds allowed us access to a large number of observations; however, the external validity extends 
only to herds of these types. This is true of the risk and mortality and culling analyses, but with 
reference to the economic model, if the parameter estimates were altered to be specific to herds 
of another type, then the results would be reflective of that herd. In this way, the economic model 
can be applicable to a wider range of situations. 
Within the datasets, it is possible that there were discrepancies in the way that the 
information was collected. While every efforts was made to make consistent the definition of 
CM cases as recorded in Dairy Comp 305 ® herd management software (Valley Agricultural 
Software, Tulare, CA), it is possible that inconsistencies were introduced across the farms and 
herdspersons involved. 
Dairy cattle replacement models have been previously developed (De Vries et al. 2006; 
Nielsen et al., 2010; Demeter et al., 2011), with inclusion of information relating to disease 
(Houben et al., 1994; Bar et al., 2008a; Cha et al., 2011). The model by Bar et al. (2008a) 
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incorporated information on generic CM, extending and building upon the assumptions of the 
optimal replacement model developed by Houben et al. (1994) and earlier asset replacement 
principles (Perrin, 1972). Cha et al. (2011) modified the original model by Bar et al. (2008a) to 
study 3 groupings of CM (gram positive, gram negative and other).  
Our motivation to develop this economic model was primarily due to the fact that the 
previous framework did not separate CM into the different pathogens that are causative or, in the 
case of Cha et al. (2011), differentiate between different cases of CM. This meant that the effects 
of CM were pooled. The influence of this is seen in more specific situations, e.g., when the 
profile of a cow results in a borderline decision (Østerås et al., 1999). Since the publication of the 
generic CM study, we had access to 30% more data, enabling us to estimate the effects of CM at 
the pathogen specific CM level. Discarded milk due to treatment after adjusting for the loss to 
milk due to disease was not previously accounted for, but now, we were able to quantify as a 
percentage the effect of discarded milk on the average cost per case. Also, by allowing more than 
one event to occur as a cow transitions from one month to another, our model better represented 
what happens in the real world. 
As with any model, however, this economic model is a simplification of reality. A study 
by Ben-Ari et al. (1983) formulated the limitations of animal production modeling in this 
framework which apply to our economic model, namely (1) uniformity – the traits of the animal 
are difficult to define and measure and the random variation in traits is large, (2) the production 
of an animal is cyclic – one needs to decide in which cycle as well as when within a cycle to 
replace the animal and (3) there is only a limited supply of replacements available (Kristensen, 
2010). Evidently, in reality, these conditions will not always be met, nor are always true. 
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Further, we did not model seasonality or an improvement in the genetic potential of 
replacement heifers over time. While the replacement heifers in our study were slightly better 
than average, the fact that replacement heifers generally improve with successive generations 
was not modeled.  
The focus here has been clinical mastitis. Subclinical mastitis (mastitis which does not 
exhibit clinical signs) is also a big contributor to the overall cost of mastitis. If subclinical 
mastitis were to be included in the economic model, this could be achieved by introducing 
additional states. The complexity of this is two-fold; firstly, we would need parameter estimates 
for these subclinical CM levels i.e., losses to milk yield, reduction in conception etc., but also, as 
we include more states in the economic model, the model becomes prohibitive, at least, to run on 
the computers that we have available now. A way around this would be running this model on a 
supercomputer, but if we want the finished product to be directly accessible to dairy farmers in 
the future, we need to keep in mind the technology that is realistically available to them.  
The problem described above relating to the expansion of the state-space which may be 
prohibitive is termed the “curse of dimensionality”. The solver in the Multilevel Hierarchic 
Markov Process (MLHMP) software which is used to develop the pathogen specific CM model 
makes it possible to give exact solutions to models with extremely large state spaces (Kristensen, 
2010). 
To show more clearly how this came to be, it is necessary to provide some history to the 
development of dynamic programming, which dates all the way back to the 1950s. In 1957, 
Bellman published a book which described the theory of a numerical method for solving 
sequential decision problems, known as the Bellman Principle of Optimality. This was followed 
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by Howard in 1960, who combined dynamic programming with the theory of the Markov chain, 
resulting in the Markov Decision Process. Howard also introduced policy iteration, a solution to 
infinite time horizon problems, as an alternative to the backward contraction method of value 
iteration.  
The application of this technique to animal replacement models was illustrated by Jenkins 
and Halter (1963); in this study, the trait of lactation number (12 levels) was all that was 
included, but served the purpose of showing that this technique could indeed be applied to such a 
problem. It was the work of Giaever (1966) that was groundbreaking, as he illustrated with 
various optimization techniques (value iteration, policy iteration and linear programming) the 
feed intake and production of a dairy cow. Studies since Giaever (1966) have contributed in 
ways other than methodology; for example, Smith (1971) was able to achieve a state space of 15 
000, as opposed to the 106 states which was the upper limit in the Giaever study. Kristensen and 
Østergaard (1982) and van Arendonk (1985, 1986) and van Arendonk and Dijkhuizen (1985) 
studied the effect of prices and conditions on the optimal replacement policy (Kristensen, 2010).  
Returning to the idea of the “curse of dimensionality”, in developing this economic 
model, it was always a balance of including detailed information being weighed against the 
increased risk of the model becoming solution prohibitive. This meant we needed to choose very 
carefully the stages and states to include. One of the criteria was ensuring these pieces of 
information were influential in deciding the optimal management decision for cows affected with 
CM. This became especially important in the founder state where policy iteration, which is 
computationally demanding, is performed. 
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At the founder level, we included the permanent milk yield potential of the cow which we 
have termed a genetic property. This feature was preserved from generic CM model developed 
by Bar et al. (2008a). In our model, this permanent milk yield potential was account for as 
deviations from an average milk curve. The meaning ascribed to permanent milk yield potential, 
however, could be very different. For example, rather than these deviations, this state could have 
been described by an index encompassing an array of features which determine the cow‟s genetic 
potential. This could have been an udder index or an estimated breeding value (EBV) for 
instance. 
This economic model has a time step of 1 month, which meant that the effects of diseases 
and decisions all applied to 1 month. A smaller time step would have led to more precise 
decision making but would result in an even larger state-space, and it is unclear whether the 
benefits of the detail would be sufficient given the benefits of modeling more detail elsewhere as 
we did.  
The value of treatment decisions is overestimated, as we have not accounted for the time 
delay in obtaining culture results or the efficacy of treatment. Further, within the current 
framework, it is not possible to account for infectivity between cows with contagious CM, 
however, the risk estimates for these pathogens reflect the incidence of CM which indirectly 
includes the fact that these pathogens have had a greater likelihood of having spread within the 
herd. Further, the economic values e.g., net return, average costs etc are point estimates. 
Standard errors around these point estimates could be generated with additional work at the 
model level, however, this was beyond the scope of this study. 
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When parameterizing this economic model with treatment costs for each pathogen, we 
accounted for palliative treatment for Escherichia coli and Klebsiella (gram-negative CM) cases. 
Not treating with antibiotics for these cases is not uncommon, however, recent research has 
demonstrated the benefits of treating non severe clinical gram-negative mastitis with ceftiofur 
hydrochloride (Schukken et al., 2011). In this study, it was demonstrated that treated animals 
clinically improved significantly more than control cows, and while there was no significant 
difference in milk production between the two groups, treated animals left the study at a lower 
rate than control animals. Inclusion of this information, in addition to a withholding period for 
treatment with anti-inflammatories (as part of palliative care) will be a focus of future work. By 
comparing two protocols i.e., antibiotic treatment of gram-negative CM with less mortality and 
no antibiotic treatment, we will be able to determine the economic value of antibiotic treatment 
of gram-negative CM. 
An application of this model is for dairy farmers to include parameter estimates specific 
to their farm and generate optimal management decisions tailored to their cows. Following 
optimization, the value of cows can be determined, and based on this, cows may be ranked 
according to their value, assisting decisions concerning how to down-size, or which cows to 
replace as necessary (Kristensen, 1989). It would probably be most effective for these results to 
be communicated to dairy farmers by personnel who have been trained to understand the results 
of the model and provide consulting services.  
Identifying whether dairy farmers need information relating to CM at the generic, gram-
positive, gram-negative or other or pathogen specific level will form the basis of future research. 
It would be ideal to integrate the time delay in asking for more information e.g., gram-positive, 
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gram-negative and other CM identification can be done on-farm immediately, compared with 
pathogen specific identification which can take days.  
An advantage of this economic model is the versatile structure, which allows for relative 
easy inclusion of additional diseases or replacement of current CM indexes with other diseases, 
for instance, calving diseases or other production limiting diseases such as lameness. The 
structure also allows for the relatively easy inclusion of new disease effects. 
 
CONCLUSIONS 
The model developed provides dairy farmers with optimal economic decisions to make 
for diseased cows experiencing clinical mastitis depending on the stage of lactation the cow is in 
and her individual characteristics. By altering the parameter estimates of the model, the results 
can be specific to any farm, providing estimates of the cost of CM, optimal replacement 
decisions and cow rankings. This model affords flexibility so that inclusion of additional 
information pertaining to other diseases of importance in dairy cattle, details of the milk yield 
distribution and genetic improvements can be introduced relatively easily. Changes can also be 
made at the founder level to permanent genetic milk yield potential and at the level of the stages 
e.g., inclusion of a subclinical CM index. Future work would include improvements in the 
aforementioned areas, as well as studying the cost and benefits of different control strategies 
targeted for the pathogen specific CM and evaluating the value of information i.e., monetary 
losses or gains to having information on CM at the pathogen-specific or gram-specific level, 
compared with merely knowing the cow is suffering from non pathogen-specific CM. 
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